



Clinical trial results:

A phase 3 multicenter, randomized, prospective, open-label trial of standard chemoimmunotherapy (FCR/BR) versus rituximab plus venetoclax (RVe) versus obinutuzumab (GA101) plus venetoclax (GVe) versus obinutuzumab plus ibrutinib plus venetoclax (GIVe) in fit patients with previously untreated chronic lymphocytic leukemia (CLL) without del(17p) or TP53 mutation.

Summary

EudraCT number	2015-004936-36
Trial protocol	SE DK DE AT FI BE IE
Global end of trial date	29 February 2024

Results information

Result version number	v1 (current)
This version publication date	12 March 2025
First version publication date	12 March 2025

Trial information

Trial identification

Sponsor protocol code	CLL13
-----------------------	-------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02950051
WHO universal trial number (UTN)	-
Other trial identifiers	Sponsor`s number: UNI-KOELN-2751

Notes:

Sponsors

Sponsor organisation name	UNIVERSITY OF COLOGNE
Sponsor organisation address	ALBERTUS-MAGNUS-PLATZ, Cologne, Germany, 50923
Public contact	Dr. med. Anna Fink, German CLL Study Group, COLOGNE UNIVERSITY HOSPITAL, KERPENER STR. 62, 50924 COLOGNE, GERMANY, +49 22147888220, anna-maria.fink@uk-koeln.de
Scientific contact	PROF. DR. MED. BARBARA EICHHORST, German CLL Study Group, COLOGNE UNIVERSITY HOSPITAL, KERPENER STR. 62, 50924 COLOGNE, GERMANY, +49 22147888220, barbara.eichhorst@uk-koeln.de

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	29 February 2024
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	29 February 2024
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective of the study is to evaluate the efficacy of obinutuzumab (GA101) plus venetoclax (GVe) versus standard chemoimmunotherapy (BR/FCR) [concerning MRD negativity measured by flow cytometry in peripheral blood (PB) at month 15] and obinutuzumab plus ibrutinib plus venetoclax (GIVe) versus standard chemoimmunotherapy (BR/FCR) [concerning progression free survival (PFS)] in previously untreated, fit CLL patients without del(17p) or TP53 mutation.

Protection of trial subjects:

Safety measures to prevent or to manage known risks associated with CLL, such as infections or cytopenia or known adverse reactions related to any of the IMPs have been included in the protocol. Chapter 8 of the protocol included sections how to prevent and manage known side effects, including detailed instruction about premedication, modifications and treatment discontinuation. The protocol includes sections with prohibited, permitted and medication used with caution for each study medication, especially for known interactions with CYP3A4 inhibitors or inducers.

Background therapy:

For a long time, chemoimmunotherapy with fludarabine, cyclophosphamid and rituximab (FCR) for patients ≤ 65 or bendamustine plus rituximab for patients > 65 years, was considered standard first-line treatment for patients with CLL. Since several novel targeted agents such as the Btk-inhibitor ibrutinib (formerly PCI-32765), the PI3K-inhibitor CAL-101 (idelalisib) and the Bcl2-antagonist venetoclax (ABT-199, GDC-0199) have become available, the treatment landscape for CLL as faced profound changes. These new targeted agents were tested in phase-II and III-studies and showed a favorable toxicity profile and a promising efficacy with a potentially synergistic mechanism of action. The PI3K-inhibitor Idelalisib has been approved for treatment of relapsed CLL as well as frontline therapy of CLL with TP53 mut/del.

The combination of venetoclax and CD20-antibodies is approved for firstline therapy (obinutuzumab) as well as in relapsed disease (rituximab). Btk-inhibitors are approved as monotherapy in firstline treatment and relapsed disease or in combination with venetoclax or CD-20 antibodies for first line therapy.

The addition of the Btk-inhibitor ibrutinib to the venetoclax plus CD20-anitbody based combination, is expected to add significant activity by targeting a third mechanism order to drive CLL cells into apoptosis.

The aim of the CLL13 trial is to evaluate, wether the standard chemoimmunotherapy in the frontline treatment of physically fit patients in CLL can be replaced by combinations of venetoclax (and ibrutinib) with anti-CD20-antibodies, which may induce extremely long lasting remissions.

Evidence for comparator:

Chemoimmunotherapy is the standard of care in first-line treatment of CLL. In patients < 65 years, the combination of fludarabine, cyclophosphamid and rituximab is considered standard treatment, while patients >65 years usually receive bendamustine plus rituximab.

However, these conventional chemoimmunotherapies are associated with side effects caused by the rather unspecific mode of action of the chemotherapy. Therefore, there is a need for alternative, chemotherapy-free regimes. Published data support that targeted agents may show a promising response rate while having a favorable safety profile with lower rates of toxicity. All agents used in this trial have been approved in firstline treatment or in relapsed disease, as monotherapy or as combination

therapy for patients with CLL.

Actual start date of recruitment	13 December 2016
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Switzerland: 82
Country: Number of subjects enrolled	Netherlands: 185
Country: Number of subjects enrolled	Sweden: 53
Country: Number of subjects enrolled	Austria: 36
Country: Number of subjects enrolled	Belgium: 31
Country: Number of subjects enrolled	Denmark: 113
Country: Number of subjects enrolled	Finland: 21
Country: Number of subjects enrolled	Germany: 333
Country: Number of subjects enrolled	Ireland: 38
Country: Number of subjects enrolled	Israel: 34
Worldwide total number of subjects	926
EEA total number of subjects	810

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	564
From 65 to 84 years	362
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Between Dec 13, 2016, and Oct 13, 2019, 1080 patients were screened for eligibility. 926 were enrolled, 154 excluded. 229 were assigned to receive chemoimmunotherapy (150 FCR, 79 BR), 237 were assigned to receive venetoclax+rituxumab, 229 were assigned to venetoclax+obinutuzumab and 231 were allocated to venetoclax+obinutuzumab+ibrutinib.

Pre-assignment

Screening details:

From 154 screening failures, 136 did not meet eligibility criteria, 4 were not included due to physician's decision and 14 due to patient's decision.

Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Blinding implementation details:

Not applicable

Arms

Are arms mutually exclusive?	Yes
Arm title	Standard chemoimmunotherapy (SCIT)

Arm description:

The SCIT treatment consists of 6 cycles, each with a precise duration of 28 days. Patients ≤ 65 years will receive 6 cycles of fludarabine, cyclophosphamide and rituximab (FCR). Patients > 65 years will receive 6 cycles of bendamustine and rituximab (BR).

Arm type	Active comparator
Investigational medicinal product name	Fludarabine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Patients will receive fludarabine on days 1-3 of cycle 1-6.

Cycle 1-6

Day 1 fludarabine 25mg/m² i.v.,

day 2 fludarabine 25mg/m² i.v.

day 3 fludarabine 25mg/m² i.v.

Investigational medicinal product name	Cyclophosphamide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Patients will receive cyclophosphamide on days 1-3 of cycle 1-6.

Cycle 1-6

Day 1 cyclophosphamide 250mg/m² i.v.,

day 2 cyclophosphamide 250mg/m² i.v.

day 3 cyclophosphamide 250mg/m² i.v.

Investigational medicinal product name	Rituximab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Patients will receive rituximab (MabThera®) intravenously before the application of chemotherapy with premedication according to clinical practice of the participating sites.

Cycle 1: 375 mg/ m² i.v.
Cycles 2-6: 500 mg/ m² i.v

Investigational medicinal product name	Rituximab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Patients will receive rituximab (MabThera®) intravenously before the application of Bendamustine with premedication according to clinical practice of the participating sites.

Cycle 1: 375 mg/ m² i.v.
Cycle 2-6: 500 mg/ m² i.v.

Investigational medicinal product name	Bendamustine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for concentrate and solution for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Patients will receive bendamustine on day 1 and 2 of cycle 1-6.

Cycle 1-6
Day 1 bendamustine 90mg/m² i.v.,
day 2 bendamustine 90mg/m² i.v.

Arm title	Venetoclax, rituximab (RVE)
------------------	-----------------------------

Arm description:

The RVE treatment consists of 12 cycles, each with a precise duration of 28 days.

Arm type	Experimental
Investigational medicinal product name	Rituximab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Patients will receive rituximab (MabThera®) intravenously:

Cycle 1:
Day 1: 375 mg/ m² i.v.

Cycle 2-6:
Day 1: 500 mg/ m² i.v.

Investigational medicinal product name	Venetoclax
Investigational medicinal product code	ABT 199
Other name	
Pharmaceutical forms	Film-coated tablet

Routes of administration	Oral use
--------------------------	----------

Dosage and administration details:

Patients will receive the first dosage of venetoclax on day 22 of cycle 1. The daily intake of venetoclax starts with a weekly dose ramp-up to final dose

Venetoclax p.o.:

Cycle 1:

Days 22-28: venetoclax 20 mg (2 tabl. at 10 mg)

Cycle 2:

Days 1-7: venetoclax 50 mg (1 tabl. at 50 mg)

Days 8-14: venetoclax 100 mg (1 tabl. at 100 mg)

Days 15-21: venetoclax 200 mg (2 tabl. at 100 mg)

Days 22-28: venetoclax 400 mg (4 tabl. at 100 mg)

Cycles 3-12:

Days 1-28: venetoclax 400 mg (4 tabl. at 100 mg)

Due to the risk of adverse events, especially tumor-lysis-syndromes (TLS), the dose of venetoclax will be increased slowly every week until the final dose of 400 mg is reached (ramp-up). In order to diagnose a TLS at an early stage certain safety measures as specified in the study protocol must be followed.

On days with administration of both, venetoclax and rituximab, oral intake of venetoclax will be followed by intravenous administration of rituximab.

Arm title	Venetoclax, obinutuzumab (GVe)
------------------	--------------------------------

Arm description:

The GVe treatment consists of 12 cycles, each with a precise duration of 28 days.

Arm type	Experimental
Investigational medicinal product name	Venetoclax
Investigational medicinal product code	ABT 199
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Patients will receive the first dosage of venetoclax on day 22 of cycle 1. The daily intake of venetoclax starts with a weekly dose ramp-up to final dose

Venetoclax p.o.:

Cycle 1:

Days 22-28: venetoclax 20 mg (2 tabl. at 10 mg)

Cycle 2:

Days 1-7: venetoclax 50 mg (1 tabl. at 50 mg)

Days 8-14: venetoclax 100 mg (1 tabl. at 100 mg)

Days 15-21: venetoclax 200 mg (2 tabl. at 100 mg)

Days 22-28: venetoclax 400 mg (4 tabl. at 100 mg)

Cycles 3-12:

Days 1-28: venetoclax 400 mg (4 tabl. at 100 mg)

Due to the risk of adverse events, especially tumor-lysis-syndromes (TLS), the dose of venetoclax will be increased slowly every week until the final dose of 400 mg is reached (ramp-up). In order to diagnose a TLS at an early stage certain safety measures as specified in the study protocol must be followed.

On days with administration of both, venetoclax and obinutuzumab, oral intake of venetoclax will be followed by intravenous administration of obinutuzumab.

Investigational medicinal product name	Obinutuzumab
Investigational medicinal product code	GA 101
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Patients will receive obinutuzumab infusions on days 1 (and 2), 8 and 15 during the first cycle, as well as on day 1 of cycles 2-6.

Obinutuzumab i.v. infusion:

Cycle 1:

Day 1: obinutuzumab 100 mg

Day 1 (or 2): obinutuzumab 900 mg

Day 8: obinutuzumab 1000 mg

Day 15: obinutuzumab 1000 mg

Cycles 2-6:

Day 1: obinutuzumab1000 mg

The first infusion of obinutuzumab may be administered at the full dose (1000 mg) on day 1 of the first cycle if the infusion of a test-dosage of 100 mg is well tolerated by the patient. Alternatively, if the first 100mg infusion on day 1 is not tolerated well, the remaining 900 mg of the first dose should be administered on day 2.

Arm title	Venetoclax, obinutuzumab, ibrutinib (GIVe)
Arm description: The GIVe treatment consists of 12 cycles (ibrutinib might be given up to 36 cycles), each with a precise duration of 28 days.	
Arm type	Experimental
Investigational medicinal product name	Venetoclax
Investigational medicinal product code	ABT 199
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Patients will receive the first dosage of venetoclax on day 22 of cycle 1. The daily intake of venetoclax starts with a weekly dose ramp-up to final dose.

Venetoclax p.o.:

Cycle 1:

Days 22-28: 20 mg (2 tabl. at 10 mg)

Cycle 2:

Days 1-7: 50 mg (1 tabl. at 50 mg)

Days 8-14: 100 mg (1 tabl. at 100 mg)

Days 15-21: 200 mg (2 tabl. at 100 mg)

Days 22-28: 400 mg (4 tabl. at 100 mg)

Cycles 3-12:

Days 1-28: 400 mg (4 tabl. at 100 mg)

Due to the risk of adverse events, especially tumor-lysis-syndromes (TLS), the dose of venetoclax will be increased slowly every week until the final dose of 400 mg is reached (ramp-up). In order to diagnose a TLS at an early stage certain safety measures as specified in the study protocol must be followed. On days with administration of more than one study drug, oral intake of ibrutinib (before breakfast) will be followed by oral intake of venetoclax (during breakfast), at least iv administration of obinutuzumab will take place if applicable.

Investigational medicinal product name	Obinutuzumab
Investigational medicinal product code	GA 101
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Patients will receive obinutuzumab infusions on days 1 (and 2), 8 and 15 during the first cycle, as well as on day 1 of cycles 2-6.

obinutuzumab i.v. infusion:

Cycle 1:

Day 1: obinutuzumab 100 mg

Day 1 (or 2): obinutuzumab 900 mg

Day 8: obinutuzumab 1000 mg

Day 15: obinutuzumab 1000 mg

Cycles 2-6:

Day 1: obinutuzumab1000 mg

Investigational medicinal product name	Ibrutinib
Investigational medicinal product code	PCI-32765
Other name	
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

Dosage and administration details:

Patients will receive ibrutinib as a daily oral dosage of 420 mg starting on cycle 1 day 1 until MRD negativity (i.e. < 10⁻⁴) in peripheral blood and confirmed by a bone marrow aspirate or by two consecutive peripheral blood samples (cycle 9/12 or 12/15; all other patients will continue treatment) or 36 months of treatment are reached.

Ibrutinib p.o.:

Cycles 1-12:

Days 1-28: 420mg daily

Cycles 13-36:

Days 1-28: ibrutinib 420 mg daily

Number of subjects in period 1	Standard chemoimmunotherapy (SCIT)	Venetoclax, rituximab (RVe)	Venetoclax, obinutuzumab (GVe)
Started	229	237	229
Completed	176	219	214
Not completed	53	18	15
Adverse event, non-fatal	32	11	9
Death	-	1	1
Non-compliance	2	-	1
Progressive disease	2	4	3
Did not receive any study treatment	13	-	1
other reason	4	2	-

Number of subjects in period 1	Venetoclax, obinutuzumab, ibrutinib (GIVe)
Started	231
Completed	199
Not completed	32
Adverse event, non-fatal	27
Death	2
Non-compliance	-
Progressive disease	-
Did not receive any study treatment	-
other reason	3

Baseline characteristics

Reporting groups

Reporting group title	Standard chemoimmunotherapy (SCIT)
-----------------------	------------------------------------

Reporting group description:

The SCIT treatment consists of 6 cycles, each with a precise duration of 28 days.
 Patients ≤ 65 years will receive 6 cycles of fludarabine, cyclophosphamide and rituximab (FCR).
 Patients > 65 years will receive 6 cycles of bendamustine and rituximab (BR).

Reporting group title	Venetoclax, rituximab (RVe)
-----------------------	-----------------------------

Reporting group description:

The RVe treatment consists of 12 cycles, each with a precise duration of 28 days.

Reporting group title	Venetoclax, obinutuzumab (GVe)
-----------------------	--------------------------------

Reporting group description:

The GVe treatment consists of 12 cycles, each with a precise duration of 28 days.

Reporting group title	Venetoclax, obinutuzumab, ibrutinib (GIVe)
-----------------------	--

Reporting group description:

The GIVe treatment consists of 12 cycles (ibrutinib might be given up to 36 cycles), each with a precise duration of 28 days.

Reporting group values	Standard chemoimmunotherapy (SCIT)	Venetoclax, rituximab (RVe)	Venetoclax, obinutuzumab (GVe)
Number of subjects	229	237	229
Age categorical Units: Subjects			
Adults (18-64 years)	145	141	139
From 65-84 years	84	96	90
85 years and over	0	0	0
Gender categorical Units: Subjects			
Female	66	62	58
Male	163	175	171
Country Units: Subjects			
Germany	85	85	81
Denmark	25	31	25
Netherlands	43	47	49
Sweden	14	13	17
Switzerland	21	21	21
Belgium	12	7	5
Austria	8	9	11
Finland	6	4	5
Ireland	8	9	10
Israel	7	11	5
Binet stage Units: Subjects			
Binet A	63	61	58
Binet B	84	92	91
Binet C	82	84	80
IGHV mutational status Units: Subjects			

unmutated	131	134	130
mutated	95	95	89
not evaluable	3	8	9
missing information	0	0	1
CLL-IPI risk group Units: Subjects			
low	36	39	32
intermediate	67	66	76
high	122	123	109
very high	0	0	0
missing information	4	9	12
Complex karyotype Units: Subjects			
< 3 aberrations	177	187	182
≥ 3 and < 5 aberrations	30	34	25
≥ 5 aberrations	16	10	11
missing information	6	6	11
Binet stage used for stratification Units: Subjects			
Binet A	61	62	60
Binet B	85	90	90
Binet C	83	85	79

Reporting group values	Venetoclax, obinutuzmab, ibrutinib (GIVe)	Total	
Number of subjects	231	926	
Age categorical Units: Subjects			
Adults (18-64 years)	139	564	
From 65-84 years	92	362	
85 years and over	0	0	
Gender categorical Units: Subjects			
Female	73	259	
Male	158	667	
Country Units: Subjects			
Germany	82	333	
Denmark	32	113	
Netherlands	46	185	
Sweden	9	53	
Switzerland	19	82	
Belgium	7	31	
Austria	8	36	
Finland	6	21	
Ireland	11	38	
Israel	11	34	
Binet stage Units: Subjects			
Binet A	63	245	
Binet B	84	351	

Binet C	84	330	
IGHV mutational status Units: Subjects			
unmutated	123	518	
mutated	101	380	
not evaluable	7	27	
missing information	0	1	
CLL-IPI risk group Units: Subjects			
low	36	143	
intermediate	85	294	
high	101	455	
very high	0	0	
missing information	9	34	
Complex karyotype Units: Subjects			
< 3 aberrations	196	742	
≥ 3 and < 5 aberrations	21	110	
≥ 5 aberrations	6	43	
missing information	8	31	
Binet stage used for stratification Units: Subjects			
Binet A	63	246	
Binet B	84	349	
Binet C	84	331	

End points

End points reporting groups

Reporting group title	Standard chemoimmunotherapy (SCIT)
Reporting group description: The SCIT treatment consists of 6 cycles, each with a precise duration of 28 days. Patients ≤ 65 years will receive 6 cycles of fludarabine, cyclophosphamide and rituximab (FCR). Patients > 65 years will receive 6 cycles of bendamustine and rituximab (BR).	
Reporting group title	Venetoclax, rituximab (RVe)
Reporting group description: The RVe treatment consists of 12 cycles, each with a precise duration of 28 days.	
Reporting group title	Venetoclax, obinutuzumab (GVe)
Reporting group description: The GVe treatment consists of 12 cycles, each with a precise duration of 28 days.	
Reporting group title	Venetoclax, obinutuzumab, ibrutinib (GIVe)
Reporting group description: The GIVe treatment consists of 12 cycles (ibrutinib might be given up to 36 cycles), each with a precise duration of 28 days.	

Primary: Progression free survival (PFS) [GIVe versus SCIT]

End point title	Progression free survival (PFS) [GIVe versus SCIT] ^[1]
End point description: One co-primary efficacy endpoint is the investigator-assessed PFS, defined as the time from randomization to the first occurrence of progression or relapse (determined using standard IWCLL guidelines [2008]), or death from any cause, whichever occurs first. For patients who have not progressed, relapsed, or died at the time of analysis, PFS will be censored on the date of the last tumor assessment. In case of initiation of subsequent anti-leukemic treatment without documented disease progression patient will be censored at last tumor assessment prior to start of subsequent therapy. If no tumor assessments were performed after the screening visit, PFS will be censored at the time of randomization + 1 day. Median PFS and the 97.5% CI will be estimated using Kaplan-Meier survival methodology, with the Kaplan-Meier survival curve presented to provide a visual description. PFS rates for 1, 2 and 3 years etc. after randomization will be reported.	
End point type	Primary
End point timeframe: Data will be collected from randomization until last visit of each study subject.	

Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The statistics for the comparisons of the other arms are reported in a separate endpoint as only the comparison between GIVE versus SCIT was considered as primary endpoint in this analysis. The other comparisons are considered as secondary endpoint and are reported as secondary endpoint accordingly.

End point values	Standard chemoimmunotherapy (SCIT)	Venetoclax, obinutuzumab, ibrutinib (GIVe)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	229	231 ^[2]		
Units: Percentage				
number (not applicable)				
1-year survival	93.4	98.3		
2-year survival	82.6	96.1		

3-year survival	75.9	91.3		
4-year survival	60.8	85.9		
5-year survival	50.7	81.3		
Median PFS (months)	61.2	0		

Notes:

[2] - Median PFS was not reached in this subgroup

Statistical analyses

Statistical analysis title	Two-sided stratified log-rank test (GIVe vs SCIT)
Statistical analysis description:	
PFS treatment comparison of GIVe and SCIT will be performed using a two-sided stratified log-rank test (considering the stratification factors age (with a cut-off of 65 years) and Binet stage). The co-primary endpoint PFS [GIVe vs. SCIT] has been formally tested during the "interim analysis of the co-primary endpoint PFS" with the data cut-off 2022.01.20. There is no alpha spend in the current analysis of the co-primary endpoint [PFS: GIVe vs. SCIT].	
Comparison groups	Standard chemoimmunotherapy (SCIT) v Venetoclax, obinutuzmab, ibrutinib (GIVe)
Number of subjects included in analysis	460
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Logrank

Statistical analysis title	Cox regression (GIVe vs SCIT)
Statistical analysis description:	
Estimates of the treatment effect will be expressed as HR including 97.5% CI estimated through a stratified Cox proportional hazards analysis (considering the stratification factors age (with a cut-off of 65 years) and Binet stage).	
Comparison groups	Standard chemoimmunotherapy (SCIT) v Venetoclax, obinutuzmab, ibrutinib (GIVe)
Number of subjects included in analysis	460
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Cox proportional hazard
Point estimate	0.344
Confidence interval	
level	Other: 97.5 %
sides	2-sided
lower limit	0.235
upper limit	0.503

Primary: MRD negativity in peripheral blood at month 15 [GIVe versus SCIT]

End point title	MRD negativity in peripheral blood at month 15 [GIVe versus SCIT] ^[3]
-----------------	--

End point description:

One co-primary objective of the study is to assess the MRD negativity rate. MRD negativity is defined as <1 CLL-cell among 10,000 leukocytes analyzed [0.01%], i.e. < 10⁻⁴. Values above [≥10⁻⁴] will be considered as MRD positive.

The MRD negativity rate in PB at MO 15 is defined as the proportion of MRD negative patients at MO 15 based on the ITT population (= number of MRD negative patients divided by the number of the ITT population). Patients without an MRD sample in peripheral blood at MO 15 will be counted as MRD positive patients.

End point type	Primary
End point timeframe:	15 months after start of treatment.

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The statistics for the comparisons of the other arms are reported in a separate endpoint as only the comparison between GVE versus SCIT was considered as primary endpoint in this analysis. The other comparisons are considered as secondary endpoint and are reported as secondary endpoint accordingly.

End point values	Standard chemoimmunotherapy (SCIT)	Venetoclax, rituximab (RVE)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	229	229		
Units: percentage				
number (confidence interval 97.5%)				
MRD negativity rate	52 (44.4 to 59.5)	86.5 (80.6 to 91.1)		

Statistical analyses

Statistical analysis title	Cochran-Mantel-Haenszel test (GVE vs SCIT)
----------------------------	--

Statistical analysis description:

MRD negativity rate of GVE and SCIT will be compared using Cochran-Mantel-Haenszel test stratified by age (with a cut-off of 65 years) and Binet stage. The co-primary endpoint MRD in PB at MO15 [GVE vs. SCIT] has been formally tested during the "co-primary endpoint analysis of MRD negativity rate at month 15" with the data cut-off 2021.02.28. There is no alpha spend in the current analysis of the co-primary endpoint [MRD in PB at MO15: GVE vs. SCIT].

Comparison groups	Standard chemoimmunotherapy (SCIT) v Venetoclax, rituximab (RVE)
Number of subjects included in analysis	458
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Cochran-Mantel-Haenszel

Secondary: Overall survival (OS)

End point title	Overall survival (OS)
-----------------	-----------------------

End point description:

Overall survival will be measured from the date of randomization to the date of death due to any cause. Patients who have not yet died at the time of analysis will be censored at the time of last observation they were assessed to be alive.

End point type	Secondary
----------------	-----------

End point timeframe:

Data for this endpoint will be collected from the date of randomization until last visit of each study

End point values	Standard chemoimmunotherapy (SCIT)	Venetoclax, rituximab (RVe)	Venetoclax, obinutuzumab (GVe)	Venetoclax, obinutuzumab, ibrutinib (GIVe)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	229 ^[4]	237 ^[5]	229 ^[6]	231 ^[7]
Units: percent				
number (not applicable)				
1-year survival	99.1	97.9	99.1	98.7
2-year survival	98.6	97.9	98.2	97
3-year survival	95.7	96.6	96.5	95.6
4-year survival	93.8	96.2	95.2	94.7
5-year survival	90.7	94.7	93.6	94.3
Median OS (months)	0	0	0	0

Notes:

[4] - Median OS was not reached in this subgroup

[5] - Median OS was not reached in this subgroup

[6] - Median OS was not reached in this subgroup

[7] - Median OS was not reached in this subgroup

Statistical analyses

Statistical analysis title	Two-sided log-rank test (GIVe vs SCIT)
Statistical analysis description:	
Treatment comparison for the secondary efficacy parameter OS will be performed using a two-sided non-stratified log-rank test. There is no alpha spend in the analysis of secondary endpoints.	
Comparison groups	Standard chemoimmunotherapy (SCIT) v Venetoclax, obinutuzumab, ibrutinib (GIVe)
Number of subjects included in analysis	460
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.175
Method	Logrank

Statistical analysis title	Cox proportional hazards analysis (GIVe vs SCIT)
Statistical analysis description:	
Estimates of the treatment effect will be expressed by the hazard ratio (HR) including the 97.5% confidence interval estimated through a non-stratified Cox proportional hazard regression model.	
Comparison groups	Venetoclax, obinutuzumab, ibrutinib (GIVe) v Standard chemoimmunotherapy (SCIT)
Number of subjects included in analysis	460
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Cox proportional hazard
Point estimate	0.617

Confidence interval	
level	Other: 97.5 %
sides	2-sided
lower limit	0.275
upper limit	1.382

Statistical analysis title	Two-sided log-rank test (GVe vs SCIT)
-----------------------------------	---------------------------------------

Statistical analysis description:

Treatment comparison for the secondary efficacy parameter OS will be performed using a two-sided non-stratified log-rank test. There is no alpha spend in the analysis of secondary endpoints.

Comparison groups	Standard chemoimmunotherapy (SCIT) v Venetoclax, obinutuzumab (GVe)
Number of subjects included in analysis	458
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.423
Method	Logrank

Statistical analysis title	Cox proportional hazards analysis (GVe vs SCIT)
-----------------------------------	---

Statistical analysis description:

Estimates of the treatment effect will be expressed by the hazard ratio (HR) including the 97.5% confidence interval estimated through a non-stratified Cox proportional hazard regression model.

Comparison groups	Venetoclax, obinutuzumab (GVe) v Standard chemoimmunotherapy (SCIT)
Number of subjects included in analysis	458
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Cox proportional hazard
Point estimate	0.762
Confidence interval	
level	Other: 97.5 %
sides	2-sided
lower limit	0.356
upper limit	1.631

Statistical analysis title	Two-sided log-rank test (RVe vs SCIT)
-----------------------------------	---------------------------------------

Statistical analysis description:

Treatment comparison for the secondary efficacy parameter OS will be performed using a two-sided non-stratified log-rank test. There is no alpha spend in the analysis of secondary endpoints.

Comparison groups	Standard chemoimmunotherapy (SCIT) v Venetoclax, rituximab (RVe)
-------------------	--

Number of subjects included in analysis	466
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.255
Method	Logrank

Statistical analysis title	Cox proportional hazards analysis (RvE vs SCIT)
-----------------------------------	---

Statistical analysis description:

Estimates of the treatment effect will be expressed by the hazard ratio (HR) including the 97.5% confidence interval estimated through a non-stratified Cox proportional hazard regression model.

Comparison groups	Standard chemoimmunotherapy (SCIT) v Venetoclax, rituximab (RvE)
Number of subjects included in analysis	466
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Cox proportional hazard
Point estimate	0.676
Confidence interval	
level	Other: 97.5 %
sides	2-sided
lower limit	0.312
upper limit	1.468

Statistical analysis title	Two-sided log-rank test (GIVe vs GVe)
-----------------------------------	---------------------------------------

Statistical analysis description:

Treatment comparison for the secondary efficacy parameter OS will be performed using a two-sided non-stratified log-rank test. There is no alpha spend in the analysis of secondary endpoints.

Comparison groups	Venetoclax, obinutuzumab (GVe) v Venetoclax, obinutuzumab, ibrutinib (GIVe)
Number of subjects included in analysis	460
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.564
Method	Logrank

Statistical analysis title	Cox proportional hazards analysis (GIVe vs GVe)
-----------------------------------	---

Statistical analysis description:

Estimates of the treatment effect will be expressed by the hazard ratio (HR) including the 97.5% confidence interval estimated through a non-stratified Cox proportional hazard regression model.

Comparison groups	Venetoclax, obinutuzumab (GVe) v Venetoclax, obinutuzumab, ibrutinib (GIVe)
-------------------	---

Number of subjects included in analysis	460
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Cox proportional hazard
Point estimate	0.806
Confidence interval	
level	Other: 97.5 %
sides	2-sided
lower limit	0.349
upper limit	1.862

Statistical analysis title	Two-sided log-rank test (GVe vs RVe)
Statistical analysis description: Treatment comparison for the secondary efficacy parameter OS will be performed using a two-sided non-stratified log-rank test. There is no alpha spend in the analysis of secondary endpoints.	
Comparison groups	Venetoclax, obinutuzumab (GVe) v Venetoclax, rituximab (RVe)
Number of subjects included in analysis	466
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.678
Method	Logrank

Statistical analysis title	Cox proportional hazards analysis (GVe vs RVe)
Statistical analysis description: Estimates of the treatment effect will be expressed by the hazard ratio (HR) including the 97.5% confidence interval estimated through a non-stratified Cox proportional hazard regression model.	
Comparison groups	Venetoclax, obinutuzumab (GVe) v Venetoclax, rituximab (RVe)
Number of subjects included in analysis	466
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Cox proportional hazard
Point estimate	1.162
Confidence interval	
level	Other: 97.5 %
sides	2-sided
lower limit	0.517
upper limit	2.613

Statistical analysis title	Two-sided log-rank test (GIVe vs RVe)
Statistical analysis description: Treatment comparison for the secondary efficacy parameter OS will be performed using a two-sided non-stratified log-rank test. There is no alpha spend in the analysis of secondary endpoints.	
Comparison groups	Venetoclax, obinutuzumab, ibrutinib (GIVe) v Venetoclax, rituximab (RVe)

Number of subjects included in analysis	468
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.784
Method	Logrank

Statistical analysis title	Cox proportional hazards analysis (GIVe vs RVe)
-----------------------------------	---

Statistical analysis description:

Estimates of the treatment effect will be expressed by the hazard ratio (HR) including the 97.5% confidence interval estimated through a non-stratified Cox proportional hazard regression model.

Comparison groups	Venetoclax, obinutuzmab, ibrutinib (GIVe) v Venetoclax, rituximab (RVe)
Number of subjects included in analysis	468
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Cox proportional hazard
Point estimate	0.901
Confidence interval	
level	Other: 97.5 %
sides	2-sided
lower limit	0.385
upper limit	2.108

Secondary: Time to next treatment (TTNT)

End point title	Time to next treatment (TTNT)
-----------------	-------------------------------

End point description:

TTNT will be measured from the date of randomization until the date of first anti-leukemic treatment. Patients for whom no subsequent anti-leukemic treatment is documented will be censored at the time of last observation they were assessed to be free from subsequent treatment.

End point type	Secondary
----------------	-----------

End point timeframe:

Data for this endpoint will be collected from the date of randomization until last visit of each study subject.

End point values	Standard chemoimmunotherapy (SCIT)	Venetoclax, rituximab (RVe)	Venetoclax, obinutuzumab (GVe)	Venetoclax, obinutuzumab, ibrutinib (GIVe)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	229 ^[8]	237 ^[9]	229 ^[10]	231 ^[11]
Units: percent				
number (not applicable)				
1-year survival	97.7	97.9	98.7	100
2-year survival	93.4	95.3	97.8	100
3-year survival	87.1	91.8	94.6	98.6
4-year survival	77.5	83.9	90	95.4

5-year survival	67.1	77.1	87.5	92.6
Median months	0	0	0	0

Notes:

[8] - Median TTNT was not reached in this subgroup

[9] - Median TTNT was not reached in this subgroup

[10] - Median TTNT was not reached in this subgroup

[11] - Median TTNT was not reached in this subgroup

Statistical analyses

Statistical analysis title	Two-sided log-rank test (GIVe vs SCIT)
-----------------------------------	--

Statistical analysis description:

Treatment comparison for the secondary efficacy parameter TTNT will be performed using a two-sided non-stratified log-rank test. There is no alpha spend in the analysis of secondary endpoints.

Comparison groups	Standard chemoimmunotherapy (SCIT) v Venetoclax, obinutuzumab, ibrutinib (GIVe)
Number of subjects included in analysis	460
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.0001
Method	Logrank

Statistical analysis title	Cox proportional hazards analysis (GIVe vs SCIT)
-----------------------------------	--

Statistical analysis description:

Estimates of the treatment effect will be expressed by the hazard ratio (HR) including the 97.5% confidence interval estimated through a non-stratified Cox proportional hazard regression model.

Comparison groups	Standard chemoimmunotherapy (SCIT) v Venetoclax, obinutuzumab, ibrutinib (GIVe)
Number of subjects included in analysis	460
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Cox proportional hazard
Point estimate	0.218
Confidence interval	
level	Other: 97.5 %
sides	2-sided
lower limit	0.123
upper limit	0.386

Statistical analysis title	Two-sided log-rank test (GVe vs SCIT)
-----------------------------------	---------------------------------------

Statistical analysis description:

Treatment comparison for the secondary efficacy parameter TTNT will be performed using a two-sided non-stratified log-rank test. There is no alpha spend in the analysis of secondary endpoints.

Comparison groups	Venetoclax, obinutuzumab (GVe) v Standard chemoimmunotherapy (SCIT)
-------------------	---

Number of subjects included in analysis	458
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.0001
Method	Logrank

Statistical analysis title	Cox proportional hazards analysis (GVe vs SCIT)
-----------------------------------	---

Statistical analysis description:

Estimates of the treatment effect will be expressed by the hazard ratio (HR) including the 97.5% confidence interval estimated through a non-stratified Cox proportional hazard regression model.

Comparison groups	Standard chemoimmunotherapy (SCIT) v Venetoclax, obinutuzumab (GVe)
Number of subjects included in analysis	458
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Cox proportional hazard
Point estimate	0.429
Confidence interval	
level	Other: 97.5 %
sides	2-sided
lower limit	0.273
upper limit	0.676

Statistical analysis title	Two-sided log-rank test (RVe vs SCIT)
-----------------------------------	---------------------------------------

Statistical analysis description:

Treatment comparison for the secondary efficacy parameter TTNT will be performed using a two-sided non-stratified log-rank test. There is no alpha spend in the analysis of secondary endpoints.

Comparison groups	Venetoclax, rituximab (RVe) v Standard chemoimmunotherapy (SCIT)
Number of subjects included in analysis	466
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.204
Method	Logrank

Statistical analysis title	Cox proportional hazards analysis (RVe vs SCIT)
-----------------------------------	---

Statistical analysis description:

Estimates of the treatment effect will be expressed by the hazard ratio (HR) including the 97.5% confidence interval estimated through a non-stratified Cox proportional hazard regression model.

Comparison groups	Standard chemoimmunotherapy (SCIT) v Venetoclax, rituximab (RVe)
-------------------	--

Number of subjects included in analysis	466
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Cox proportional hazard
Point estimate	0.806
Confidence interval	
level	Other: 97.5 %
sides	2-sided
lower limit	0.55
upper limit	1.181

Statistical analysis title	Two-sided log-rank test (GIVe vs GVe)
-----------------------------------	---------------------------------------

Statistical analysis description:

Treatment comparison for the secondary efficacy parameter TTNT will be performed using a two-sided non-stratified log-rank test. There is no alpha spend in the analysis of secondary endpoints.

Comparison groups	Venetoclax, obinutuzumab (GVe) v Venetoclax, obinutuzumab, ibrutinib (GIVE)
Number of subjects included in analysis	460
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.01
Method	Logrank

Statistical analysis title	Cox proportional hazards analysis (GIVe vs GVe)
-----------------------------------	---

Statistical analysis description:

Estimates of the treatment effect will be expressed by the hazard ratio (HR) including the 97.5% confidence interval estimated through a non-stratified Cox proportional hazard regression model.

Comparison groups	Venetoclax, obinutuzumab, ibrutinib (GIVE) v Venetoclax, obinutuzumab (GVe)
Number of subjects included in analysis	460
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Cox proportional hazard
Point estimate	0.498
Confidence interval	
level	Other: 97.5 %
sides	2-sided
lower limit	0.268
upper limit	0.925

Statistical analysis title	Two-sided log-rank test (GVe vs RVe)
-----------------------------------	--------------------------------------

Statistical analysis description:

Treatment comparison for the secondary efficacy parameter TTNT will be performed using a two-sided non-stratified log-rank test. There is no alpha spend in the analysis of secondary endpoints.

Comparison groups	Venetoclax, obinutuzumab (GVe) v Venetoclax, rituximab (RVe)
-------------------	--

Number of subjects included in analysis	466
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0014
Method	Logrank

Statistical analysis title	Cox proportional hazards analysis (GVe vs RVe)
-----------------------------------	--

Statistical analysis description:

Estimates of the treatment effect will be expressed by the hazard ratio (HR) including the 97.5% confidence interval estimated through a non-stratified Cox proportional hazard regression model.

Comparison groups	Venetoclax, rituximab (Rve) v Venetoclax, obinutuzumab (Gve)
Number of subjects included in analysis	466
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Cox proportional hazard
Point estimate	0.529
Confidence interval	
level	Other: 97.5 %
sides	2-sided
lower limit	0.337
upper limit	0.833

Statistical analysis title	Two-sided log-rank test (GIVE vs RVE)
-----------------------------------	---------------------------------------

Statistical analysis description:

Treatment comparison for the secondary efficacy parameter TTNT will be performed using a two-sided non-stratified log-rank test. There is no alpha spend in the analysis of secondary endpoints.

Comparison groups	Venetoclax, rituximab (Rve) v Venetoclax, obinutuzumab, ibrutinib (GIVE)
Number of subjects included in analysis	468
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.0001
Method	Logrank

Statistical analysis title	Cox proportional hazards analysis (GIVE vs RVE)
-----------------------------------	---

Statistical analysis description:

Estimates of the treatment effect will be expressed by the hazard ratio (HR) including the 97.5% confidence interval estimated through a non-stratified Cox proportional hazard regression model.

Comparison groups	Venetoclax, rituximab (Rve) v Venetoclax, obinutuzumab, ibrutinib (GIVE)
-------------------	--

Number of subjects included in analysis	468
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Cox proportional hazard
Point estimate	0.266
Confidence interval	
level	Other: 97.5 %
sides	2-sided
lower limit	0.151
upper limit	0.471

Secondary: Response rate at month 15

End point title	Response rate at month 15
End point description:	
The overall response rate (ORR) will be defined as the proportion of patients having achieved a CR/CRi, clinical CR/CRi or PR (including PR with lymphocytosis) (according to the iwCLL guidelines (2008)) at MO 15 (= number of patients with response CR/CRi, clinical CR/CRi or PR (with or without lymphocytosis) divided by the ITT population).	
End point type	Secondary
End point timeframe:	
15 months after start of treatment.	

End point values	Standard chemoimmunotherapy (SCIT)	Venetoclax, rituximab (RVe)	Venetoclax, obinutuzumab (GVe)	Venetoclax, obinutuzumab, ibrutinib (GIVe)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	229	237	229	231
Units: Patients				
CR	73	112	124	128
CRi	9	2	4	9
Clinical CR	51	29	21	24
Clinical CRi	5	0	3	4
PR	47	78	68	53
SD	3	0	0	0
PD	7	1	2	1
Missing	34	15	7	12

Statistical analyses

No statistical analyses for this end point

Secondary: PFS (all other comparisons except for [GIVe versus SCIT])

End point title	PFS (all other comparisons except for [GIVe versus SCIT])
-----------------	---

End point description:

Progression-free survival is defined as the time from randomization to the first occurrence of progression or relapse (determined using standard IWCLL guidelines [2008]), or death from any cause, whichever occurs first. For patients who have not progressed, relapsed, or died at the time of analysis, PFS will be censored on the date of the last tumor assessment. In case of initiation of subsequent anti-leukemic treatment without documented disease progression patient will be censored at last tumor assessment prior to start of subsequent therapy. If no tumor assessments were performed after the screening visit, PFS will be censored at the time of randomization + 1 day.

Median PFS and the 97.5% CI will be estimated using Kaplan-Meier survival methodology, with the Kaplan-Meier survival curve presented to provide a visual description. PFS rates for 1, 2 and 3 years etc. after randomization will be reported.

End point type	Secondary
----------------	-----------

End point timeframe:

Data will be collected from randomization until last visit of each study subject

End point values	Standard chemoimmunotherapy (SCIT)	Venetoclax, rituximab (RVe)	Venetoclax, obinutuzumab (GVe)	Venetoclax, obinutuzumab, ibrutinib (GIVe)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	229	237	229 ^[12]	231 ^[13]
Units: percent				
number (not applicable)				
1-year survival	93.4	96.6	97.4	98.3
2-year survival	82.6	91.9	92.5	96.1
3-year survival	75.9	80.7	88.6	91.3
4-year survival	60.8	71.1	81.9	85.9
5-year survival	50.7	57.4	69.8	81.3
Median PFS (months)	61.2	64.5	0	0

Notes:

[12] - Median PFS was not reached in this subgroup

[13] - Median PFS was not reached in this subgroup

Statistical analyses

Statistical analysis title	Two-sided log-rank test (GVe vs SCIT)
-----------------------------------	---------------------------------------

Statistical analysis description:

PFS treatment comparisons will be performed using two-sided stratified log-rank tests (considering the stratification factors age (with a cut-off of 65 years) and Binet stage). There is no alpha spend in the current analysis of the co-primary endpoint of PFS.

Comparison groups	Venetoclax, obinutuzumab (GVe) v Standard chemoimmunotherapy (SCIT)
Number of subjects included in analysis	458
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.0001
Method	Logrank

Statistical analysis title	Cox proportional hazards analysis (GVe vs SCIT)
-----------------------------------	---

Statistical analysis description:

Estimates of the treatment effect will be expressed as HR including 97.5% CI estimated through a stratified Cox proportional hazards analysis (considering the stratification factors age (with a cut-off of 65 years) and Binet stage).

Comparison groups	Standard chemoimmunotherapy (SCIT) v Venetoclax, obinutuzumab (GVe)
Number of subjects included in analysis	458
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Cox proportional hazard
Point estimate	0.544
Confidence interval	
level	Other: 97.5 %
sides	2-sided
lower limit	0.389
upper limit	0.761

Statistical analysis title	Two-sided log-rank test (RVe vs SCIT)
-----------------------------------	---------------------------------------

Statistical analysis description:

PFS treatment comparisons will be performed using two-sided stratified log-rank tests (considering the stratification factors age (with a cut-off of 65 years) and Binet stage). There is no alpha spend in the current analysis of the co-primary endpoint of PFS.

Comparison groups	Standard chemoimmunotherapy (SCIT) v Venetoclax, rituximab (RVe)
Number of subjects included in analysis	466
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.53
Method	Logrank

Statistical analysis title	Cox proportional hazards analysis (RVe vs SCIT)
-----------------------------------	---

Statistical analysis description:

Estimates of the treatment effect will be expressed as HR including 97.5% CI estimated through a stratified Cox proportional hazards analysis (considering the stratification factors age (with a cut-off of 65 years) and Binet stage).

Comparison groups	Standard chemoimmunotherapy (SCIT) v Venetoclax, rituximab (RVe)
Number of subjects included in analysis	466
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Cox proportional hazard
Point estimate	0.919
Confidence interval	
level	Other: 97.5 %
sides	2-sided
lower limit	0.681
upper limit	1.241

Statistical analysis title	Two-sided log-rank test (GIVe vs GVe)
Statistical analysis description:	
PFS treatment comparisons will be performed using two-sided stratified log-rank tests (considering the stratification factors age (with a cut-off of 65 years) and Binet stage). There is no alpha spend in the current analysis of the co-primary endpoint of PFS.	
Comparison groups	Venetoclax, obinutuzumab (GVe) v Venetoclax, obinutuzmab, ibrutinib (GIVe)
Number of subjects included in analysis	460
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0046
Method	Logrank

Statistical analysis title	Cox proportional hazards analysis (GIVe vs GVe)
Statistical analysis description:	
Estimates of the treatment effect will be expressed as HR including 97.5% CI estimated through a stratified Cox proportional hazards analysis (considering the stratification factors age (with a cut-off of 65 years) and Binet stage).	
Comparison groups	Venetoclax, obinutuzumab (GVe) v Venetoclax, obinutuzmab, ibrutinib (GIVe)
Number of subjects included in analysis	460
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Cox proportional hazard
Point estimate	0.607
Confidence interval	
level	Other: 97.5 %
sides	2-sided
lower limit	0.407
upper limit	0.905

Statistical analysis title	Two-sided log-rank test (GVe vs RVe)
Statistical analysis description:	
PFS treatment comparisons will be performed using two-sided stratified log-rank tests (considering the stratification factors age (with a cut-off of 65 years) and Binet stage). There is no alpha spend in the current analysis of the co-primary endpoint of PFS.	
Comparison groups	Venetoclax, obinutuzumab (GVe) v Venetoclax, rituximab (RVe)
Number of subjects included in analysis	466
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.00019
Method	Logrank

Statistical analysis title	Cox proportional hazards analysis (GVe vs RVe)
Statistical analysis description:	
Estimates of the treatment effect will be expressed as HR including 97.5% CI estimated through a stratified Cox proportional hazards analysis (considering the stratification factors age (with a cut-off of 65 years) and Binet stage).	
Comparison groups	Venetoclax, obinutuzumab (GVe) v Venetoclax, rituximab (RVe)
Number of subjects included in analysis	466
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Cox proportional hazard
Point estimate	0.586
Confidence interval	
level	Other: 97.5 %
sides	2-sided
lower limit	0.424
upper limit	0.811

Statistical analysis title	Two-sided log-rank test (GIVe vs RVe)
Statistical analysis description:	
PFS treatment comparisons will be performed using two-sided stratified log-rank tests (considering the stratification factors age (with a cut-off of 65 years) and Binet stage). There is no alpha spend in the current analysis of the co-primary endpoint of PFS.	
Comparison groups	Venetoclax, obinutuzumab, ibrutinib (GIVe) v Venetoclax, rituximab (RVe)
Number of subjects included in analysis	468
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.0001
Method	Logrank

Statistical analysis title	Cox proportional hazards analysis (GIVe vs RVe)
Statistical analysis description:	
Estimates of the treatment effect will be expressed as HR including 97.5% CI estimated through a stratified Cox proportional hazards analysis (considering the stratification factors age (with a cut-off of 65 years) and Binet stage).	
Comparison groups	Venetoclax, obinutuzumab, ibrutinib (GIVe) v Venetoclax, rituximab (RVe)
Number of subjects included in analysis	468
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Cox proportional hazard
Point estimate	0.347
Confidence interval	
level	Other: 97.5 %
sides	2-sided
lower limit	0.238
upper limit	0.506

Secondary: MRD negativity in peripheral blood at month 15 (except for [GVe versus SCIT])

End point title	MRD negativity in peripheral blood at month 15 (except for [GVe versus SCIT])
-----------------	---

End point description:

MRD negativity is defined as <1 CLL-cell among 10,000 leukocytes analyzed [0.01%], i.e. < 10⁻⁴. Values above [$\geq 10^{-4}$] will be considered as MRD positive.

The MRD negativity rate in PB at MO 15 is defined as the proportion of MRD negative patients at MO 15 based on the ITT population (= number of MRD negative patients divided by the number of the ITT population). Patients without an MRD sample in peripheral blood at MO 15 will be counted as MRD positive patients.

End point type	Secondary
----------------	-----------

End point timeframe:

15 months after start of treatment.

End point values	Standard chemoimmunotherapy (SCIT)	Venetoclax, rituximab (Rve)	Venetoclax, obinutuzumab (Gve)	Venetoclax, obinutuzumab, ibrutinib (GIVE)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	229	237	229	231
Units: percent				
number (confidence interval 97.5%)				
MRD negativity rate	52 (44.4 to 59.5)	57 (49.5 to 64.2)	86.5 (80.6 to 91.1)	92.2 (87.3 to 95.7)

Statistical analyses

Statistical analysis title	Cochran-Mantel-Haenszel test (GIVE vs SCIT)
-----------------------------------	---

Statistical analysis description:

MRD negativity rates of treatment groups will be compared using Cochran-Mantel-Haenszel test stratified by age (with a cut-off of 65 years) and Binet stage. There is no alpha spend in the current analysis of the co-primary endpoint of MRD negativity rate at month 15.

Comparison groups	Standard chemoimmunotherapy (SCIT) v Venetoclax, obinutuzumab, ibrutinib (GIVE)
-------------------	---

Number of subjects included in analysis	460
---	-----

Analysis specification	Pre-specified
------------------------	---------------

Analysis type	other
---------------	-------

P-value	< 0.0001
---------	----------

Method	Cochran-Mantel-Haenszel
--------	-------------------------

Statistical analysis title	Cochran-Mantel-Haenszel test (Rve vs SCIT)
-----------------------------------	--

Statistical analysis description:

MRD negativity rates of treatment groups will be compared using Cochran-Mantel-Haenszel test

stratified by age (with a cut-off of 65 years) and Binet stage. There is no alpha spend in the current analysis of the co-primary endpoint of MRD negativity rate at month 15.

Comparison groups	Standard chemoimmunotherapy (SCIT) v Venetoclax, rituximab (RvE)
Number of subjects included in analysis	466
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.317
Method	Cochran-Mantel-Haenszel

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Timeframe for AE

Adverse event reporting additional description:

AE additional description

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	19.0
--------------------	------

Reporting groups

Reporting group title	GVe arm
-----------------------	---------

Reporting group description: -

Reporting group title	SCIT arm
-----------------------	----------

Reporting group description: -

Reporting group title	RVe arm
-----------------------	---------

Reporting group description: -

Reporting group title	GIVe arm
-----------------------	----------

Reporting group description: -

Serious adverse events	GVe arm	SCIT arm	RVe arm
Total subjects affected by serious adverse events			
subjects affected / exposed	136 / 228 (59.65%)	145 / 216 (67.13%)	131 / 237 (55.27%)
number of deaths (all causes)	15	19	15
number of deaths resulting from adverse events	14	18	14
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acute myeloid leukaemia	Additional description: Acute myeloid leukaemia		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adenocarcinoma pancreas	Additional description: Adenocarcinoma pancreas		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Basal cell carcinoma	Additional description: Basal cell carcinoma		
subjects affected / exposed	3 / 228 (1.32%)	4 / 216 (1.85%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	1 / 3	3 / 5	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Bladder cancer	Additional description: Bladder cancer			
	subjects affected / exposed	1 / 228 (0.44%)	1 / 216 (0.46%)	1 / 237 (0.42%)
	occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Bowen's disease	Additional description: Bowen's disease			
	subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breast cancer	Additional description: Breast cancer			
	subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	2 / 237 (0.84%)
	occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 2
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chondrosarcoma	Additional description: Chondrosarcoma			
	subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Central nervous system leukaemia	Additional description: Central nervous system leukaemia			
	subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colon cancer	Additional description: Colon cancer			
	subjects affected / exposed	0 / 228 (0.00%)	2 / 216 (0.93%)	0 / 237 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 2	0 / 0
Dedifferentiated liposarcoma	Additional description: Dedifferentiated liposarcoma			
	subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Follicular lymphoma	Additional description: Follicular lymphoma			
	subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Glioblastoma	Additional description: Glioblastoma			

subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Hepatocellular carcinoma			
Additional description: Hepatocellular carcinoma			
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Hypopharyngeal cancer			
Additional description: Hypopharyngeal cancer			
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lipoma			
Additional description: Lipoma			
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant neoplasm of unknown primary site			
Additional description: Malignant neoplasm of unknown primary site			
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Lung adenocarcinoma			
Additional description: Lung adenocarcinoma			
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung neoplasm malignant			
Additional description: Lung neoplasm malignant			
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Malignant melanoma			
Additional description: Malignant melanoma			
subjects affected / exposed	2 / 228 (0.88%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mantle cell lymphoma			
Additional description: Mantle cell lymphoma			

subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningioma	Additional description: Meningioma		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningioma benign	Additional description: Meningioma benign		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastatic gastric cancer	Additional description: Metastatic gastric cancer		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Myelodysplastic syndrome	Additional description: Myelodysplastic syndrome		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myxoid liposarcoma	Additional description: Myxoid liposarcoma		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Non-small cell lung cancer	Additional description: Non-small cell lung cancer		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal adenocarcinoma	Additional description: Oesophageal adenocarcinoma		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Oesophageal carcinoma	Additional description: Oesophageal carcinoma		

subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ovarian adenoma	Additional description: Ovarian adenoma		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Phaeochromocytoma	Additional description: Phaeochromocytoma		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Plasma cell myeloma	Additional description: Plasma cell myeloma		
subjects affected / exposed	0 / 228 (0.00%)	2 / 216 (0.93%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Papillary thyroid cancer	Additional description: Papillary thyroid cancer		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Polycythaemia vera	Additional description: Polycythaemia vera		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostate cancer	Additional description: Prostate cancer		
subjects affected / exposed	4 / 228 (1.75%)	3 / 216 (1.39%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	1 / 4	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Prostate cancer metastatic	Additional description: Prostate cancer metastatic		
subjects affected / exposed	1 / 228 (0.44%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Rectal adenocarcinoma	Additional description: Rectal adenocarcinoma		

subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal cancer	Additional description: Rectal cancer		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	2 / 237 (0.84%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal Cell Carcinoma	Additional description: Renal Cell Carcinoma		
subjects affected / exposed	1 / 228 (0.44%)	2 / 216 (0.93%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Richter's syndrome	Additional description: Richter's syndrome		
subjects affected / exposed	7 / 228 (3.07%)	5 / 216 (2.31%)	6 / 237 (2.53%)
occurrences causally related to treatment / all	0 / 7	1 / 5	0 / 6
deaths causally related to treatment / all	0 / 2	1 / 3	0 / 4
Salivary gland adenoma	Additional description: Salivary gland adenoma		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Salivary gland cancer	Additional description: Salivary gland cancer		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seborrhoeic keratosis	Additional description: Seborrhoeic keratosis		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma of skin	Additional description: Squamous cell carcinoma of skin		
subjects affected / exposed	1 / 228 (0.44%)	1 / 216 (0.46%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	1 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin squamous cell carcinoma metastatic	Additional description: Skin squamous cell carcinoma metastatic		

subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
Small cell lung cancer	Additional description: Small cell lung cancer		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Soft tissue sarcoma	Additional description: Soft tissue sarcoma		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal cord neoplasm	Additional description: Spinal cord neoplasm		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma	Additional description: Squamous cell carcinoma		
subjects affected / exposed	4 / 228 (1.75%)	6 / 216 (2.78%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 4	2 / 6	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterine leiomyoma	Additional description: Uterine leiomyoma		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders	Additional description: Aortic aneurysm		
Aortic aneurysm	Additional description: Aortic aneurysm		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic stenosis	Additional description: Aortic stenosis		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blue toe syndrome	Additional description: Blue toe syndrome		

subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Deep vein thrombosis	Additional description: Deep vein thrombosis		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension	Additional description: Hypertension		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	2 / 237 (0.84%)
occurrences causally related to treatment / all	0 / 1	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive crisis	Additional description: Hypertensive crisis		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension	Additional description: Hypotension		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Orthostatic hypotension	Additional description: Orthostatic hypotension		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral arterial occlusive disease	Additional description: Peripheral arterial occlusive disease		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral ischaemia	Additional description: Peripheral ischaemia		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Polyarteritis nodosa	Additional description: Polyarteritis nodosa		

subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombophlebitis	Additional description: Thrombophlebitis		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures	Additional description: Chest tube removal		
Chest tube removal	Additional description: Chest tube removal		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystectomy	Additional description: Cholecystectomy		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary arterial stent insertion	Additional description: Coronary arterial stent insertion		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery bypass	Additional description: Coronary artery bypass		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epidermoid cyst excision	Additional description: Epidermoid cyst excision		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ethmoid sinus surgery	Additional description: Ethmoid sinus surgery		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrectomy	Additional description: Gastrectomy		

subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hip arthroplasty	Additional description: Hip arthroplasty		
subjects affected / exposed	1 / 228 (0.44%)	1 / 216 (0.46%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hip surgery	Additional description: Hip surgery		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Adverse drug reaction	Additional description: Adverse drug reaction		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthenia	Additional description: Asthenia		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain	Additional description: Chest pain		
subjects affected / exposed	1 / 228 (0.44%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Death	Additional description: Death		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue	Additional description: Fatigue		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration	Additional description: General physical health deterioration		

subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza like illness	Additional description: Influenza like illness		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malaise	Additional description: Malaise		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema peripheral	Additional description: Oedema peripheral		
subjects affected / exposed	1 / 228 (0.44%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Puncture site haematoma	Additional description: Puncture site haematoma		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia	Additional description: Pyrexia		
subjects affected / exposed	8 / 228 (3.51%)	10 / 216 (4.63%)	8 / 237 (3.38%)
occurrences causally related to treatment / all	7 / 8	11 / 12	5 / 8
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders	Additional description: Anaphylactic reaction		
Anaphylactic reaction	Additional description: Anaphylactic reaction		
subjects affected / exposed	3 / 228 (1.32%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	1 / 3	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytokine release syndrome	Additional description: Cytokine release syndrome		
subjects affected / exposed	2 / 228 (0.88%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	2 / 2	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug hypersensitivity	Additional description: Drug hypersensitivity		

subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypersensitivity	Additional description: Hypersensitivity		
subjects affected / exposed	1 / 228 (0.44%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sarcoidosis	Additional description: Sarcoidosis		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Benign prostatic hyperplasia	Additional description: Benign prostatic hyperplasia		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Genital prolapse	Additional description: Genital prolapse		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Menorrhagia	Additional description: Menorrhagia		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectocele	Additional description: Rectocele		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Bronchial obstruction	Additional description: Bronchial obstruction		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0

Bronchitis chronic subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Bronchitis chronic		
	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
	0 / 1	0 / 0	0 / 0
	0 / 0	0 / 0	0 / 0
Dyspnoea subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Dyspnoea		
	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
	0 / 1	0 / 0	0 / 0
	0 / 0	0 / 0	0 / 0
Nasal septum disorder subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Nasal septum disorder		
	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
	0 / 1	0 / 0	0 / 0
	0 / 0	0 / 0	0 / 0
Obliterative bronchiolitis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Obliterative bronchiolitis		
	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
	0 / 0	0 / 0	0 / 1
	0 / 0	0 / 0	0 / 0
Pleural effusion subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Pleural effusion		
	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
	1 / 1	0 / 0	0 / 0
	0 / 0	0 / 0	0 / 0
Pleuritic pain subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Pleuritic pain		
	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
	0 / 1	0 / 0	0 / 0
	0 / 0	0 / 0	0 / 0
Pneumonitis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Pneumonitis		
	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
	1 / 1	0 / 0	0 / 0
	0 / 0	0 / 0	0 / 0
Pneumothorax subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Pneumothorax		
	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
	0 / 0	0 / 0	0 / 1
	0 / 0	0 / 0	0 / 0
Pulmonary embolism	Additional description: Pulmonary embolism		

subjects affected / exposed	2 / 228 (0.88%)	2 / 216 (0.93%)	3 / 237 (1.27%)
occurrences causally related to treatment / all	1 / 2	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary fibrosis	Additional description: Pulmonary fibrosis		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary mass	Additional description: Pulmonary mass		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure	Additional description: Respiratory failure		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper-airway cough syndrome	Additional description: Upper-airway cough syndrome		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders	Additional description: Completed suicide		
Completed suicide	Additional description: Completed suicide		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Delirium	Additional description: Delirium		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depression	Additional description: Depression		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Insomnia	Additional description: Insomnia		

subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicide attempt	Additional description: Suicide attempt		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations	Additional description: Blood lactate dehydrogenase increased		
Blood lactate dehydrogenase increased	Additional description: Blood lactate dehydrogenase increased		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	2 / 237 (0.84%)
occurrences causally related to treatment / all	1 / 1	0 / 0	3 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood creatine increased	Additional description: Blood creatine increased		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood creatine phosphokinase increased	Additional description: Blood creatine phosphokinase increased		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood creatinine increased	Additional description: Blood creatinine increased		
subjects affected / exposed	2 / 228 (0.88%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood phosphorus increased	Additional description: Blood phosphorus increased		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood potassium increased	Additional description: Blood potassium increased		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic enzyme increased	Additional description: Hepatic enzyme increased		

subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Medical observation	Additional description: Medical observation		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial necrosis marker increased	Additional description: Myocardial necrosis marker increased		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
N-terminal prohormone brain natriuretic peptide increased	Additional description: N-terminal prohormone brain natriuretic peptide increased		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostatic specific antigen increased	Additional description: Prostatic specific antigen increased		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SARS-CoV-2 test positive	Additional description: SARS-CoV-2 test positive		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transaminases increased	Additional description: Transaminases increased		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Alcohol poisoning	Additional description: Alcohol poisoning		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Ankle fracture subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Ankle fracture		
	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
	0 / 0	0 / 0	0 / 1
	0 / 0	0 / 0	0 / 0
Forearm fracture subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Forearm fracture		
	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
	0 / 1	0 / 0	0 / 0
	0 / 0	0 / 0	0 / 0
Facial bones fracture subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Facial bones fracture		
	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
	0 / 1	0 / 0	0 / 0
	0 / 0	0 / 0	0 / 0
Fall subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Fall		
	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
	0 / 0	0 / 1	0 / 0
	0 / 0	0 / 0	0 / 0
Femoral neck fracture subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Femoral neck fracture		
	0 / 228 (0.00%)	1 / 216 (0.46%)	1 / 237 (0.42%)
	0 / 0	0 / 1	0 / 1
	0 / 0	0 / 0	0 / 0
Femur fracture subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Femur fracture		
	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
	0 / 0	0 / 1	0 / 0
	0 / 0	0 / 0	0 / 0
Fibula fracture subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Fibula fracture		
	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
	0 / 1	0 / 0	0 / 0
	0 / 0	0 / 0	0 / 0
Foot fracture subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Foot fracture		
	0 / 228 (0.00%)	2 / 216 (0.93%)	0 / 237 (0.00%)
	0 / 0	0 / 2	0 / 0
	0 / 0	0 / 0	0 / 0
Hand fracture	Additional description: Hand fracture		

subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hip fracture	Additional description: Hip fracture		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Humerus fracture	Additional description: Humerus fracture		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infusion related reaction	Additional description: Infusion related reaction		
subjects affected / exposed	20 / 228 (8.77%)	9 / 216 (4.17%)	20 / 237 (8.44%)
occurrences causally related to treatment / all	22 / 22	10 / 12	22 / 22
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Kidney rupture	Additional description: Kidney rupture		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lumbar vertebral fracture	Additional description: Lumbar vertebral fracture		
subjects affected / exposed	0 / 228 (0.00%)	2 / 216 (0.93%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple fractures	Additional description: Multiple fractures		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple injuries	Additional description: Multiple injuries		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meniscus injury	Additional description: Meniscus injury		

subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural haematoma	Additional description: Post procedural haematoma		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Procedural intestinal perforation	Additional description: Procedural intestinal perforation		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reactive gastropathy	Additional description: Reactive gastropathy		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Silicosis	Additional description: Silicosis		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Road traffic accident	Additional description: Road traffic accident		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skull fracture	Additional description: Skull fracture		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal compression fracture	Additional description: Spinal compression fracture		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal fracture	Additional description: Spinal fracture		

subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thermal burn	Additional description: Thermal burn		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haematoma	Additional description: Subdural haematoma		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thoracic vertebral fracture	Additional description: Thoracic vertebral fracture		
subjects affected / exposed	1 / 228 (0.44%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tibia fracture	Additional description: Tibia fracture		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ulna fracture	Additional description: Ulna fracture		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wrist fracture	Additional description: Wrist fracture		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Adenomatous polyposis coli	Additional description: Adenomatous polyposis coli		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			

Acute coronary syndrome subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Acute coronary syndrome		
	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
	0 / 0	1 / 1	0 / 0
	0 / 0	0 / 0	0 / 0
Acute myocardial infarction subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Acute myocardial infarction		
	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
	0 / 0	0 / 0	0 / 0
	0 / 0	0 / 0	0 / 0
Atrial tachycardia subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Atrial tachycardia		
	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
	0 / 0	0 / 0	0 / 0
	0 / 0	0 / 0	0 / 0
Aortic valve disease subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Aortic valve disease		
	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
	0 / 0	0 / 0	0 / 1
	0 / 0	0 / 0	0 / 0
Arteriosclerosis coronary artery subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Arteriosclerosis coronary artery		
	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
	0 / 0	0 / 0	0 / 1
	0 / 0	0 / 0	0 / 0
Atrial fibrillation subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Atrial fibrillation		
	3 / 228 (1.32%)	7 / 216 (3.24%)	3 / 237 (1.27%)
	2 / 4	2 / 7	0 / 3
	0 / 0	0 / 0	0 / 0
Atrial flutter subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Atrial flutter		
	0 / 228 (0.00%)	1 / 216 (0.46%)	1 / 237 (0.42%)
	0 / 0	0 / 1	0 / 1
	0 / 0	0 / 0	0 / 0
Angina pectoris subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Angina pectoris		
	2 / 228 (0.88%)	1 / 216 (0.46%)	0 / 237 (0.00%)
	0 / 2	2 / 4	0 / 0
	0 / 0	0 / 0	0 / 0
Atrioventricular block	Additional description: Atrioventricular block		

subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac arrest	Additional description: Cardiac arrest		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Cardiac failure	Additional description: Cardiac failure		
subjects affected / exposed	2 / 228 (0.88%)	1 / 216 (0.46%)	2 / 237 (0.84%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Cardiac failure congestive	Additional description: Cardiac failure congestive		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiomyopathy	Additional description: Cardiomyopathy		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery disease	Additional description: Coronary artery disease		
subjects affected / exposed	3 / 228 (1.32%)	1 / 216 (0.46%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intracardiac thrombus	Additional description: Intracardiac thrombus		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction	Additional description: Myocardial infarction		
subjects affected / exposed	0 / 228 (0.00%)	2 / 216 (0.93%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocarditis	Additional description: Myocarditis		

subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericarditis	Additional description: Pericarditis		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Palpitations	Additional description: Palpitations		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericardial effusion	Additional description: Pericardial effusion		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinus node dysfunction	Additional description: Sinus node dysfunction		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stress cardiomyopathy	Additional description: Stress cardiomyopathy		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Supraventricular tachycardia	Additional description: Supraventricular tachycardia		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular fibrillation	Additional description: Ventricular fibrillation		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Carotid artery stenosis	Additional description: Carotid artery stenosis		

subjects affected / exposed	2 / 228 (0.88%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Carotid artery occlusion	Additional description: Carotid artery occlusion		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebellar stroke	Additional description: Cerebellar stroke		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral haemorrhage	Additional description: Cerebral haemorrhage		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral ischaemia	Additional description: Cerebral ischaemia		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident	Additional description: Cerebrovascular accident		
subjects affected / exposed	0 / 228 (0.00%)	2 / 216 (0.93%)	2 / 237 (0.84%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysaesthesia	Additional description: Dysaesthesia		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dizziness	Additional description: Dizziness		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embolic cerebral infarction	Additional description: Embolic cerebral infarction		

subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalitis autoimmune			
Additional description: Encephalitis autoimmune			
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epilepsy			
Additional description: Epilepsy			
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhagic stroke			
Additional description: Haemorrhagic stroke			
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Headache			
Additional description: Headache			
subjects affected / exposed	1 / 228 (0.44%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			
Additional description: Ischaemic stroke			
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Myasthenia gravis			
Additional description: Myasthenia gravis			
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Polyneuropathy			
Additional description: Polyneuropathy			
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
Additional description: Seizure			

subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope	Additional description: Syncope		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombotic stroke	Additional description: Thrombotic stroke		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxic leukoencephalopathy	Additional description: Toxic leukoencephalopathy		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient global amnesia	Additional description: Transient global amnesia		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack	Additional description: Transient ischaemic attack		
subjects affected / exposed	0 / 228 (0.00%)	2 / 216 (0.93%)	2 / 237 (0.84%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vocal cord paresis	Additional description: Vocal cord paresis		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders	Additional description: Anaemia		
Anaemia	Additional description: Anaemia		
subjects affected / exposed	2 / 228 (0.88%)	4 / 216 (1.85%)	2 / 237 (0.84%)
occurrences causally related to treatment / all	1 / 2	2 / 4	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aplasia pure red cell	Additional description: Aplasia pure red cell		

subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Autoimmune haemolytic anaemia	Additional description: Autoimmune haemolytic anaemia		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Autoimmune neutropenia	Additional description: Autoimmune neutropenia		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile neutropenia	Additional description: Febrile neutropenia		
subjects affected / exposed	8 / 228 (3.51%)	21 / 216 (9.72%)	7 / 237 (2.95%)
occurrences causally related to treatment / all	6 / 8	23 / 26	7 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemolytic anaemia	Additional description: Haemolytic anaemia		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune thrombocytopenia	Additional description: Immune thrombocytopenia		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukostasis syndrome	Additional description: Leukostasis syndrome		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphadenitis	Additional description: Lymphadenitis		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphocytosis	Additional description: Lymphocytosis		

subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenia	Additional description: Neutropenia		
subjects affected / exposed	4 / 228 (1.75%)	2 / 216 (0.93%)	3 / 237 (1.27%)
occurrences causally related to treatment / all	4 / 4	2 / 2	4 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancytopenia	Additional description: Pancytopenia		
subjects affected / exposed	2 / 228 (0.88%)	1 / 216 (0.46%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	2 / 2	1 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Splenomegaly	Additional description: Splenomegaly		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia	Additional description: Thrombocytopenia		
subjects affected / exposed	8 / 228 (3.51%)	2 / 216 (0.93%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	7 / 8	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders	Additional description: Vertigo		
Vertigo	Additional description: Vertigo		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vertigo positional	Additional description: Vertigo positional		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders	Additional description: Acute macular outer retinopathy		
Acute macular outer retinopathy	Additional description: Acute macular outer retinopathy		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cataract	Additional description: Cataract		

subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dacryostenosis acquired	Additional description: Dacryostenosis acquired		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eyelid cyst	Additional description: Eyelid cyst		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Macular hole	Additional description: Macular hole		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Optic ischaemic neuropathy	Additional description: Optic ischaemic neuropathy		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retinal detachment	Additional description: Retinal detachment		
subjects affected / exposed	2 / 228 (0.88%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Venous stasis retinopathy	Additional description: Venous stasis retinopathy		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain	Additional description: Abdominal pain		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal hernia	Additional description: Abdominal hernia		

subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain upper	Additional description: Abdominal pain upper		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea	Additional description: Diarrhoea		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulum intestinal	Additional description: Diverticulum intestinal		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal perforation	Additional description: Duodenal perforation		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal ulcer haemorrhage	Additional description: Duodenal ulcer haemorrhage		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enlarged uvula	Additional description: Enlarged uvula		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epiploic appendagitis	Additional description: Epiploic appendagitis		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erosive oesophagitis	Additional description: Erosive oesophagitis		

subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis	Additional description: Gastritis		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis erosive	Additional description: Gastritis erosive		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage	Additional description: Gastrointestinal haemorrhage		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrooesophageal reflux disease	Additional description: Gastrooesophageal reflux disease		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhagic erosive gastritis	Additional description: Haemorrhagic erosive gastritis		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus	Additional description: Ileus		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Impaired gastric emptying	Additional description: Impaired gastric emptying		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia	Additional description: Inguinal hernia		

subjects affected / exposed	0 / 228 (0.00%)	3 / 216 (1.39%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Irritable bowel syndrome	Additional description: Irritable bowel syndrome		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea	Additional description: Nausea		
subjects affected / exposed	1 / 228 (0.44%)	1 / 216 (0.46%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 2	2 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal rupture	Additional description: Oesophageal rupture		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis	Additional description: Pancreatitis		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatolithiasis	Additional description: Pancreatolithiasis		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stomatitis	Additional description: Stomatitis		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage	Additional description: Upper gastrointestinal haemorrhage		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders	Additional description: Bile duct stenosis		
Bile duct stenosis	Additional description: Bile duct stenosis		

subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Biliary colic			
Additional description: Biliary colic			
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis			
Additional description: Cholecystitis			
subjects affected / exposed	3 / 228 (1.32%)	4 / 216 (1.85%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 3	0 / 4	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis acute			
Additional description: Cholecystitis acute			
subjects affected / exposed	2 / 228 (0.88%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholelithiasis			
Additional description: Cholelithiasis			
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gallbladder polyp			
Additional description: Gallbladder polyp			
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatotoxicity			
Additional description: Hepatotoxicity			
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Liver disorder			
Additional description: Liver disorder			
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subcapsular hepatic haematoma			
Additional description: Subcapsular hepatic haematoma			

subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Actinic keratosis	Additional description: Actinic keratosis		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dermatitis			
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dermatitis allergic			
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erythema multiforme			
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash			
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash maculo-papular			
subjects affected / exposed	1 / 228 (0.44%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury	Additional description: Acute kidney injury		
subjects affected / exposed	0 / 228 (0.00%)	2 / 216 (0.93%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Nephrolithiasis			
Additional description: Nephrolithiasis			

subjects affected / exposed	2 / 228 (0.88%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal colic	Additional description: Renal colic		
subjects affected / exposed	1 / 228 (0.44%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ureterolithiasis	Additional description: Ureterolithiasis		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urethral caruncle	Additional description: Urethral caruncle		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urethral stenosis	Additional description: Urethral stenosis		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary retention	Additional description: Urinary retention		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders	Additional description: Goitre		
Goitre	Additional description: Goitre		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperthyroidism	Additional description: Hyperthyroidism		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			

Arthralgia	Additional description: Arthralgia		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back pain	Additional description: Back pain		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bursitis	Additional description: Bursitis		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dupuytren's contracture	Additional description: Dupuytren's contracture		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gouty arthritis	Additional description: Gouty arthritis		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemarthrosis	Additional description: Haemarthrosis		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematoma muscle	Additional description: Haematoma muscle		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercreatinaemia	Additional description: Hypercreatinaemia		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc protrusion	Additional description: Intervertebral disc protrusion		

subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal pain	Additional description: Musculoskeletal pain		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain in extremity	Additional description: Pain in extremity		
subjects affected / exposed	1 / 228 (0.44%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteochondrosis	Additional description: Osteochondrosis		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteonecrosis	Additional description: Osteonecrosis		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoporotic fracture	Additional description: Osteoporotic fracture		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis	Additional description: Osteoarthritis		
subjects affected / exposed	4 / 228 (1.75%)	2 / 216 (0.93%)	2 / 237 (0.84%)
occurrences causally related to treatment / all	0 / 4	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Periarthritis	Additional description: Periarthritis		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Polymyalgia rheumatica	Additional description: Polymyalgia rheumatica		

subjects affected / exposed	2 / 228 (0.88%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rotator cuff syndrome	Additional description: Rotator cuff syndrome		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Scleroderma	Additional description: Scleroderma		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal column stenosis	Additional description: Spinal column stenosis		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal pain	Additional description: Spinal pain		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tenosynovitis	Additional description: Tenosynovitis		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations	Additional description: Anal abscess		
Anal abscess	Additional description: Anal abscess		
subjects affected / exposed	1 / 228 (0.44%)	1 / 216 (0.46%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	1 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abscess limb	Additional description: Abscess limb		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abscess	Additional description: Abscess		

subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis	Additional description: Appendicitis		
subjects affected / exposed	2 / 228 (0.88%)	1 / 216 (0.46%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	1 / 2	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis perforated	Additional description: Appendicitis perforated		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asymptomatic COVID-19	Additional description: Asymptomatic COVID-19		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacteraemia	Additional description: Bacteraemia		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacterial infection	Additional description: Bacterial infection		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atypical pneumonia	Additional description: Atypical pneumonia		
subjects affected / exposed	0 / 228 (0.00%)	2 / 216 (0.93%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Bronchitis	Additional description: Bronchitis		
subjects affected / exposed	1 / 228 (0.44%)	2 / 216 (0.93%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchopulmonary aspergillosis	Additional description: Bronchopulmonary aspergillosis		

subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral aspergillosis	Additional description: Cerebral aspergillosis		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Cellulitis	Additional description: Cellulitis		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic sinusitis	Additional description: Chronic sinusitis		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Corona virus infection	Additional description: Corona virus infection		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronavirus infection	Additional description: Coronavirus infection		
subjects affected / exposed	0 / 228 (0.00%)	3 / 216 (1.39%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19	Additional description: COVID-19		
subjects affected / exposed	13 / 228 (5.70%)	6 / 216 (2.78%)	13 / 237 (5.49%)
occurrences causally related to treatment / all	0 / 13	0 / 6	0 / 14
deaths causally related to treatment / all	0 / 3	0 / 2	0 / 0
COVID-19 pneumonia	Additional description: COVID-19 pneumonia		
subjects affected / exposed	1 / 228 (0.44%)	1 / 216 (0.46%)	3 / 237 (1.27%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cryptococcal fungaemia	Additional description: Cryptococcal fungaemia		

subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystitis			
Additional description: Cystitis			
subjects affected / exposed	0 / 228 (0.00%)	2 / 216 (0.93%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytomegalovirus infection			
Additional description: Cytomegalovirus infection			
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytomegalovirus infection reactivation			
Additional description: Cytomegalovirus infection reactivation			
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
Additional description: Diverticulitis			
subjects affected / exposed	1 / 228 (0.44%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalitis fungal			
Additional description: Encephalitis fungal			
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocarditis			
Additional description: Endocarditis			
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erysipelas			
Additional description: Erysipelas			
subjects affected / exposed	3 / 228 (1.32%)	4 / 216 (1.85%)	2 / 237 (0.84%)
occurrences causally related to treatment / all	0 / 3	2 / 4	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epididymitis			
Additional description: Epididymitis			

subjects affected / exposed	3 / 228 (1.32%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	2 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epstein-Barr virus infection	Additional description: Epstein-Barr virus infection		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Enterocolitis infectious	Additional description: Enterocolitis infectious		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia urinary tract infection	Additional description: Escherichia urinary tract infection		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile infection	Additional description: Febrile infection		
subjects affected / exposed	0 / 228 (0.00%)	5 / 216 (2.31%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	5 / 5	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia bacteraemia	Additional description: Escherichia bacteraemia		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gallbladder empyema	Additional description: Gallbladder empyema		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis	Additional description: Gastroenteritis		
subjects affected / exposed	2 / 228 (0.88%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal infection	Additional description: Gastrointestinal infection		

subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Genital herpes zoster	Additional description: Genital herpes zoster		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Giardiasis	Additional description: Giardiasis		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Hepatitis B	Additional description: Hepatitis B		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Hepatitis B reactivation	Additional description: Hepatitis B reactivation		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Hepatitis E	Additional description: Hepatitis E		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Herpes zoster	Additional description: Herpes zoster		
subjects affected / exposed	0 / 228 (0.00%)	8 / 216 (3.70%)	2 / 237 (0.84%)
occurrences causally related to treatment / all	0 / 0	4 / 8	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Herpes zoster meningoencephalitis	Additional description: Herpes zoster meningoencephalitis		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Herpes zoster reactivation	Additional description: Herpes zoster reactivation		

subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Impetigo	Additional description: Impetigo		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infected seroma	Additional description: Infected seroma		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection	Additional description: Infection		
subjects affected / exposed	3 / 228 (1.32%)	5 / 216 (2.31%)	6 / 237 (2.53%)
occurrences causally related to treatment / all	2 / 3	3 / 6	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infectious pleural effusion	Additional description: Infectious pleural effusion		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infective exacerbation of chronic obstructive airways disease	Additional description: Infective exacerbation of chronic obstructive airways disease		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza	Additional description: Influenza		
subjects affected / exposed	2 / 228 (0.88%)	7 / 216 (3.24%)	7 / 237 (2.95%)
occurrences causally related to treatment / all	0 / 2	2 / 7	2 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Keratitis bacterial	Additional description: Keratitis bacterial		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Kidney infection	Additional description: Kidney infection		

subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngitis	Additional description: Laryngitis		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection	Additional description: Lower respiratory tract infection		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Lung infection	Additional description: Lung infection		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lyme disease	Additional description: Lyme disease		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymph gland infection	Additional description: Lymph gland infection		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Localised infection	Additional description: Localised infection		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis	Additional description: Meningitis		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis viral	Additional description: Meningitis viral		

subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mycoplasma infection	Additional description: Mycoplasma infection		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenic infection	Additional description: Neutropenic infection		
subjects affected / exposed	2 / 228 (0.88%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	2 / 2	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myelitis	Additional description: Myelitis		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteomyelitis	Additional description: Osteomyelitis		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic abscess	Additional description: Pelvic abscess		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngitis	Additional description: Pharyngitis		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Papilloma viral infection	Additional description: Papilloma viral infection		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Parainfluenzae virus infection	Additional description: Parainfluenzae virus infection		

subjects affected / exposed	0 / 228 (0.00%)	2 / 216 (0.93%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural infection	Additional description: Pleural infection		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumocystis jirovecii pneumonia	Additional description: Pneumocystis jirovecii pneumonia		
subjects affected / exposed	0 / 228 (0.00%)	3 / 216 (1.39%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia	Additional description: Pneumonia		
subjects affected / exposed	17 / 228 (7.46%)	18 / 216 (8.33%)	17 / 237 (7.17%)
occurrences causally related to treatment / all	12 / 25	12 / 24	4 / 19
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 1
Pneumonia adenoviral	Additional description: Pneumonia adenoviral		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia influenzal	Additional description: Pneumonia influenzal		
subjects affected / exposed	0 / 228 (0.00%)	2 / 216 (0.93%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia legionella	Additional description: Pneumonia legionella		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia mycoplasmal	Additional description: Pneumonia mycoplasmal		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia pneumococcal	Additional description: Pneumonia pneumococcal		

subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia staphylococcal			
Additional description: Pneumonia staphylococcal			
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia streptococcal			
Additional description: Pneumonia streptococcal			
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia fungal			
Additional description: Pneumonia fungal			
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pseudomonas infection			
Additional description: Pseudomonas infection			
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	2 / 237 (0.84%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal abscess			
Additional description: Rectal abscess			
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus infection			
Additional description: Respiratory syncytial virus infection			
subjects affected / exposed	0 / 228 (0.00%)	2 / 216 (0.93%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	2 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
Additional description: Respiratory tract infection			
subjects affected / exposed	2 / 228 (0.88%)	0 / 216 (0.00%)	2 / 237 (0.84%)
occurrences causally related to treatment / all	2 / 2	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sialoadenitis			
Additional description: Sialoadenitis			

subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
Additional description: Sepsis			
subjects affected / exposed	3 / 228 (1.32%)	3 / 216 (1.39%)	2 / 237 (0.84%)
occurrences causally related to treatment / all	0 / 3	2 / 3	1 / 2
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 1
Septic shock			
Additional description: Septic shock			
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Sinobronchitis			
Additional description: Sinobronchitis			
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin infection			
Additional description: Skin infection			
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinusitis			
Additional description: Sinusitis			
subjects affected / exposed	2 / 228 (0.88%)	1 / 216 (0.46%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 2	0 / 1	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal infection			
Additional description: Staphylococcal infection			
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Streptococcal infection			
Additional description: Streptococcal infection			
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Streptococcal sepsis			
Additional description: Streptococcal sepsis			

subjects affected / exposed	0 / 228 (0.00%)	2 / 216 (0.93%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subcutaneous abscess			
Additional description: Subcutaneous abscess			
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suspected COVID-19			
Additional description: Suspected COVID-19			
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal sepsis			
Additional description: Staphylococcal sepsis			
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tooth abscess			
Additional description: Tooth abscess			
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tooth infection			
Additional description: Tooth infection			
subjects affected / exposed	2 / 228 (0.88%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
Additional description: Upper respiratory tract infection			
subjects affected / exposed	1 / 228 (0.44%)	1 / 216 (0.46%)	3 / 237 (1.27%)
occurrences causally related to treatment / all	0 / 1	1 / 1	2 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
Additional description: Viral infection			
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vestibular neuronitis			
Additional description: Vestibular neuronitis			

subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection	Additional description: Urinary tract infection		
subjects affected / exposed	2 / 228 (0.88%)	4 / 216 (1.85%)	6 / 237 (2.53%)
occurrences causally related to treatment / all	1 / 5	2 / 4	5 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders	Additional description: Dehydration		
Dehydration	Additional description: Dehydration		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperphosphataemia	Additional description: Hyperphosphataemia		
subjects affected / exposed	1 / 228 (0.44%)	1 / 216 (0.46%)	4 / 237 (1.69%)
occurrences causally related to treatment / all	1 / 1	1 / 1	5 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia	Additional description: Hyperglycaemia		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia	Additional description: Hyperkalaemia		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	2 / 237 (0.84%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia	Additional description: Hyponatraemia		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperuricaemia	Additional description: Hyperuricaemia		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	3 / 237 (1.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	3 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoglycaemia	Additional description: Hypoglycaemia		

subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0

Hypokalaemia	Additional description: Hypokalaemia		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Hypophosphataemia	Additional description: Hypophosphataemia		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Tumour lysis syndrome	Additional description: Tumour lysis syndrome		
subjects affected / exposed	9 / 228 (3.95%)	4 / 216 (1.85%)	11 / 237 (4.64%)
occurrences causally related to treatment / all	9 / 9	4 / 4	12 / 12
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	GIVe arm		
Total subjects affected by serious adverse events			
subjects affected / exposed	146 / 231 (63.20%)		
number of deaths (all causes)	13		
number of deaths resulting from adverse events	13		

Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Additional description: Acute myeloid leukaemia		
Acute myeloid leukaemia			
subjects affected / exposed	2 / 231 (0.87%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	1 / 1		

Adenocarcinoma pancreas	Additional description: Adenocarcinoma pancreas		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Basal cell carcinoma	Additional description: Basal cell carcinoma		
subjects affected / exposed	4 / 231 (1.73%)		
occurrences causally related to treatment / all	3 / 5		
deaths causally related to treatment / all	0 / 0		

Bladder cancer subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Bladder cancer	
	0 / 231 (0.00%)	
	0 / 0	
Bowen's disease subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Bowen's disease	
	0 / 231 (0.00%)	
	0 / 0	
Breast cancer subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Breast cancer	
	0 / 231 (0.00%)	
	0 / 0	
Chondrosarcoma subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Chondrosarcoma	
	0 / 231 (0.00%)	
	0 / 0	
Central nervous system leukaemia subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Central nervous system leukaemia	
	0 / 231 (0.00%)	
	0 / 0	
Colon cancer subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Colon cancer	
	1 / 231 (0.43%)	
	1 / 1	
Dedifferentiated liposarcoma subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Dedifferentiated liposarcoma	
	0 / 231 (0.00%)	
	0 / 0	
Follicular lymphoma subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Follicular lymphoma	
	1 / 231 (0.43%)	
	0 / 1	
Glioblastoma	Additional description: Glioblastoma	

subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Hepatocellular carcinoma			
Additional description: Hepatocellular carcinoma			
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypopharyngeal cancer			
Additional description: Hypopharyngeal cancer			
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lipoma			
Additional description: Lipoma			
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Malignant neoplasm of unknown primary site			
Additional description: Malignant neoplasm of unknown primary site			
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lung adenocarcinoma			
Additional description: Lung adenocarcinoma			
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Lung neoplasm malignant			
Additional description: Lung neoplasm malignant			
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Malignant melanoma			
Additional description: Malignant melanoma			
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Mantle cell lymphoma			
Additional description: Mantle cell lymphoma			

subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Meningioma	Additional description: Meningioma		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Meningioma benign	Additional description: Meningioma benign		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metastatic gastric cancer	Additional description: Metastatic gastric cancer		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Myelodysplastic syndrome	Additional description: Myelodysplastic syndrome		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Myxoid liposarcoma	Additional description: Myxoid liposarcoma		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Non-small cell lung cancer	Additional description: Non-small cell lung cancer		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Oesophageal adenocarcinoma	Additional description: Oesophageal adenocarcinoma		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Oesophageal carcinoma	Additional description: Oesophageal carcinoma		

subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Ovarian adenoma	Additional description: Ovarian adenoma		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Phaeochromocytoma	Additional description: Phaeochromocytoma		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Plasma cell myeloma	Additional description: Plasma cell myeloma		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Papillary thyroid cancer	Additional description: Papillary thyroid cancer		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Polycythaemia vera	Additional description: Polycythaemia vera		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Prostate cancer	Additional description: Prostate cancer		
subjects affected / exposed	4 / 231 (1.73%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 1		
Prostate cancer metastatic	Additional description: Prostate cancer metastatic		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Rectal adenocarcinoma	Additional description: Rectal adenocarcinoma		

subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Rectal cancer	Additional description: Rectal cancer		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal Cell Carcinoma	Additional description: Renal Cell Carcinoma		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Richter's syndrome	Additional description: Richter's syndrome		
subjects affected / exposed	2 / 231 (0.87%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 1		
Salivary gland adenoma	Additional description: Salivary gland adenoma		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Salivary gland cancer	Additional description: Salivary gland cancer		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Seborrhoeic keratosis	Additional description: Seborrhoeic keratosis		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Squamous cell carcinoma of skin	Additional description: Squamous cell carcinoma of skin		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Skin squamous cell carcinoma metastatic	Additional description: Skin squamous cell carcinoma metastatic		

subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Small cell lung cancer	Additional description: Small cell lung cancer		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	1 / 1		

Soft tissue sarcoma	Additional description: Soft tissue sarcoma		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Spinal cord neoplasm	Additional description: Spinal cord neoplasm		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Squamous cell carcinoma	Additional description: Squamous cell carcinoma		
subjects affected / exposed	3 / 231 (1.30%)		
occurrences causally related to treatment / all	2 / 3		
deaths causally related to treatment / all	0 / 0		

Uterine leiomyoma	Additional description: Uterine leiomyoma		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Vascular disorders			

Aortic aneurysm	Additional description: Aortic aneurysm		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Aortic stenosis	Additional description: Aortic stenosis		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Blue toe syndrome	Additional description: Blue toe syndrome		

subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		

Deep vein thrombosis	Additional description: Deep vein thrombosis		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Hypertension	Additional description: Hypertension		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		

Hypertensive crisis	Additional description: Hypertensive crisis		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Hypotension	Additional description: Hypotension		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Orthostatic hypotension	Additional description: Orthostatic hypotension		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Peripheral arterial occlusive disease	Additional description: Peripheral arterial occlusive disease		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Peripheral ischaemia	Additional description: Peripheral ischaemia		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Polyarteritis nodosa	Additional description: Polyarteritis nodosa		

subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Thrombophlebitis	Additional description: Thrombophlebitis		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Surgical and medical procedures	Additional description: Chest tube removal		
Chest tube removal	Additional description: Chest tube removal		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cholecystectomy	Additional description: Cholecystectomy		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Coronary arterial stent insertion	Additional description: Coronary arterial stent insertion		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Coronary artery bypass	Additional description: Coronary artery bypass		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Epidermoid cyst excision	Additional description: Epidermoid cyst excision		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ethmoid sinus surgery	Additional description: Ethmoid sinus surgery		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrectomy	Additional description: Gastrectomy		

subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hip arthroplasty	Additional description: Hip arthroplasty		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hip surgery	Additional description: Hip surgery		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Adverse drug reaction	Additional description: Adverse drug reaction		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Asthenia	Additional description: Asthenia		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Chest pain	Additional description: Chest pain		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Death	Additional description: Death		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Fatigue	Additional description: Fatigue		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General physical health deterioration	Additional description: General physical health deterioration		

subjects affected / exposed	2 / 231 (0.87%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
Influenza like illness	Additional description: Influenza like illness		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Malaise	Additional description: Malaise		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Oedema peripheral	Additional description: Oedema peripheral		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Puncture site haematoma	Additional description: Puncture site haematoma		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pyrexia	Additional description: Pyrexia		
subjects affected / exposed	4 / 231 (1.73%)		
occurrences causally related to treatment / all	4 / 4		
deaths causally related to treatment / all	0 / 0		
Immune system disorders	Additional description: Anaphylactic reaction		
Anaphylactic reaction	Additional description: Anaphylactic reaction		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cytokine release syndrome	Additional description: Cytokine release syndrome		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Drug hypersensitivity	Additional description: Drug hypersensitivity		

subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypersensitivity	Additional description: Hypersensitivity		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sarcoidosis	Additional description: Sarcoidosis		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Reproductive system and breast disorders			
Benign prostatic hyperplasia	Additional description: Benign prostatic hyperplasia		
subjects affected / exposed	3 / 231 (1.30%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Genital prolapse	Additional description: Genital prolapse		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Menorrhagia	Additional description: Menorrhagia		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Rectocele	Additional description: Rectocele		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Bronchial obstruction	Additional description: Bronchial obstruction		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Bronchitis chronic subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Bronchitis chronic	
	0 / 231 (0.00%)	
	0 / 0	
Dyspnoea subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Dyspnoea	
	0 / 231 (0.00%)	
	0 / 0	
Nasal septum disorder subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Nasal septum disorder	
	0 / 231 (0.00%)	
	0 / 0	
Obliterative bronchiolitis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Obliterative bronchiolitis	
	0 / 231 (0.00%)	
	0 / 0	
Pleural effusion subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Pleural effusion	
	1 / 231 (0.43%)	
	0 / 1	
Pleuritic pain subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Pleuritic pain	
	0 / 231 (0.00%)	
	0 / 0	
Pneumonitis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Pneumonitis	
	0 / 231 (0.00%)	
	0 / 0	
Pneumothorax subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Pneumothorax	
	2 / 231 (0.87%)	
	0 / 2	
Pulmonary embolism	Additional description: Pulmonary embolism	

subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary fibrosis	Additional description: Pulmonary fibrosis		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Pulmonary mass	Additional description: Pulmonary mass		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory failure	Additional description: Respiratory failure		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Upper-airway cough syndrome	Additional description: Upper-airway cough syndrome		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders	Additional description: Completed suicide		
Completed suicide	Additional description: Completed suicide		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Delirium	Additional description: Delirium		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Depression	Additional description: Depression		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Insomnia	Additional description: Insomnia		

subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Suicide attempt			
Additional description: Suicide attempt			
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Investigations			
Blood lactate dehydrogenase increased			
Additional description: Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Blood creatine increased			
Additional description: Blood creatine increased			
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Blood creatine phosphokinase increased			
Additional description: Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Blood creatinine increased			
Additional description: Blood creatinine increased			
subjects affected / exposed	3 / 231 (1.30%)		
occurrences causally related to treatment / all	2 / 3		
deaths causally related to treatment / all	0 / 0		
Blood phosphorus increased			
Additional description: Blood phosphorus increased			
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Blood potassium increased			
Additional description: Blood potassium increased			
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatic enzyme increased			
Additional description: Hepatic enzyme increased			

subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Medical observation	Additional description: Medical observation		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Myocardial necrosis marker increased	Additional description: Myocardial necrosis marker increased		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
N-terminal prohormone brain natriuretic peptide increased	Additional description: N-terminal prohormone brain natriuretic peptide increased		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Prostatic specific antigen increased	Additional description: Prostatic specific antigen increased		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
SARS-CoV-2 test positive	Additional description: SARS-CoV-2 test positive		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Transaminases increased	Additional description: Transaminases increased		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Alcohol poisoning	Additional description: Alcohol poisoning		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Ankle fracture subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Ankle fracture	
	1 / 231 (0.43%)	
	0 / 1	
	0 / 0	
Forearm fracture subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Forearm fracture	
	0 / 231 (0.00%)	
	0 / 0	
	0 / 0	
Facial bones fracture subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Facial bones fracture	
	0 / 231 (0.00%)	
	0 / 0	
	0 / 0	
Fall subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Fall	
	0 / 231 (0.00%)	
	0 / 0	
	0 / 0	
Femoral neck fracture subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Femoral neck fracture	
	1 / 231 (0.43%)	
	0 / 1	
	0 / 0	
Femur fracture subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Femur fracture	
	1 / 231 (0.43%)	
	0 / 1	
	0 / 0	
Fibula fracture subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Fibula fracture	
	0 / 231 (0.00%)	
	0 / 0	
	0 / 0	
Foot fracture subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Foot fracture	
	0 / 231 (0.00%)	
	0 / 0	
	0 / 0	
Hand fracture	Additional description: Hand fracture	

subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hip fracture			
Additional description: Hip fracture			
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Humerus fracture			
Additional description: Humerus fracture			
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infusion related reaction			
Additional description: Infusion related reaction			
subjects affected / exposed	11 / 231 (4.76%)		
occurrences causally related to treatment / all	10 / 11		
deaths causally related to treatment / all	0 / 0		
Kidney rupture			
Additional description: Kidney rupture			
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lumbar vertebral fracture			
Additional description: Lumbar vertebral fracture			
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Multiple fractures			
Additional description: Multiple fractures			
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Multiple injuries			
Additional description: Multiple injuries			
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Meniscus injury			
Additional description: Meniscus injury			

subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Post procedural haematoma	Additional description: Post procedural haematoma		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Procedural intestinal perforation	Additional description: Procedural intestinal perforation		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Reactive gastropathy	Additional description: Reactive gastropathy		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Silicosis	Additional description: Silicosis		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Road traffic accident	Additional description: Road traffic accident		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Skull fracture	Additional description: Skull fracture		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Spinal compression fracture	Additional description: Spinal compression fracture		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Spinal fracture	Additional description: Spinal fracture		

subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Thermal burn	Additional description: Thermal burn		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Subdural haematoma	Additional description: Subdural haematoma		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Thoracic vertebral fracture	Additional description: Thoracic vertebral fracture		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tibia fracture	Additional description: Tibia fracture		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Ulna fracture	Additional description: Ulna fracture		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Wrist fracture	Additional description: Wrist fracture		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Congenital, familial and genetic disorders			
Adenomatous polyposis coli	Additional description: Adenomatous polyposis coli		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			

Acute coronary syndrome	Additional description: Acute coronary syndrome	
subjects affected / exposed	0 / 231 (0.00%)	
occurrences causally related to treatment / all	0 / 0	
deaths causally related to treatment / all	0 / 0	
Acute myocardial infarction	Additional description: Acute myocardial infarction	
subjects affected / exposed	3 / 231 (1.30%)	
occurrences causally related to treatment / all	1 / 3	
deaths causally related to treatment / all	0 / 0	
Atrial tachycardia	Additional description: Atrial tachycardia	
subjects affected / exposed	1 / 231 (0.43%)	
occurrences causally related to treatment / all	0 / 1	
deaths causally related to treatment / all	0 / 0	
Aortic valve disease	Additional description: Aortic valve disease	
subjects affected / exposed	1 / 231 (0.43%)	
occurrences causally related to treatment / all	0 / 1	
deaths causally related to treatment / all	0 / 0	
Arteriosclerosis coronary artery	Additional description: Arteriosclerosis coronary artery	
subjects affected / exposed	0 / 231 (0.00%)	
occurrences causally related to treatment / all	0 / 0	
deaths causally related to treatment / all	0 / 0	
Atrial fibrillation	Additional description: Atrial fibrillation	
subjects affected / exposed	6 / 231 (2.60%)	
occurrences causally related to treatment / all	4 / 7	
deaths causally related to treatment / all	0 / 0	
Atrial flutter	Additional description: Atrial flutter	
subjects affected / exposed	0 / 231 (0.00%)	
occurrences causally related to treatment / all	0 / 0	
deaths causally related to treatment / all	0 / 0	
Angina pectoris	Additional description: Angina pectoris	
subjects affected / exposed	1 / 231 (0.43%)	
occurrences causally related to treatment / all	1 / 1	
deaths causally related to treatment / all	0 / 0	
Atrioventricular block	Additional description: Atrioventricular block	

subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac arrest	Additional description: Cardiac arrest		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac failure	Additional description: Cardiac failure		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac failure congestive	Additional description: Cardiac failure congestive		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiomyopathy	Additional description: Cardiomyopathy		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Coronary artery disease	Additional description: Coronary artery disease		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Intracardiac thrombus	Additional description: Intracardiac thrombus		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Myocardial infarction	Additional description: Myocardial infarction		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Myocarditis	Additional description: Myocarditis		

subjects affected / exposed	2 / 231 (0.87%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
Pericarditis	Additional description: Pericarditis		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Palpitations	Additional description: Palpitations		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pericardial effusion	Additional description: Pericardial effusion		
subjects affected / exposed	2 / 231 (0.87%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Sinus node dysfunction	Additional description: Sinus node dysfunction		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Stress cardiomyopathy	Additional description: Stress cardiomyopathy		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Supraventricular tachycardia	Additional description: Supraventricular tachycardia		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Ventricular fibrillation	Additional description: Ventricular fibrillation		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Carotid artery stenosis	Additional description: Carotid artery stenosis		

subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Carotid artery occlusion	Additional description: Carotid artery occlusion		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cerebellar stroke	Additional description: Cerebellar stroke		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cerebral haemorrhage	Additional description: Cerebral haemorrhage		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Cerebral ischaemia	Additional description: Cerebral ischaemia		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cerebrovascular accident	Additional description: Cerebrovascular accident		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Dysaesthesia	Additional description: Dysaesthesia		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dizziness	Additional description: Dizziness		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Embolic cerebral infarction	Additional description: Embolic cerebral infarction		

subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Encephalitis autoimmune			
Additional description: Encephalitis autoimmune			
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Epilepsy			
Additional description: Epilepsy			
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Haemorrhagic stroke			
Additional description: Haemorrhagic stroke			
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Headache			
Additional description: Headache			
subjects affected / exposed	2 / 231 (0.87%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
Ischaemic stroke			
Additional description: Ischaemic stroke			
subjects affected / exposed	2 / 231 (0.87%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Myasthenia gravis			
Additional description: Myasthenia gravis			
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Polyneuropathy			
Additional description: Polyneuropathy			
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Seizure			
Additional description: Seizure			

subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Syncope	Additional description: Syncope		
subjects affected / exposed	2 / 231 (0.87%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		

Thrombotic stroke	Additional description: Thrombotic stroke		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Toxic leukoencephalopathy	Additional description: Toxic leukoencephalopathy		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	1 / 1		

Transient global amnesia	Additional description: Transient global amnesia		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Transient ischaemic attack	Additional description: Transient ischaemic attack		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Vocal cord paresis	Additional description: Vocal cord paresis		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Blood and lymphatic system disorders			
Anaemia	Additional description: Anaemia		
subjects affected / exposed	2 / 231 (0.87%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		

Aplasia pure red cell	Additional description: Aplasia pure red cell		

subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Autoimmune haemolytic anaemia			
Additional description: Autoimmune haemolytic anaemia			
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Autoimmune neutropenia			
Additional description: Autoimmune neutropenia			
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Febrile neutropenia			
Additional description: Febrile neutropenia			
subjects affected / exposed	17 / 231 (7.36%)		
occurrences causally related to treatment / all	17 / 18		
deaths causally related to treatment / all	0 / 0		
Haemolytic anaemia			
Additional description: Haemolytic anaemia			
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Immune thrombocytopenia			
Additional description: Immune thrombocytopenia			
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Leukostasis syndrome			
Additional description: Leukostasis syndrome			
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Lymphadenitis			
Additional description: Lymphadenitis			
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lymphocytosis			
Additional description: Lymphocytosis			

subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Neutropenia	Additional description: Neutropenia		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pancytopenia	Additional description: Pancytopenia		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Splenomegaly	Additional description: Splenomegaly		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Thrombocytopenia	Additional description: Thrombocytopenia		
subjects affected / exposed	2 / 231 (0.87%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
Ear and labyrinth disorders			
Vertigo	Additional description: Vertigo		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vertigo positional	Additional description: Vertigo positional		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Eye disorders			
Acute macular outer retinopathy	Additional description: Acute macular outer retinopathy		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cataract	Additional description: Cataract		

subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dacryostenosis acquired	Additional description: Dacryostenosis acquired		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Eyelid cyst	Additional description: Eyelid cyst		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Macular hole	Additional description: Macular hole		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Optic ischaemic neuropathy	Additional description: Optic ischaemic neuropathy		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Retinal detachment	Additional description: Retinal detachment		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Venous stasis retinopathy	Additional description: Venous stasis retinopathy		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Abdominal pain	Additional description: Abdominal pain		
subjects affected / exposed	2 / 231 (0.87%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Abdominal hernia	Additional description: Abdominal hernia		

subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Abdominal pain upper	Additional description: Abdominal pain upper		
subjects affected / exposed	2 / 231 (0.87%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
Diarrhoea	Additional description: Diarrhoea		
subjects affected / exposed	4 / 231 (1.73%)		
occurrences causally related to treatment / all	5 / 6		
deaths causally related to treatment / all	0 / 0		
Diverticulum intestinal	Additional description: Diverticulum intestinal		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Duodenal perforation	Additional description: Duodenal perforation		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Duodenal ulcer haemorrhage	Additional description: Duodenal ulcer haemorrhage		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Enlarged uvula	Additional description: Enlarged uvula		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Epiplonic appendagitis	Additional description: Epiplonic appendagitis		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Erosive oesophagitis	Additional description: Erosive oesophagitis		

subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Gastritis	Additional description: Gastritis		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Gastritis erosive	Additional description: Gastritis erosive		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Gastrointestinal haemorrhage	Additional description: Gastrointestinal haemorrhage		
subjects affected / exposed	2 / 231 (0.87%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		

Gastrooesophageal reflux disease	Additional description: Gastrooesophageal reflux disease		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Haemorrhagic erosive gastritis	Additional description: Haemorrhagic erosive gastritis		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Ileus	Additional description: Ileus		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Impaired gastric emptying	Additional description: Impaired gastric emptying		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Inguinal hernia	Additional description: Inguinal hernia		

subjects affected / exposed	2 / 231 (0.87%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Irritable bowel syndrome	Additional description: Irritable bowel syndrome		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nausea	Additional description: Nausea		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Oesophageal rupture	Additional description: Oesophageal rupture		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Pancreatitis	Additional description: Pancreatitis		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pancreatolithiasis	Additional description: Pancreatolithiasis		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Stomatitis	Additional description: Stomatitis		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Upper gastrointestinal haemorrhage	Additional description: Upper gastrointestinal haemorrhage		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Bile duct stenosis	Additional description: Bile duct stenosis		

subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Biliary colic			
Additional description: Biliary colic			
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Cholecystitis			
Additional description: Cholecystitis			
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cholecystitis acute			
Additional description: Cholecystitis acute			
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cholelithiasis			
Additional description: Cholelithiasis			
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gallbladder polyp			
Additional description: Gallbladder polyp			
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatotoxicity			
Additional description: Hepatotoxicity			
subjects affected / exposed	2 / 231 (0.87%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
Liver disorder			
Additional description: Liver disorder			
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Subcapsular hepatic haematoma			
Additional description: Subcapsular hepatic haematoma			

subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			
Actinic keratosis	Additional description: Actinic keratosis		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dermatitis	Additional description: Dermatitis		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Dermatitis allergic	Additional description: Dermatitis allergic		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Erythema multiforme	Additional description: Erythema multiforme		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Rash	Additional description: Rash		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Rash maculo-papular	Additional description: Rash maculo-papular		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Acute kidney injury	Additional description: Acute kidney injury		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Nephrolithiasis	Additional description: Nephrolithiasis		

subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal colic	Additional description: Renal colic		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ureterolithiasis	Additional description: Ureterolithiasis		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urethral caruncle	Additional description: Urethral caruncle		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urethral stenosis	Additional description: Urethral stenosis		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urinary retention	Additional description: Urinary retention		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Endocrine disorders			
Goitre	Additional description: Goitre		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hyperthyroidism	Additional description: Hyperthyroidism		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			

Arthralgia	Additional description: Arthralgia	
subjects affected / exposed	2 / 231 (0.87%)	
occurrences causally related to treatment / all	0 / 2	
deaths causally related to treatment / all	0 / 0	
Back pain	Additional description: Back pain	
subjects affected / exposed	1 / 231 (0.43%)	
occurrences causally related to treatment / all	0 / 1	
deaths causally related to treatment / all	0 / 0	
Bursitis	Additional description: Bursitis	
subjects affected / exposed	0 / 231 (0.00%)	
occurrences causally related to treatment / all	0 / 0	
deaths causally related to treatment / all	0 / 0	
Dupuytren's contracture	Additional description: Dupuytren's contracture	
subjects affected / exposed	1 / 231 (0.43%)	
occurrences causally related to treatment / all	0 / 1	
deaths causally related to treatment / all	0 / 0	
Gouty arthritis	Additional description: Gouty arthritis	
subjects affected / exposed	0 / 231 (0.00%)	
occurrences causally related to treatment / all	0 / 0	
deaths causally related to treatment / all	0 / 0	
Haemarthrosis	Additional description: Haemarthrosis	
subjects affected / exposed	1 / 231 (0.43%)	
occurrences causally related to treatment / all	1 / 1	
deaths causally related to treatment / all	0 / 0	
Haematoma muscle	Additional description: Haematoma muscle	
subjects affected / exposed	0 / 231 (0.00%)	
occurrences causally related to treatment / all	0 / 0	
deaths causally related to treatment / all	0 / 0	
Hypercreatinaemia	Additional description: Hypercreatinaemia	
subjects affected / exposed	1 / 231 (0.43%)	
occurrences causally related to treatment / all	1 / 1	
deaths causally related to treatment / all	0 / 0	
Intervertebral disc protrusion	Additional description: Intervertebral disc protrusion	

subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal pain	Additional description: Musculoskeletal pain		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Pain in extremity	Additional description: Pain in extremity		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Osteochondrosis	Additional description: Osteochondrosis		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Osteonecrosis	Additional description: Osteonecrosis		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Osteoporotic fracture	Additional description: Osteoporotic fracture		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Osteoarthritis	Additional description: Osteoarthritis		
subjects affected / exposed	2 / 231 (0.87%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Periarthritis	Additional description: Periarthritis		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Polymyalgia rheumatica	Additional description: Polymyalgia rheumatica		

subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Rotator cuff syndrome	Additional description: Rotator cuff syndrome		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Scleroderma	Additional description: Scleroderma		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Spinal column stenosis	Additional description: Spinal column stenosis		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Spinal pain	Additional description: Spinal pain		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tenosynovitis	Additional description: Tenosynovitis		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations	Additional description: Anal abscess		
Anal abscess	Additional description: Anal abscess		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
Abscess limb	Additional description: Abscess limb		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Abscess	Additional description: Abscess		

subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Appendicitis	Additional description: Appendicitis		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Appendicitis perforated	Additional description: Appendicitis perforated		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Asymptomatic COVID-19	Additional description: Asymptomatic COVID-19		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bacteraemia	Additional description: Bacteraemia		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Bacterial infection	Additional description: Bacterial infection		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Atypical pneumonia	Additional description: Atypical pneumonia		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bronchitis	Additional description: Bronchitis		
subjects affected / exposed	3 / 231 (1.30%)		
occurrences causally related to treatment / all	2 / 3		
deaths causally related to treatment / all	0 / 0		
Bronchopulmonary aspergillosis	Additional description: Bronchopulmonary aspergillosis		

subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
Cerebral aspergillosis			
Additional description: Cerebral aspergillosis			
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cellulitis			
Additional description: Cellulitis			
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Chronic sinusitis			
Additional description: Chronic sinusitis			
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Corona virus infection			
Additional description: Corona virus infection			
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Coronavirus infection			
Additional description: Coronavirus infection			
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
COVID-19			
Additional description: COVID-19			
subjects affected / exposed	8 / 231 (3.46%)		
occurrences causally related to treatment / all	0 / 8		
deaths causally related to treatment / all	0 / 1		
COVID-19 pneumonia			
Additional description: COVID-19 pneumonia			
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cryptococcal fungaemia			
Additional description: Cryptococcal fungaemia			

subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Cystitis			
Additional description: Cystitis			
subjects affected / exposed	2 / 231 (0.87%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Cytomegalovirus infection			
Additional description: Cytomegalovirus infection			
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cytomegalovirus infection reactivation			
Additional description: Cytomegalovirus infection reactivation			
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Diverticulitis			
Additional description: Diverticulitis			
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Encephalitis fungal			
Additional description: Encephalitis fungal			
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	1 / 1		
Endocarditis			
Additional description: Endocarditis			
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Erysipelas			
Additional description: Erysipelas			
subjects affected / exposed	2 / 231 (0.87%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Epididymitis			
Additional description: Epididymitis			

subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Epstein-Barr virus infection	Additional description: Epstein-Barr virus infection		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Enterocolitis infectious	Additional description: Enterocolitis infectious		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Escherichia urinary tract infection	Additional description: Escherichia urinary tract infection		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Febrile infection	Additional description: Febrile infection		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Escherichia bacteraemia	Additional description: Escherichia bacteraemia		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gallbladder empyema	Additional description: Gallbladder empyema		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastroenteritis	Additional description: Gastroenteritis		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal infection	Additional description: Gastrointestinal infection		

subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Genital herpes zoster	Additional description: Genital herpes zoster		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Giardiasis	Additional description: Giardiasis		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		

Hepatitis B	Additional description: Hepatitis B		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Hepatitis B reactivation	Additional description: Hepatitis B reactivation		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Hepatitis E	Additional description: Hepatitis E		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		

Herpes zoster	Additional description: Herpes zoster		
subjects affected / exposed	2 / 231 (0.87%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		

Herpes zoster meningoencephalitis	Additional description: Herpes zoster meningoencephalitis		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Herpes zoster reactivation	Additional description: Herpes zoster reactivation		

subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Impetigo	Additional description: Impetigo		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infected seroma	Additional description: Infected seroma		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infection	Additional description: Infection		
subjects affected / exposed	5 / 231 (2.16%)		
occurrences causally related to treatment / all	3 / 6		
deaths causally related to treatment / all	0 / 0		
Infectious pleural effusion	Additional description: Infectious pleural effusion		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infective exacerbation of chronic obstructive airways disease	Additional description: Infective exacerbation of chronic obstructive airways disease		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Influenza	Additional description: Influenza		
subjects affected / exposed	5 / 231 (2.16%)		
occurrences causally related to treatment / all	0 / 5		
deaths causally related to treatment / all	0 / 0		
Keratitis bacterial	Additional description: Keratitis bacterial		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Kidney infection	Additional description: Kidney infection		

subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Laryngitis	Additional description: Laryngitis		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lower respiratory tract infection	Additional description: Lower respiratory tract infection		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lung infection	Additional description: Lung infection		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lyme disease	Additional description: Lyme disease		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lymph gland infection	Additional description: Lymph gland infection		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Localised infection	Additional description: Localised infection		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Meningitis	Additional description: Meningitis		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Meningitis viral	Additional description: Meningitis viral		

subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		

Mycoplasma infection	Additional description: Mycoplasma infection		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Neutropenic infection	Additional description: Neutropenic infection		
subjects affected / exposed	2 / 231 (0.87%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		

Myelitis	Additional description: Myelitis		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Osteomyelitis	Additional description: Osteomyelitis		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Pelvic abscess	Additional description: Pelvic abscess		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Pharyngitis	Additional description: Pharyngitis		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Papilloma viral infection	Additional description: Papilloma viral infection		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Parainfluenzae virus infection	Additional description: Parainfluenzae virus infection		

subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pleural infection	Additional description: Pleural infection		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Pneumocystis jirovecii pneumonia	Additional description: Pneumocystis jirovecii pneumonia		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonia	Additional description: Pneumonia		
subjects affected / exposed	19 / 231 (8.23%)		
occurrences causally related to treatment / all	14 / 22		
deaths causally related to treatment / all	0 / 0		
Pneumonia adenoviral	Additional description: Pneumonia adenoviral		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pneumonia influenzal	Additional description: Pneumonia influenzal		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonia legionella	Additional description: Pneumonia legionella		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonia mycoplasmal	Additional description: Pneumonia mycoplasmal		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pneumonia pneumococcal	Additional description: Pneumonia pneumococcal		

subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonia staphylococcal			
Additional description: Pneumonia staphylococcal			
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Pneumonia streptococcal			
Additional description: Pneumonia streptococcal			
subjects affected / exposed	2 / 231 (0.87%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
Pneumonia fungal			
Additional description: Pneumonia fungal			
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Pseudomonas infection			
Additional description: Pseudomonas infection			
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Rectal abscess			
Additional description: Rectal abscess			
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory syncytial virus infection			
Additional description: Respiratory syncytial virus infection			
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory tract infection			
Additional description: Respiratory tract infection			
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sialoadenitis			
Additional description: Sialoadenitis			

subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Sepsis	Additional description: Sepsis		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Septic shock	Additional description: Septic shock		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Sinobronchitis	Additional description: Sinobronchitis		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Skin infection	Additional description: Skin infection		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Sinusitis	Additional description: Sinusitis		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Staphylococcal infection	Additional description: Staphylococcal infection		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Streptococcal infection	Additional description: Streptococcal infection		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		

Streptococcal sepsis	Additional description: Streptococcal sepsis		

subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Subcutaneous abscess			
Additional description: Subcutaneous abscess			
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Suspected COVID-19			
Additional description: Suspected COVID-19			
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Staphylococcal sepsis			
Additional description: Staphylococcal sepsis			
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Tooth abscess			
Additional description: Tooth abscess			
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tooth infection			
Additional description: Tooth infection			
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Upper respiratory tract infection			
Additional description: Upper respiratory tract infection			
subjects affected / exposed	4 / 231 (1.73%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Viral infection			
Additional description: Viral infection			
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vestibular neuronitis			
Additional description: Vestibular neuronitis			

subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Urinary tract infection	Additional description: Urinary tract infection		
subjects affected / exposed	7 / 231 (3.03%)		
occurrences causally related to treatment / all	4 / 9		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders	Additional description: Dehydration		
Dehydration	Additional description: Dehydration		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hyperphosphataemia	Additional description: Hyperphosphataemia		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Hyperglycaemia	Additional description: Hyperglycaemia		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hyperkalaemia	Additional description: Hyperkalaemia		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Hyponatraemia	Additional description: Hyponatraemia		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hyperuricaemia	Additional description: Hyperuricaemia		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Hypoglycaemia	Additional description: Hypoglycaemia		

subjects affected / exposed	0 / 231 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Hypokalaemia	Additional description: Hypokalaemia		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Hypophosphataemia	Additional description: Hypophosphataemia		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		

Tumour lysis syndrome	Additional description: Tumour lysis syndrome		
subjects affected / exposed	6 / 231 (2.60%)		
occurrences causally related to treatment / all	6 / 6		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	GVe arm	SCIT arm	RVe arm
Total subjects affected by non-serious adverse events			
subjects affected / exposed	224 / 228 (98.25%)	214 / 216 (99.07%)	233 / 237 (98.31%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma of colon	Additional description: Adenocarcinoma of colon		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences (all)	0	0	0
Anogenital warts	Additional description: Anogenital warts		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences (all)	0	1	0
Angiomyolipoma	Additional description: Angiomyolipoma		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences (all)	1	0	0
Basal cell carcinoma	Additional description: Basal cell carcinoma		
subjects affected / exposed	5 / 228 (2.19%)	15 / 216 (6.94%)	11 / 237 (4.64%)
occurrences (all)	5	19	14

Benign soft tissue neoplasm subjects affected / exposed occurrences (all)	Additional description: Benign soft tissue neoplasm		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Bowen's disease subjects affected / exposed occurrences (all)	Additional description: Bowen's disease		
	0 / 228 (0.00%) 0	1 / 216 (0.46%) 2	1 / 237 (0.42%) 1
Choroid melanoma subjects affected / exposed occurrences (all)	Additional description: Choroid melanoma		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Colon adenoma subjects affected / exposed occurrences (all)	Additional description: Colon adenoma		
	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Colon cancer subjects affected / exposed occurrences (all)	Additional description: Colon cancer		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	2 / 237 (0.84%) 2
Cutaneous T-cell lymphoma subjects affected / exposed occurrences (all)	Additional description: Cutaneous T-cell lymphoma		
	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Erythroplasia subjects affected / exposed occurrences (all)	Additional description: Erythroplasia		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Fibroma subjects affected / exposed occurrences (all)	Additional description: Fibroma		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Haemangioma subjects affected / exposed occurrences (all)	Additional description: Haemangioma		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	2 / 237 (0.84%) 2
Haemangioma of liver subjects affected / exposed occurrences (all)	Additional description: Haemangioma of liver		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Keratoacanthoma subjects affected / exposed occurrences (all)	Additional description: Keratoacanthoma		
	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Lipoma subjects affected / exposed occurrences (all)	Additional description: Lipoma		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0

Malignant melanoma subjects affected / exposed occurrences (all)	Additional description: Malignant melanoma		
	3 / 228 (1.32%) 4	2 / 216 (0.93%) 2	1 / 237 (0.42%) 1
Melanocytic naevus subjects affected / exposed occurrences (all)	Additional description: Melanocytic naevus		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Malignant melanoma in situ subjects affected / exposed occurrences (all)	Additional description: Malignant melanoma in situ		
	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Myelodysplastic syndrome subjects affected / exposed occurrences (all)	Additional description: Myelodysplastic syndrome		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Myelofibrosis subjects affected / exposed occurrences (all)	Additional description: Myelofibrosis		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Non-small cell lung cancer subjects affected / exposed occurrences (all)	Additional description: Non-small cell lung cancer		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Papilloma subjects affected / exposed occurrences (all)	Additional description: Papilloma		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Plasmacytoma subjects affected / exposed occurrences (all)	Additional description: Plasmacytoma		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Polycythaemia vera subjects affected / exposed occurrences (all)	Additional description: Polycythaemia vera		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Prostate cancer subjects affected / exposed occurrences (all)	Additional description: Prostate cancer		
	1 / 228 (0.44%) 1	1 / 216 (0.46%) 1	1 / 237 (0.42%) 1
Schwannoma subjects affected / exposed occurrences (all)	Additional description: Schwannoma		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Seborrhoeic keratosis subjects affected / exposed occurrences (all)	Additional description: Seborrhoeic keratosis		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0

Richter's syndrome subjects affected / exposed occurrences (all)	Additional description: Richter's syndrome		
	1 / 228 (0.44%) 1	1 / 216 (0.46%) 1	1 / 237 (0.42%) 1
Skin papilloma subjects affected / exposed occurrences (all)	Additional description: Skin papilloma		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	3 / 237 (1.27%) 3
Squamous cell carcinoma subjects affected / exposed occurrences (all)	Additional description: Squamous cell carcinoma		
	3 / 228 (1.32%) 3	5 / 216 (2.31%) 7	1 / 237 (0.42%) 1
T-cell lymphoma subjects affected / exposed occurrences (all)	Additional description: T-cell lymphoma		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Thyroid neoplasm subjects affected / exposed occurrences (all)	Additional description: Thyroid neoplasm		
	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Transitional cell carcinoma subjects affected / exposed occurrences (all)	Additional description: Transitional cell carcinoma		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Vascular disorders			
Aortic aneurysm subjects affected / exposed occurrences (all)	Additional description: Aortic aneurysm		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Aortic dilatation subjects affected / exposed occurrences (all)	Additional description: Aortic dilatation		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Arteriosclerosis subjects affected / exposed occurrences (all)	Additional description: Arteriosclerosis		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Blood pressure fluctuation subjects affected / exposed occurrences (all)	Additional description: Blood pressure fluctuation		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Blue toe syndrome subjects affected / exposed occurrences (all)	Additional description: Blue toe syndrome		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Circulatory collapse	Additional description: Circulatory collapse		

subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Deep vein thrombosis	Additional description: Deep vein thrombosis		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Embolism	Additional description: Embolism		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	1 / 237 (0.42%) 1
Flushing	Additional description: Flushing		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	1 / 216 (0.46%) 1	1 / 237 (0.42%) 1
Gestational hypertension	Additional description: Gestational hypertension		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Haematoma	Additional description: Haematoma		
subjects affected / exposed occurrences (all)	9 / 228 (3.95%) 9	4 / 216 (1.85%) 5	4 / 237 (1.69%) 4
Haemorrhage	Additional description: Haemorrhage		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Hot flush	Additional description: Hot flush		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	2 / 216 (0.93%) 3	5 / 237 (2.11%) 6
Hypotension	Additional description: Hypotension		
subjects affected / exposed occurrences (all)	5 / 228 (2.19%) 5	10 / 216 (4.63%) 11	5 / 237 (2.11%) 7
Hypertensive crisis	Additional description: Hypertensive crisis		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	2 / 237 (0.84%) 3
Hypertension	Additional description: Hypertension		
subjects affected / exposed occurrences (all)	23 / 228 (10.09%) 25	6 / 216 (2.78%) 10	17 / 237 (7.17%) 17
Peripheral arterial occlusive disease	Additional description: Peripheral arterial occlusive disease		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Peripheral coldness	Additional description: Peripheral coldness		

subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Phlebitis	Additional description: Phlebitis		
subjects affected / exposed occurrences (all)	3 / 228 (1.32%) 3	4 / 216 (1.85%) 4	2 / 237 (0.84%) 2
Poor peripheral circulation	Additional description: Poor peripheral circulation		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Raynaud's phenomenon	Additional description: Raynaud's phenomenon		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Thrombophlebitis	Additional description: Thrombophlebitis		
subjects affected / exposed occurrences (all)	2 / 228 (0.88%) 2	2 / 216 (0.93%) 2	0 / 237 (0.00%) 0
Thrombophlebitis superficial	Additional description: Thrombophlebitis superficial		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Thrombosis	Additional description: Thrombosis		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Varicose vein	Additional description: Varicose vein		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Vasculitis	Additional description: Vasculitis		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Venous thrombosis	Additional description: Venous thrombosis		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Surgical and medical procedures	Additional description: Cranial remodelling therapy		
Cranial remodelling therapy subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Endodontic procedure	Additional description: Endodontic procedure		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0

Joint irrigation subjects affected / exposed occurrences (all)	Additional description: Joint irrigation		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Mastoidectomy subjects affected / exposed occurrences (all)	Additional description: Mastoidectomy		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Polypectomy subjects affected / exposed occurrences (all)	Additional description: Polypectomy		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Tooth extraction subjects affected / exposed occurrences (all)	Additional description: Tooth extraction		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
General disorders and administration site conditions Axillary pain subjects affected / exposed occurrences (all)	Additional description: Axillary pain		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Asthenia subjects affected / exposed occurrences (all)	Additional description: Asthenia		
	5 / 228 (2.19%) 5	9 / 216 (4.17%) 10	2 / 237 (0.84%) 2
Catheter site extravasation subjects affected / exposed occurrences (all)	Additional description: Catheter site extravasation		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Catheter site pain subjects affected / exposed occurrences (all)	Additional description: Catheter site pain		
	0 / 228 (0.00%) 0	2 / 216 (0.93%) 2	1 / 237 (0.42%) 1
Catheter site swelling subjects affected / exposed occurrences (all)	Additional description: Catheter site swelling		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Chest discomfort subjects affected / exposed occurrences (all)	Additional description: Chest discomfort		
	4 / 228 (1.75%) 4	1 / 216 (0.46%) 1	3 / 237 (1.27%) 3
Chest pain subjects affected / exposed occurrences (all)	Additional description: Chest pain		
	2 / 228 (0.88%) 3	11 / 216 (5.09%) 11	7 / 237 (2.95%) 7
Chills	Additional description: Chills		

subjects affected / exposed occurrences (all)	13 / 228 (5.70%) 13	13 / 216 (6.02%) 15	13 / 237 (5.49%) 14
Catheter site bruise	Additional description: Catheter site bruise		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Cyst	Additional description: Cyst		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Drug intolerance	Additional description: Drug intolerance		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Discomfort	Additional description: Discomfort		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Extravasation	Additional description: Extravasation		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	2 / 216 (0.93%) 2	0 / 237 (0.00%) 0
Face oedema	Additional description: Face oedema		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Fatigue	Additional description: Fatigue		
subjects affected / exposed occurrences (all)	76 / 228 (33.33%) 92	74 / 216 (34.26%) 91	79 / 237 (33.33%) 92
Feeling cold	Additional description: Feeling cold		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Gait disturbance	Additional description: Gait disturbance		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Feeling hot	Additional description: Feeling hot		
subjects affected / exposed occurrences (all)	2 / 228 (0.88%) 2	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
General physical health deterioration	Additional description: General physical health deterioration		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	2 / 237 (0.84%) 2
Inflammation	Additional description: Inflammation		

subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Induration	Additional description: Induration		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Influenza like illness	Additional description: Influenza like illness		
subjects affected / exposed occurrences (all)	26 / 228 (11.40%) 32	10 / 216 (4.63%) 11	11 / 237 (4.64%) 12
Infusion site extravasation	Additional description: Infusion site extravasation		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	2 / 237 (0.84%) 2
Injection site pain	Additional description: Injection site pain		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	3 / 216 (1.39%) 3	0 / 237 (0.00%) 0
Injection site reaction	Additional description: Injection site reaction		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	1 / 237 (0.42%) 1
Injection site swelling	Additional description: Injection site swelling		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Malaise	Additional description: Malaise		
subjects affected / exposed occurrences (all)	6 / 228 (2.63%) 6	2 / 216 (0.93%) 4	6 / 237 (2.53%) 6
Mass	Additional description: Mass		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Mucosal inflammation	Additional description: Mucosal inflammation		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	3 / 216 (1.39%) 3	3 / 237 (1.27%) 4
Non-cardiac chest pain	Additional description: Non-cardiac chest pain		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	2 / 237 (0.84%) 2
Oedema	Additional description: Oedema		
subjects affected / exposed occurrences (all)	5 / 228 (2.19%) 6	9 / 216 (4.17%) 12	4 / 237 (1.69%) 5
Oedema peripheral	Additional description: Oedema peripheral		

subjects affected / exposed occurrences (all)	6 / 228 (2.63%) 6	10 / 216 (4.63%) 13	14 / 237 (5.91%) 14
Pain	Additional description: Pain		
subjects affected / exposed occurrences (all)	8 / 228 (3.51%) 8	4 / 216 (1.85%) 4	0 / 237 (0.00%) 0
Papillitis	Additional description: Papillitis		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Peripheral oedema neonatal	Additional description: Peripheral oedema neonatal		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Peripheral swelling	Additional description: Peripheral swelling		
subjects affected / exposed occurrences (all)	3 / 228 (1.32%) 3	2 / 216 (0.93%) 2	4 / 237 (1.69%) 4
Pyrexia	Additional description: Pyrexia		
subjects affected / exposed occurrences (all)	52 / 228 (22.81%) 70	45 / 216 (20.83%) 67	30 / 237 (12.66%) 32
Swelling	Additional description: Swelling		
subjects affected / exposed occurrences (all)	2 / 228 (0.88%) 2	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Systemic inflammatory response syndrome	Additional description: Systemic inflammatory response syndrome		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Thirst	Additional description: Thirst		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Tissue infiltration	Additional description: Tissue infiltration		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Immune system disorders			
Anaphylactic reaction	Additional description: Anaphylactic reaction		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Autoimmune disorder	Additional description: Autoimmune disorder		

subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	2 / 237 (0.84%) 2
Cytokine release syndrome	Additional description: Cytokine release syndrome		
subjects affected / exposed occurrences (all)	3 / 228 (1.32%) 4	1 / 216 (0.46%) 1	4 / 237 (1.69%) 4
Drug hypersensitivity	Additional description: Drug hypersensitivity		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	2 / 237 (0.84%) 2
Hypersensitivity	Additional description: Hypersensitivity		
subjects affected / exposed occurrences (all)	10 / 228 (4.39%) 10	15 / 216 (6.94%) 16	4 / 237 (1.69%) 5
Hypogammaglobulinaemia	Additional description: Hypogammaglobulinaemia		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	1 / 237 (0.42%) 1
Immune reconstitution inflammatory syndrome	Additional description: Immune reconstitution inflammatory syndrome		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Immunodeficiency	Additional description: Immunodeficiency		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	2 / 216 (0.93%) 2	0 / 237 (0.00%) 0
Seasonal allergy	Additional description: Seasonal allergy		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Secondary immunodeficiency	Additional description: Secondary immunodeficiency		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	1 / 216 (0.46%) 1	1 / 237 (0.42%) 1
Selective IgG subclass deficiency	Additional description: Selective IgG subclass deficiency		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Reproductive system and breast disorders			
Balanoposthitis	Additional description: Balanoposthitis		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Benign prostatic hyperplasia	Additional description: Benign prostatic hyperplasia		

subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Breast induration	Additional description: Breast induration		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Breast pain	Additional description: Breast pain		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	2 / 237 (0.84%) 2
Dyspareunia	Additional description: Dyspareunia		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Endometriosis	Additional description: Endometriosis		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Erectile dysfunction	Additional description: Erectile dysfunction		
subjects affected / exposed occurrences (all)	2 / 228 (0.88%) 2	2 / 216 (0.93%) 2	1 / 237 (0.42%) 1
Haematospermia	Additional description: Haematospermia		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Hypomenorrhoea	Additional description: Hypomenorrhoea		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Menopausal symptoms	Additional description: Menopausal symptoms		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Menorrhagia	Additional description: Menorrhagia		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Menstruation irregular	Additional description: Menstruation irregular		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Nipple pain	Additional description: Nipple pain		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Ovarian hyperfunction	Additional description: Ovarian hyperfunction		

subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Penis disorder	Additional description: Penis disorder		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Pelvic pain	Additional description: Pelvic pain		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Prostatic hypoplasia	Additional description: Prostatic hypoplasia		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Prostatitis	Additional description: Prostatitis		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Scrotal oedema	Additional description: Scrotal oedema		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Testicular disorder	Additional description: Testicular disorder		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Testicular pain	Additional description: Testicular pain		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Vaginal haemorrhage	Additional description: Vaginal haemorrhage		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Vaginal discharge	Additional description: Vaginal discharge		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Vulvovaginal pruritus	Additional description: Vulvovaginal pruritus		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Respiratory, thoracic and mediastinal disorders			
Asthma	Additional description: Asthma		

subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Bronchospasm	Additional description: Bronchospasm		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Chronic obstructive pulmonary disease	Additional description: Chronic obstructive pulmonary disease		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 4
Cough	Additional description: Cough		
subjects affected / exposed occurrences (all)	37 / 228 (16.23%) 45	25 / 216 (11.57%) 26	19 / 237 (8.02%) 20
Dysaesthesia pharynx	Additional description: Dysaesthesia pharynx		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Dysphonia	Additional description: Dysphonia		
subjects affected / exposed occurrences (all)	3 / 228 (1.32%) 3	3 / 216 (1.39%) 4	4 / 237 (1.69%) 5
Dyspnoea	Additional description: Dyspnoea		
subjects affected / exposed occurrences (all)	11 / 228 (4.82%) 11	14 / 216 (6.48%) 14	21 / 237 (8.86%) 26
Dyspnoea exertional	Additional description: Dyspnoea exertional		
subjects affected / exposed occurrences (all)	3 / 228 (1.32%) 3	3 / 216 (1.39%) 3	3 / 237 (1.27%) 3
Epistaxis	Additional description: Epistaxis		
subjects affected / exposed occurrences (all)	3 / 228 (1.32%) 3	3 / 216 (1.39%) 3	4 / 237 (1.69%) 5
Haemoptysis	Additional description: Haemoptysis		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Hiccups	Additional description: Hiccups		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 2	0 / 237 (0.00%) 0
Hyperventilation	Additional description: Hyperventilation		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0

Interstitial lung disease subjects affected / exposed occurrences (all)	Additional description: Interstitial lung disease		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Laryngeal inflammation subjects affected / exposed occurrences (all)	Additional description: Laryngeal inflammation		
	1 / 228 (0.44%) 1	2 / 216 (0.93%) 2	1 / 237 (0.42%) 1
Nasal congestion subjects affected / exposed occurrences (all)	Additional description: Nasal congestion		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Nasal discomfort subjects affected / exposed occurrences (all)	Additional description: Nasal discomfort		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Nasal dryness subjects affected / exposed occurrences (all)	Additional description: Nasal dryness		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Nasal inflammation subjects affected / exposed occurrences (all)	Additional description: Nasal inflammation		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Nasal obstruction subjects affected / exposed occurrences (all)	Additional description: Nasal obstruction		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Nasal ulcer subjects affected / exposed occurrences (all)	Additional description: Nasal ulcer		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Oropharyngeal pain subjects affected / exposed occurrences (all)	Additional description: Oropharyngeal pain		
	13 / 228 (5.70%) 14	8 / 216 (3.70%) 10	14 / 237 (5.91%) 16
Pharyngeal inflammation subjects affected / exposed occurrences (all)	Additional description: Pharyngeal inflammation		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Pleural effusion subjects affected / exposed occurrences (all)	Additional description: Pleural effusion		
	1 / 228 (0.44%) 1	2 / 216 (0.93%) 2	0 / 237 (0.00%) 0
Pneumonitis subjects affected / exposed occurrences (all)	Additional description: Pneumonitis		
	1 / 228 (0.44%) 1	1 / 216 (0.46%) 1	2 / 237 (0.84%) 2

Productive cough subjects affected / exposed occurrences (all)	Additional description: Productive cough		
	1 / 228 (0.44%) 2	3 / 216 (1.39%) 3	4 / 237 (1.69%) 4
Pulmonary embolism subjects affected / exposed occurrences (all)	Additional description: Pulmonary embolism		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Pulmonary hypertension subjects affected / exposed occurrences (all)	Additional description: Pulmonary hypertension		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Pulmonary pain subjects affected / exposed occurrences (all)	Additional description: Pulmonary pain		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Rhinitis allergic subjects affected / exposed occurrences (all)	Additional description: Rhinitis allergic		
	2 / 228 (0.88%) 2	0 / 216 (0.00%) 0	1 / 237 (0.42%) 2
Respiratory alkalosis subjects affected / exposed occurrences (all)	Additional description: Respiratory alkalosis		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Rhinorrhoea subjects affected / exposed occurrences (all)	Additional description: Rhinorrhoea		
	3 / 228 (1.32%) 3	1 / 216 (0.46%) 1	1 / 237 (0.42%) 1
Sinus pain subjects affected / exposed occurrences (all)	Additional description: Sinus pain		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Sleep apnoea syndrome subjects affected / exposed occurrences (all)	Additional description: Sleep apnoea syndrome		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Tachypnoea subjects affected / exposed occurrences (all)	Additional description: Tachypnoea		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Throat clearing subjects affected / exposed occurrences (all)	Additional description: Throat clearing		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Throat irritation subjects affected / exposed occurrences (all)	Additional description: Throat irritation		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0

Throatache subjects affected / exposed occurrences (all)	Additional description: Throatache		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Upper-airway cough syndrome subjects affected / exposed occurrences (all)	Additional description: Upper-airway cough syndrome		
	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Wheezing subjects affected / exposed occurrences (all)	Additional description: Wheezing		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Psychiatric disorders			
Abnormal dreams subjects affected / exposed occurrences (all)	Additional description: Abnormal dreams		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Agitation subjects affected / exposed occurrences (all)	Additional description: Agitation		
	1 / 228 (0.44%) 1	1 / 216 (0.46%) 1	2 / 237 (0.84%) 2
Aggression subjects affected / exposed occurrences (all)	Additional description: Aggression		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Adjustment disorder subjects affected / exposed occurrences (all)	Additional description: Adjustment disorder		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Anxiety subjects affected / exposed occurrences (all)	Additional description: Anxiety		
	3 / 228 (1.32%) 3	3 / 216 (1.39%) 3	3 / 237 (1.27%) 3
Apathy subjects affected / exposed occurrences (all)	Additional description: Apathy		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Bruxism subjects affected / exposed occurrences (all)	Additional description: Bruxism		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Confusional state subjects affected / exposed occurrences (all)	Additional description: Confusional state		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Depression	Additional description: Depression		

subjects affected / exposed occurrences (all)	2 / 228 (0.88%) 2	4 / 216 (1.85%) 5	4 / 237 (1.69%) 4
Delirium	Additional description: Delirium		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Depressed mood	Additional description: Depressed mood		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Disorientation	Additional description: Disorientation		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Hallucination	Additional description: Hallucination		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Hyperarousal	Additional description: Hyperarousal		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Illusion	Additional description: Illusion		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Insomnia	Additional description: Insomnia		
subjects affected / exposed occurrences (all)	7 / 228 (3.07%) 9	11 / 216 (5.09%) 11	10 / 237 (4.22%) 10
Irritability	Additional description: Irritability		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Panic attack	Additional description: Panic attack		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 2
Restlessness	Additional description: Restlessness		
subjects affected / exposed occurrences (all)	2 / 228 (0.88%) 2	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Sleep disorder	Additional description: Sleep disorder		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	6 / 237 (2.53%) 8
Somnambulism	Additional description: Somnambulism		

subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences (all)	1	0	0
Stress	Additional description: Stress		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences (all)	0	0	1
Investigations			
Activated partial thromboplastin time prolonged	Additional description: Activated partial thromboplastin time prolonged		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences (all)	0	0	0
Alanine aminotransferase increased	Additional description: Alanine aminotransferase increased		
subjects affected / exposed	15 / 228 (6.58%)	1 / 216 (0.46%)	3 / 237 (1.27%)
occurrences (all)	16	1	3
Amylase increased	Additional description: Amylase increased		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences (all)	0	0	1
Aspartate aminotransferase increased	Additional description: Aspartate aminotransferase increased		
subjects affected / exposed	10 / 228 (4.39%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences (all)	10	0	0
Blood immunoglobulin G decreased	Additional description: Blood immunoglobulin G decreased		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences (all)	0	1	0
Basophil count decreased	Additional description: Basophil count decreased		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences (all)	0	0	1
Blood alkaline phosphatase increased	Additional description: Blood alkaline phosphatase increased		
subjects affected / exposed	4 / 228 (1.75%)	1 / 216 (0.46%)	2 / 237 (0.84%)
occurrences (all)	4	1	2
Blood bilirubin increased	Additional description: Blood bilirubin increased		
subjects affected / exposed	4 / 228 (1.75%)	0 / 216 (0.00%)	3 / 237 (1.27%)
occurrences (all)	7	0	3
Blood calcium decreased	Additional description: Blood calcium decreased		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences (all)	0	0	0
Blood chloride increased	Additional description: Blood chloride increased		

subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	2 / 237 (0.84%) 2
Blood creatine increased	Additional description: Blood creatine increased		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Blood creatinine increased	Additional description: Blood creatinine increased		
subjects affected / exposed occurrences (all)	5 / 228 (2.19%) 6	7 / 216 (3.24%) 7	13 / 237 (5.49%) 19
Blood glucose increased	Additional description: Blood glucose increased		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Blood immunoglobulin M decreased	Additional description: Blood immunoglobulin M decreased		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Blood lactate dehydrogenase increased	Additional description: Blood lactate dehydrogenase increased		
subjects affected / exposed occurrences (all)	2 / 228 (0.88%) 2	1 / 216 (0.46%) 1	9 / 237 (3.80%) 11
Blood phosphorus increased	Additional description: Blood phosphorus increased		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	1 / 216 (0.46%) 1	6 / 237 (2.53%) 8
Blood potassium decreased	Additional description: Blood potassium decreased		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Blood potassium increased	Additional description: Blood potassium increased		
subjects affected / exposed occurrences (all)	2 / 228 (0.88%) 2	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Blood pressure increased	Additional description: Blood pressure increased		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Blood thyroid stimulating hormone increased	Additional description: Blood thyroid stimulating hormone increased		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Blood urea increased	Additional description: Blood urea increased		

subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 2
Blood uric acid decreased subjects affected / exposed occurrences (all)	Additional description: Blood uric acid decreased		
	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Blood uric acid increased subjects affected / exposed occurrences (all)	Additional description: Blood uric acid increased		
	2 / 228 (0.88%) 2	0 / 216 (0.00%) 0	2 / 237 (0.84%) 2
Body temperature increased subjects affected / exposed occurrences (all)	Additional description: Body temperature increased		
	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Blood iron decreased subjects affected / exposed occurrences (all)	Additional description: Blood iron decreased		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Cardiac murmur subjects affected / exposed occurrences (all)	Additional description: Cardiac murmur		
	2 / 228 (0.88%) 2	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Bronchoscopy subjects affected / exposed occurrences (all)	Additional description: Bronchoscopy		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
C-reactive protein subjects affected / exposed occurrences (all)	Additional description: C-reactive protein		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
C-reactive protein increased subjects affected / exposed occurrences (all)	Additional description: C-reactive protein increased		
	2 / 228 (0.88%) 3	2 / 216 (0.93%) 2	2 / 237 (0.84%) 2
Cortisol decreased subjects affected / exposed occurrences (all)	Additional description: Cortisol decreased		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Enterococcus test positive subjects affected / exposed occurrences (all)	Additional description: Enterococcus test positive		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Eosinophil count decreased subjects affected / exposed occurrences (all)	Additional description: Eosinophil count decreased		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Free haemoglobin present	Additional description: Free haemoglobin present		

subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences (all)	0	0	0
Gamma-glutamyltransferase increased	Additional description: Gamma-glutamyltransferase increased		
subjects affected / exposed	6 / 228 (2.63%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences (all)	7	1	0
Glomerular filtration rate decreased	Additional description: Glomerular filtration rate decreased		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences (all)	0	0	1
Heart rate irregular	Additional description: Heart rate irregular		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences (all)	0	1	0
Hepatic enzyme abnormal	Additional description: Hepatic enzyme abnormal		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences (all)	0	0	0
Hepatic enzyme increased	Additional description: Hepatic enzyme increased		
subjects affected / exposed	5 / 228 (2.19%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences (all)	5	0	2
Hepatitis B DNA increased	Additional description: Hepatitis B DNA increased		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences (all)	1	0	0
Immunoglobulins decreased	Additional description: Immunoglobulins decreased		
subjects affected / exposed	2 / 228 (0.88%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences (all)	2	1	0
Inflammatory marker increased	Additional description: Inflammatory marker increased		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences (all)	0	0	1
International normalised ratio increased	Additional description: International normalised ratio increased		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences (all)	1	0	0
Intraocular pressure increased	Additional description: Intraocular pressure increased		
subjects affected / exposed	2 / 228 (0.88%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences (all)	2	0	0
Left ventricular end-diastolic pressure decreased	Additional description: Left ventricular end-diastolic pressure decreased		

subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Lipase increased	Additional description: Lipase increased		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Liver function test increased	Additional description: Liver function test increased		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Monocyte count decreased	Additional description: Monocyte count decreased		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 2
Myocardial necrosis marker increased	Additional description: Myocardial necrosis marker increased		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
N-terminal prohormone brain natriuretic peptide increased	Additional description: N-terminal prohormone brain natriuretic peptide increased		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	2 / 216 (0.93%) 2	0 / 237 (0.00%) 0
Neutrophil count decreased	Additional description: Neutrophil count decreased		
subjects affected / exposed occurrences (all)	33 / 228 (14.47%) 56	22 / 216 (10.19%) 27	31 / 237 (13.08%) 44
Platelet count decreased	Additional description: Platelet count decreased		
subjects affected / exposed occurrences (all)	14 / 228 (6.14%) 19	8 / 216 (3.70%) 9	8 / 237 (3.38%) 8
Procalcitonin increased	Additional description: Procalcitonin increased		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Reticulocyte count decreased	Additional description: Reticulocyte count decreased		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
SARS-CoV-2 test positive	Additional description: SARS-CoV-2 test positive		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	2 / 216 (0.93%) 2	1 / 237 (0.42%) 1
Serum ferritin decreased	Additional description: Serum ferritin decreased		

subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Transaminases increased	Additional description: Transaminases increased		
subjects affected / exposed occurrences (all)	2 / 228 (0.88%) 2	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Transferrin decreased	Additional description: Transferrin decreased		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Vitamin B12 decreased	Additional description: Vitamin B12 decreased		
subjects affected / exposed occurrences (all)	2 / 228 (0.88%) 2	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Weight decreased	Additional description: Weight decreased		
subjects affected / exposed occurrences (all)	7 / 228 (3.07%) 9	6 / 216 (2.78%) 6	2 / 237 (0.84%) 2
Weight increased	Additional description: Weight increased		
subjects affected / exposed occurrences (all)	8 / 228 (3.51%) 8	5 / 216 (2.31%) 9	6 / 237 (2.53%) 6
White blood cell count decreased	Additional description: White blood cell count decreased		
subjects affected / exposed occurrences (all)	8 / 228 (3.51%) 13	9 / 216 (4.17%) 9	5 / 237 (2.11%) 8
White blood cell count increased	Additional description: White blood cell count increased		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	1 / 237 (0.42%) 1
Injury, poisoning and procedural complications			
Arthropod bite	Additional description: Arthropod bite		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	1 / 216 (0.46%) 1	4 / 237 (1.69%) 4
Animal bite	Additional description: Animal bite		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Bone contusion	Additional description: Bone contusion		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Chest injury	Additional description: Chest injury		

subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Clavicle fracture	Additional description: Clavicle fracture		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Contusion	Additional description: Contusion		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	1 / 216 (0.46%) 1	1 / 237 (0.42%) 1
Ear canal injury	Additional description: Ear canal injury		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Epicondylitis	Additional description: Epicondylitis		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Face injury	Additional description: Face injury		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Fall	Additional description: Fall		
subjects affected / exposed occurrences (all)	5 / 228 (2.19%) 5	3 / 216 (1.39%) 4	0 / 237 (0.00%) 0
Foreign body in eye	Additional description: Foreign body in eye		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Fracture	Additional description: Fracture		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Hand fracture	Additional description: Hand fracture		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Head injury	Additional description: Head injury		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Infusion related reaction	Additional description: Infusion related reaction		
subjects affected / exposed occurrences (all)	101 / 228 (44.30%) 111	65 / 216 (30.09%) 74	67 / 237 (28.27%) 88
Injury	Additional description: Injury		

subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Ligament injury	Additional description: Ligament injury		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Joint capsule rupture	Additional description: Joint capsule rupture		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Ligament sprain	Additional description: Ligament sprain		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Limb injury	Additional description: Limb injury		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	2 / 216 (0.93%) 2	0 / 237 (0.00%) 0
Mallet finger	Additional description: Mallet finger		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	1 / 237 (0.42%) 1
Meniscus injury	Additional description: Meniscus injury		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Mouth injury	Additional description: Mouth injury		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Multiple fractures	Additional description: Multiple fractures		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Muscle strain	Additional description: Muscle strain		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Nasal injury	Additional description: Nasal injury		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Paravenous drug administration	Additional description: Paravenous drug administration		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	2 / 216 (0.93%) 2	0 / 237 (0.00%) 0
Procedural pain	Additional description: Procedural pain		

subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Post-traumatic neck syndrome	Additional description: Post-traumatic neck syndrome		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Road traffic accident	Additional description: Road traffic accident		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Scar	Additional description: Scar		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Skin abrasion	Additional description: Skin abrasion		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Skin wound	Additional description: Skin wound		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Spinal compression fracture	Additional description: Spinal compression fracture		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Spinal fracture	Additional description: Spinal fracture		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Tendon rupture	Additional description: Tendon rupture		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Thermal burn	Additional description: Thermal burn		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	1 / 237 (0.42%) 1
Thoracic vertebral fracture	Additional description: Thoracic vertebral fracture		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Tooth injury	Additional description: Tooth injury		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Transfusion reaction	Additional description: Transfusion reaction		

subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Traumatic ear amputation	Additional description: Traumatic ear amputation		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Traumatic haematoma	Additional description: Traumatic haematoma		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Vascular access complication	Additional description: Vascular access complication		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Wrist fracture	Additional description: Wrist fracture		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Wound	Additional description: Wound		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Wound complication	Additional description: Wound complication		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	2 / 237 (0.84%) 2
Congenital, familial and genetic disorders			
Cryptorchism	Additional description: Cryptorchism		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Glycogen storage disease type I	Additional description: Glycogen storage disease type I		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Hydrocele	Additional description: Hydrocele		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Ichthyosis	Additional description: Ichthyosis		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Phimosis	Additional description: Phimosis		

subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Cardiac disorders	Additional description: Cardiac disorders		
Acute coronary syndrome subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Angina pectoris subjects affected / exposed occurrences (all)	3 / 228 (1.32%) 3	2 / 216 (0.93%) 2	4 / 237 (1.69%) 5
Arteriosclerosis coronary artery subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Arrhythmia subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	1 / 216 (0.46%) 1	1 / 237 (0.42%) 1
Atrial fibrillation subjects affected / exposed occurrences (all)	5 / 228 (2.19%) 5	5 / 216 (2.31%) 5	5 / 237 (2.11%) 6
Atrial flutter subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	2 / 216 (0.93%) 3	1 / 237 (0.42%) 1
Atrial thrombosis subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Atrioventricular block second degree subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Bradycardia subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	2 / 216 (0.93%) 2	1 / 237 (0.42%) 1
Bundle branch block right subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Cardiac discomfort subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1

Cardiac failure subjects affected / exposed occurrences (all)	Additional description: Cardiac failure		
	1 / 228 (0.44%) 1	3 / 216 (1.39%) 3	2 / 237 (0.84%) 2
Cardiovascular disorder subjects affected / exposed occurrences (all)	Additional description: Cardiovascular disorder		
	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	1 / 237 (0.42%) 1
Coronary artery disease subjects affected / exposed occurrences (all)	Additional description: Coronary artery disease		
	2 / 228 (0.88%) 2	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Coronary artery stenosis subjects affected / exposed occurrences (all)	Additional description: Coronary artery stenosis		
	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Extrasystoles subjects affected / exposed occurrences (all)	Additional description: Extrasystoles		
	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Hypertensive heart disease subjects affected / exposed occurrences (all)	Additional description: Hypertensive heart disease		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Myocardial ischaemia subjects affected / exposed occurrences (all)	Additional description: Myocardial ischaemia		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Palpitations subjects affected / exposed occurrences (all)	Additional description: Palpitations		
	3 / 228 (1.32%) 3	2 / 216 (0.93%) 2	3 / 237 (1.27%) 3
Pericardial effusion subjects affected / exposed occurrences (all)	Additional description: Pericardial effusion		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Right ventricular failure subjects affected / exposed occurrences (all)	Additional description: Right ventricular failure		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Sinus tachycardia subjects affected / exposed occurrences (all)	Additional description: Sinus tachycardia		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Supraventricular tachycardia subjects affected / exposed occurrences (all)	Additional description: Supraventricular tachycardia		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0

Tachycardia	Additional description: Tachycardia		
subjects affected / exposed	3 / 228 (1.32%)	2 / 216 (0.93%)	4 / 237 (1.69%)
occurrences (all)	4	2	4
Tachycardia paroxysmal	Additional description: Tachycardia paroxysmal		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences (all)	0	1	0
Ventricular extrasystoles	Additional description: Ventricular extrasystoles		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	2 / 237 (0.84%)
occurrences (all)	0	0	2
Nervous system disorders			
Ageusia	Additional description: Ageusia		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences (all)	0	0	0
Amnesia	Additional description: Amnesia		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences (all)	1	0	1
Aphasia	Additional description: Aphasia		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	2 / 237 (0.84%)
occurrences (all)	1	0	2
Ataxia	Additional description: Ataxia		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences (all)	0	0	0
Balance disorder	Additional description: Balance disorder		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences (all)	0	0	1
Burning sensation	Additional description: Burning sensation		
subjects affected / exposed	2 / 228 (0.88%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences (all)	2	0	0
Carpal tunnel syndrome	Additional description: Carpal tunnel syndrome		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	4 / 237 (1.69%)
occurrences (all)	1	0	4
Cervicobrachial syndrome	Additional description: Cervicobrachial syndrome		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences (all)	0	0	0
Carotid artery stenosis	Additional description: Carotid artery stenosis		

subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Concentration impairment	Additional description: Concentration impairment		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Cognitive disorder	Additional description: Cognitive disorder		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Cubital tunnel syndrome	Additional description: Cubital tunnel syndrome		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Depressed level of consciousness	Additional description: Depressed level of consciousness		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Disturbance in attention	Additional description: Disturbance in attention		
subjects affected / exposed occurrences (all)	5 / 228 (2.19%) 5	2 / 216 (0.93%) 2	3 / 237 (1.27%) 3
Dizziness	Additional description: Dizziness		
subjects affected / exposed occurrences (all)	21 / 228 (9.21%) 28	12 / 216 (5.56%) 15	20 / 237 (8.44%) 24
Dizziness postural	Additional description: Dizziness postural		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Dysaesthesia	Additional description: Dysaesthesia		
subjects affected / exposed occurrences (all)	2 / 228 (0.88%) 2	2 / 216 (0.93%) 2	2 / 237 (0.84%) 2
Dysgeusia	Additional description: Dysgeusia		
subjects affected / exposed occurrences (all)	6 / 228 (2.63%) 6	9 / 216 (4.17%) 9	3 / 237 (1.27%) 3
Facial paralysis	Additional description: Facial paralysis		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Formication	Additional description: Formication		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Hand-arm vibration syndrome	Additional description: Hand-arm vibration syndrome		

subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Head discomfort	Additional description: Head discomfort		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Headache	Additional description: Headache		
subjects affected / exposed occurrences (all)	36 / 228 (15.79%) 45	22 / 216 (10.19%) 29	23 / 237 (9.70%) 26
Hypoaesthesia	Additional description: Hypoaesthesia		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	2 / 237 (0.84%) 2
Hypertonia	Additional description: Hypertonia		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Hypotonia	Additional description: Hypotonia		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Intention tremor	Additional description: Intention tremor		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Lumbar radiculopathy	Additional description: Lumbar radiculopathy		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Memory impairment	Additional description: Memory impairment		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	1 / 237 (0.42%) 2
Mental impairment	Additional description: Mental impairment		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Migraine	Additional description: Migraine		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	1 / 216 (0.46%) 1	1 / 237 (0.42%) 1
Muscle spasticity	Additional description: Muscle spasticity		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Neuromuscular blockade	Additional description: Neuromuscular blockade		

subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Olfactory nerve disorder	Additional description: Olfactory nerve disorder		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Neuropathy peripheral	Additional description: Neuropathy peripheral		
subjects affected / exposed occurrences (all)	3 / 228 (1.32%) 3	4 / 216 (1.85%) 4	1 / 237 (0.42%) 1
Orthostatic intolerance	Additional description: Orthostatic intolerance		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Paraesthesia	Additional description: Paraesthesia		
subjects affected / exposed occurrences (all)	3 / 228 (1.32%) 3	4 / 216 (1.85%) 4	3 / 237 (1.27%) 3
Parkinson's disease	Additional description: Parkinson's disease		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Parosmia	Additional description: Parosmia		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Peripheral motor neuropathy	Additional description: Peripheral motor neuropathy		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Peripheral sensory neuropathy	Additional description: Peripheral sensory neuropathy		
subjects affected / exposed occurrences (all)	3 / 228 (1.32%) 4	2 / 216 (0.93%) 2	5 / 237 (2.11%) 5
Polyneuropathy	Additional description: Polyneuropathy		
subjects affected / exposed occurrences (all)	3 / 228 (1.32%) 3	3 / 216 (1.39%) 4	2 / 237 (0.84%) 2
Post herpetic neuralgia	Additional description: Post herpetic neuralgia		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Presyncope	Additional description: Presyncope		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	2 / 216 (0.93%) 2	0 / 237 (0.00%) 0
Restless legs syndrome	Additional description: Restless legs syndrome		

subjects affected / exposed occurrences (all)	2 / 228 (0.88%) 2	0 / 216 (0.00%) 0	2 / 237 (0.84%) 2
Sciatica	Additional description: Sciatica		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Sensory disturbance	Additional description: Sensory disturbance		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Syncope	Additional description: Syncope		
subjects affected / exposed occurrences (all)	4 / 228 (1.75%) 4	4 / 216 (1.85%) 4	2 / 237 (0.84%) 2
Somnolence	Additional description: Somnolence		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Taste disorder	Additional description: Taste disorder		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	1 / 216 (0.46%) 1	1 / 237 (0.42%) 1
Transient global amnesia	Additional description: Transient global amnesia		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Tremor	Additional description: Tremor		
subjects affected / exposed occurrences (all)	3 / 228 (1.32%) 3	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Trigeminal neuralgia	Additional description: Trigeminal neuralgia		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Visual field defect	Additional description: Visual field defect		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	2 / 237 (0.84%) 3
Blood and lymphatic system disorders			
Agranulocytosis	Additional description: Agranulocytosis		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Anaemia	Additional description: Anaemia		
subjects affected / exposed occurrences (all)	17 / 228 (7.46%) 21	31 / 216 (14.35%) 42	20 / 237 (8.44%) 27

Autoimmune haemolytic anaemia subjects affected / exposed occurrences (all)	Additional description: Autoimmune haemolytic anaemia		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Bicytopenia subjects affected / exposed occurrences (all)	Additional description: Bicytopenia		
	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Eosinophilia subjects affected / exposed occurrences (all)	Additional description: Eosinophilia		
	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Febrile neutropenia subjects affected / exposed occurrences (all)	Additional description: Febrile neutropenia		
	2 / 228 (0.88%) 4	6 / 216 (2.78%) 6	3 / 237 (1.27%) 3
Granulocytopenia subjects affected / exposed occurrences (all)	Additional description: Granulocytopenia		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	2 / 237 (0.84%) 2
Haemolysis subjects affected / exposed occurrences (all)	Additional description: Haemolysis		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Haemorrhagic diathesis subjects affected / exposed occurrences (all)	Additional description: Haemorrhagic diathesis		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Hypoglobulinaemia subjects affected / exposed occurrences (all)	Additional description: Hypoglobulinaemia		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Immune thrombocytopenia subjects affected / exposed occurrences (all)	Additional description: Immune thrombocytopenia		
	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	1 / 237 (0.42%) 1
Iron deficiency anaemia subjects affected / exposed occurrences (all)	Additional description: Iron deficiency anaemia		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Leukocytosis subjects affected / exposed occurrences (all)	Additional description: Leukocytosis		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	2 / 237 (0.84%) 2
Leukopenia subjects affected / exposed occurrences (all)	Additional description: Leukopenia		
	20 / 228 (8.77%) 30	33 / 216 (15.28%) 48	12 / 237 (5.06%) 22

Lymph node pain	Additional description: Lymph node pain		
subjects affected / exposed	2 / 228 (0.88%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences (all)	2	1	0
Lymphadenitis	Additional description: Lymphadenitis		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences (all)	0	1	0
Lymphadenopathy	Additional description: Lymphadenopathy		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences (all)	0	1	0
Macrocytosis	Additional description: Macrocytosis		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences (all)	0	0	0
Microcytic anaemia	Additional description: Microcytic anaemia		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences (all)	0	0	0
Neutropenia	Additional description: Neutropenia		
subjects affected / exposed	111 / 228 (48.68%)	107 / 216 (49.54%)	108 / 237 (45.57%)
occurrences (all)	272	209	231
Pancytopenia	Additional description: Pancytopenia		
subjects affected / exposed	0 / 228 (0.00%)	2 / 216 (0.93%)	0 / 237 (0.00%)
occurrences (all)	0	2	0
Reticulocytosis	Additional description: Reticulocytosis		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences (all)	0	0	1
Thrombocytopenia	Additional description: Thrombocytopenia		
subjects affected / exposed	34 / 228 (14.91%)	32 / 216 (14.81%)	18 / 237 (7.59%)
occurrences (all)	40	44	28
Ear and labyrinth disorders			
Auditory disorder	Additional description: Auditory disorder		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences (all)	0	0	1
Deafness	Additional description: Deafness		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences (all)	1	0	0
Deafness unilateral	Additional description: Deafness unilateral		

subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Ear haemorrhage	Additional description: Ear haemorrhage		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Ear pain	Additional description: Ear pain		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	3 / 216 (1.39%) 3	3 / 237 (1.27%) 3
Hypoacusis	Additional description: Hypoacusis		
subjects affected / exposed occurrences (all)	2 / 228 (0.88%) 2	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Middle ear effusion	Additional description: Middle ear effusion		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Middle ear inflammation	Additional description: Middle ear inflammation		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Tinnitus	Additional description: Tinnitus		
subjects affected / exposed occurrences (all)	6 / 228 (2.63%) 6	0 / 216 (0.00%) 0	4 / 237 (1.69%) 4
Vertigo positional	Additional description: Vertigo positional		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Vertigo	Additional description: Vertigo		
subjects affected / exposed occurrences (all)	6 / 228 (2.63%) 6	8 / 216 (3.70%) 8	9 / 237 (3.80%) 9
Eye disorders	Additional description: Eye disorders		
Blepharitis	Additional description: Blepharitis		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Cataract	Additional description: Cataract		
subjects affected / exposed occurrences (all)	2 / 228 (0.88%) 2	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Conjunctival haemorrhage	Additional description: Conjunctival haemorrhage		
subjects affected / exposed occurrences (all)	2 / 228 (0.88%) 2	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0

Corneal erosion subjects affected / exposed occurrences (all)	Additional description: Corneal erosion		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Diplopia subjects affected / exposed occurrences (all)	Additional description: Diplopia		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Dry eye subjects affected / exposed occurrences (all)	Additional description: Dry eye		
	1 / 228 (0.44%) 1	2 / 216 (0.93%) 2	1 / 237 (0.42%) 1
Erythema of eyelid subjects affected / exposed occurrences (all)	Additional description: Erythema of eyelid		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Exophthalmos subjects affected / exposed occurrences (all)	Additional description: Exophthalmos		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Eye haemorrhage subjects affected / exposed occurrences (all)	Additional description: Eye haemorrhage		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	2 / 237 (0.84%) 2
Eye inflammation subjects affected / exposed occurrences (all)	Additional description: Eye inflammation		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Eye irritation subjects affected / exposed occurrences (all)	Additional description: Eye irritation		
	0 / 228 (0.00%) 0	2 / 216 (0.93%) 2	0 / 237 (0.00%) 0
Eye oedema subjects affected / exposed occurrences (all)	Additional description: Eye oedema		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Eye pain subjects affected / exposed occurrences (all)	Additional description: Eye pain		
	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Eyelid haematoma subjects affected / exposed occurrences (all)	Additional description: Eyelid haematoma		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Eyelid oedema subjects affected / exposed occurrences (all)	Additional description: Eyelid oedema		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1

Eyelid ptosis subjects affected / exposed occurrences (all)	Additional description: Eyelid ptosis		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Eye disorder subjects affected / exposed occurrences (all)	Additional description: Eye disorder		
	2 / 228 (0.88%) 2	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Glaucoma subjects affected / exposed occurrences (all)	Additional description: Glaucoma		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Hyalosis asteroid subjects affected / exposed occurrences (all)	Additional description: Hyalosis asteroid		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Lacrimation increased subjects affected / exposed occurrences (all)	Additional description: Lacrimation increased		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Ocular hyperaemia subjects affected / exposed occurrences (all)	Additional description: Ocular hyperaemia		
	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	1 / 237 (0.42%) 1
Ocular hypertension subjects affected / exposed occurrences (all)	Additional description: Ocular hypertension		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Panophthalmitis subjects affected / exposed occurrences (all)	Additional description: Panophthalmitis		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Periorbital oedema subjects affected / exposed occurrences (all)	Additional description: Periorbital oedema		
	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Photophobia subjects affected / exposed occurrences (all)	Additional description: Photophobia		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Retinal haemorrhage subjects affected / exposed occurrences (all)	Additional description: Retinal haemorrhage		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Uveitis subjects affected / exposed occurrences (all)	Additional description: Uveitis		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0

Vitreous detachment subjects affected / exposed occurrences (all)	Additional description: Vitreous detachment		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Vitreous disorder subjects affected / exposed occurrences (all)	Additional description: Vitreous disorder		
	1 / 228 (0.44%) 1	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Vitreous haemorrhage subjects affected / exposed occurrences (all)	Additional description: Vitreous haemorrhage		
	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Visual impairment subjects affected / exposed occurrences (all)	Additional description: Visual impairment		
	1 / 228 (0.44%) 1	1 / 216 (0.46%) 1	3 / 237 (1.27%) 3
Vision blurred subjects affected / exposed occurrences (all)	Additional description: Vision blurred		
	4 / 228 (1.75%) 4	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Gastrointestinal disorders Abdominal pain upper subjects affected / exposed occurrences (all)	Additional description: Abdominal pain upper		
	11 / 228 (4.82%) 12	8 / 216 (3.70%) 8	11 / 237 (4.64%) 12
Abdominal pain lower subjects affected / exposed occurrences (all)	Additional description: Abdominal pain lower		
	1 / 228 (0.44%) 1	3 / 216 (1.39%) 3	0 / 237 (0.00%) 0
Abdominal pain subjects affected / exposed occurrences (all)	Additional description: Abdominal pain		
	6 / 228 (2.63%) 6	5 / 216 (2.31%) 6	14 / 237 (5.91%) 17
Abdominal distension subjects affected / exposed occurrences (all)	Additional description: Abdominal distension		
	3 / 228 (1.32%) 3	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Abdominal discomfort subjects affected / exposed occurrences (all)	Additional description: Abdominal discomfort		
	3 / 228 (1.32%) 3	2 / 216 (0.93%) 2	4 / 237 (1.69%) 4
Anal ulcer subjects affected / exposed occurrences (all)	Additional description: Anal ulcer		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Anal pruritus	Additional description: Anal pruritus		

subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Anal incontinence	Additional description: Anal incontinence		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Anal haemorrhage	Additional description: Anal haemorrhage		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Anal fissure	Additional description: Anal fissure		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	3 / 216 (1.39%) 3	0 / 237 (0.00%) 0
Angular cheilitis	Additional description: Angular cheilitis		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Aphthous ulcer	Additional description: Aphthous ulcer		
subjects affected / exposed occurrences (all)	3 / 228 (1.32%) 3	0 / 216 (0.00%) 0	2 / 237 (0.84%) 2
Cheilitis	Additional description: Cheilitis		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Coeliac disease	Additional description: Coeliac disease		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Colitis	Additional description: Colitis		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Constipation	Additional description: Constipation		
subjects affected / exposed occurrences (all)	28 / 228 (12.28%) 31	64 / 216 (29.63%) 73	28 / 237 (11.81%) 31
Crohn's disease	Additional description: Crohn's disease		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Dental caries	Additional description: Dental caries		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Diarrhoea	Additional description: Diarrhoea		

subjects affected / exposed occurrences (all)	74 / 228 (32.46%) 108	27 / 216 (12.50%) 31	72 / 237 (30.38%) 97
Diarrhoea haemorrhagic	Additional description: Diarrhoea haemorrhagic		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Defaecation disorder	Additional description: Defaecation disorder		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Diverticulum intestinal	Additional description: Diverticulum intestinal		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Dry mouth	Additional description: Dry mouth		
subjects affected / exposed occurrences (all)	3 / 228 (1.32%) 3	5 / 216 (2.31%) 5	2 / 237 (0.84%) 2
Dyspepsia	Additional description: Dyspepsia		
subjects affected / exposed occurrences (all)	17 / 228 (7.46%) 19	3 / 216 (1.39%) 3	10 / 237 (4.22%) 10
Dysphagia	Additional description: Dysphagia		
subjects affected / exposed occurrences (all)	2 / 228 (0.88%) 2	3 / 216 (1.39%) 3	2 / 237 (0.84%) 2
Enterovirus infection	Additional description: Enterovirus infection		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Epigastric discomfort	Additional description: Epigastric discomfort		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	3 / 237 (1.27%) 3
Faeces discoloured	Additional description: Faeces discoloured		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Gastric haemorrhage	Additional description: Gastric haemorrhage		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Flatulence	Additional description: Flatulence		
subjects affected / exposed occurrences (all)	9 / 228 (3.95%) 11	3 / 216 (1.39%) 3	4 / 237 (1.69%) 4
Food poisoning	Additional description: Food poisoning		

subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Frequent bowel movements	Additional description: Frequent bowel movements		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Giant cell epulis	Additional description: Giant cell epulis		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Gingival bleeding	Additional description: Gingival bleeding		
subjects affected / exposed occurrences (all)	2 / 228 (0.88%) 2	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Gastritis	Additional description: Gastritis		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	1 / 216 (0.46%) 1	1 / 237 (0.42%) 1
Gastrointestinal haemorrhage	Additional description: Gastrointestinal haemorrhage		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Gastrointestinal motility disorder	Additional description: Gastrointestinal motility disorder		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Gastrointestinal pain	Additional description: Gastrointestinal pain		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Gastrointestinal tract irritation	Additional description: Gastrointestinal tract irritation		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Gastrooesophageal reflux disease	Additional description: Gastrooesophageal reflux disease		
subjects affected / exposed occurrences (all)	2 / 228 (0.88%) 2	5 / 216 (2.31%) 5	9 / 237 (3.80%) 9
Gingival discolouration	Additional description: Gingival discolouration		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Haemorrhoidal haemorrhage	Additional description: Haemorrhoidal haemorrhage		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Haematochezia	Additional description: Haematochezia		

subjects affected / exposed occurrences (all)	2 / 228 (0.88%) 2	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Haemorrhoids	Additional description: Haemorrhoids		
subjects affected / exposed occurrences (all)	4 / 228 (1.75%) 4	1 / 216 (0.46%) 1	3 / 237 (1.27%) 3
Inguinal hernia	Additional description: Inguinal hernia		
subjects affected / exposed occurrences (all)	2 / 228 (0.88%) 2	0 / 216 (0.00%) 0	2 / 237 (0.84%) 2
Lip dry	Additional description: Lip dry		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Lip pain	Additional description: Lip pain		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Mouth haemorrhage	Additional description: Mouth haemorrhage		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Mouth ulceration	Additional description: Mouth ulceration		
subjects affected / exposed occurrences (all)	2 / 228 (0.88%) 2	2 / 216 (0.93%) 2	3 / 237 (1.27%) 6
Nausea	Additional description: Nausea		
subjects affected / exposed occurrences (all)	69 / 228 (30.26%) 87	93 / 216 (43.06%) 132	64 / 237 (27.00%) 86
Odynophagia	Additional description: Odynophagia		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Oesophagitis	Additional description: Oesophagitis		
subjects affected / exposed occurrences (all)	2 / 228 (0.88%) 2	0 / 216 (0.00%) 0	2 / 237 (0.84%) 2
Oral dysaesthesia	Additional description: Oral dysaesthesia		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Oral mucosal blistering	Additional description: Oral mucosal blistering		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Oral mucosal erythema	Additional description: Oral mucosal erythema		

subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Oral pain	Additional description: Oral pain		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Paraesthesia oral	Additional description: Paraesthesia oral		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Periodontal disease	Additional description: Periodontal disease		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Proctalgia	Additional description: Proctalgia		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Rectal haemorrhage	Additional description: Rectal haemorrhage		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Rectal polyp	Additional description: Rectal polyp		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Salivary gland calculus	Additional description: Salivary gland calculus		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Stomatitis	Additional description: Stomatitis		
subjects affected / exposed occurrences (all)	6 / 228 (2.63%) 6	3 / 216 (1.39%) 3	3 / 237 (1.27%) 5
Tongue coated	Additional description: Tongue coated		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Tongue discomfort	Additional description: Tongue discomfort		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Tongue disorder	Additional description: Tongue disorder		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Tongue dry	Additional description: Tongue dry		

subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Tooth loss	Additional description: Tooth loss		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Toothache	Additional description: Toothache		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	4 / 237 (1.69%) 4
Vomiting	Additional description: Vomiting		
subjects affected / exposed occurrences (all)	14 / 228 (6.14%) 17	40 / 216 (18.52%) 55	16 / 237 (6.75%) 21
Hepatobiliary disorders	Additional description: Cholecystitis		
Cholecystitis subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Cholelithiasis	Additional description: Cholelithiasis		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Hepatic pain	Additional description: Hepatic pain		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Hepatic steatosis	Additional description: Hepatic steatosis		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Hepatotoxicity	Additional description: Hepatotoxicity		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Hyperbilirubinaemia	Additional description: Hyperbilirubinaemia		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Liver disorder	Additional description: Liver disorder		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Portal vein dilatation	Additional description: Portal vein dilatation		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1

Portal vein thrombosis subjects affected / exposed occurrences (all)	Additional description: Portal vein thrombosis		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Skin and subcutaneous tissue disorders	Additional description: Actinic keratosis		
	5 / 228 (2.19%) 5	0 / 216 (0.00%) 0	5 / 237 (2.11%) 5
Actinic keratosis subjects affected / exposed occurrences (all)	Additional description: Alopecia		
	2 / 228 (0.88%) 2	4 / 216 (1.85%) 4	6 / 237 (2.53%) 6
Alopecia subjects affected / exposed occurrences (all)	Additional description: Blister		
	1 / 228 (0.44%) 1	1 / 216 (0.46%) 1	1 / 237 (0.42%) 1
Blister subjects affected / exposed occurrences (all)	Additional description: Blood blister		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Blood blister subjects affected / exposed occurrences (all)	Additional description: Cafe au lait spots		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Cafe au lait spots subjects affected / exposed occurrences (all)	Additional description: Dermatitis		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	2 / 237 (0.84%) 2
Dermatitis subjects affected / exposed occurrences (all)	Additional description: Dermatitis acneiform		
	1 / 228 (0.44%) 1	2 / 216 (0.93%) 2	0 / 237 (0.00%) 0
Dermatitis acneiform subjects affected / exposed occurrences (all)	Additional description: Dermatitis allergic		
	1 / 228 (0.44%) 1	2 / 216 (0.93%) 3	0 / 237 (0.00%) 0
Dermatitis allergic subjects affected / exposed occurrences (all)	Additional description: Dermatitis atopic		
	2 / 228 (0.88%) 2	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Dermatitis atopic subjects affected / exposed occurrences (all)	Additional description: Dermatitis contact		
	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Dermatitis contact subjects affected / exposed occurrences (all)	Additional description: Dermatitis exfoliative		
Dermatitis exfoliative			

subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Dermatitis exfoliative generalised	Additional description: Dermatitis exfoliative generalised		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Decubitus ulcer	Additional description: Decubitus ulcer		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Drug eruption	Additional description: Drug eruption		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Dry skin	Additional description: Dry skin		
subjects affected / exposed occurrences (all)	16 / 228 (7.02%) 18	8 / 216 (3.70%) 8	8 / 237 (3.38%) 8
Ecchymosis	Additional description: Ecchymosis		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Eczema	Additional description: Eczema		
subjects affected / exposed occurrences (all)	5 / 228 (2.19%) 5	3 / 216 (1.39%) 3	13 / 237 (5.49%) 13
Eczema nummular	Additional description: Eczema nummular		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Erythema	Additional description: Erythema		
subjects affected / exposed occurrences (all)	6 / 228 (2.63%) 7	3 / 216 (1.39%) 4	3 / 237 (1.27%) 4
Erythema nodosum	Additional description: Erythema nodosum		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Eosinophilic cellulitis	Additional description: Eosinophilic cellulitis		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Erythema multiforme	Additional description: Erythema multiforme		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Hand dermatitis	Additional description: Hand dermatitis		

subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Hyperkeratosis	Additional description: Hyperkeratosis		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Hyperhidrosis	Additional description: Hyperhidrosis		
subjects affected / exposed occurrences (all)	7 / 228 (3.07%) 8	3 / 216 (1.39%) 3	3 / 237 (1.27%) 3
Hypertrichosis	Additional description: Hypertrichosis		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Intertrigo	Additional description: Intertrigo		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Lentigo	Additional description: Lentigo		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Lichen planus	Additional description: Lichen planus		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Neurodermatitis	Additional description: Neurodermatitis		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Nail discolouration	Additional description: Nail discolouration		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Nail dystrophy	Additional description: Nail dystrophy		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Nail pitting	Additional description: Nail pitting		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Nail ridging	Additional description: Nail ridging		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Nail toxicity	Additional description: Nail toxicity		

subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Night sweats	Additional description: Night sweats		
subjects affected / exposed occurrences (all)	7 / 228 (3.07%) 7	8 / 216 (3.70%) 9	4 / 237 (1.69%) 4
Onychoclasia	Additional description: Onychoclasia		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	2 / 237 (0.84%) 2
Onycholysis	Additional description: Onycholysis		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Papule	Additional description: Papule		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Pemphigoid	Additional description: Pemphigoid		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Petechiae	Additional description: Petechiae		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Pigmentation disorder	Additional description: Pigmentation disorder		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Rash generalised	Additional description: Rash generalised		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Rash erythematous	Additional description: Rash erythematous		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Pruritus	Additional description: Pruritus		
subjects affected / exposed occurrences (all)	15 / 228 (6.58%) 16	17 / 216 (7.87%) 17	19 / 237 (8.02%) 20
Pruritus generalised	Additional description: Pruritus generalised		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Psoriasis	Additional description: Psoriasis		

subjects affected / exposed occurrences (all)	4 / 228 (1.75%) 4	2 / 216 (0.93%) 2	3 / 237 (1.27%) 3
Purpura	Additional description: Purpura		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Rash	Additional description: Rash		
subjects affected / exposed occurrences (all)	27 / 228 (11.84%) 29	33 / 216 (15.28%) 38	32 / 237 (13.50%) 36
Rash macular	Additional description: Rash macular		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Rash maculo-papular	Additional description: Rash maculo-papular		
subjects affected / exposed occurrences (all)	3 / 228 (1.32%) 3	10 / 216 (4.63%) 14	8 / 237 (3.38%) 9
Rash pruritic	Additional description: Rash pruritic		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	2 / 216 (0.93%) 2	0 / 237 (0.00%) 0
Rash papular	Additional description: Rash papular		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Rosacea	Additional description: Rosacea		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Solar dermatitis	Additional description: Solar dermatitis		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Skin burning sensation	Additional description: Skin burning sensation		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Skin discolouration	Additional description: Skin discolouration		
subjects affected / exposed occurrences (all)	2 / 228 (0.88%) 2	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Skin discomfort	Additional description: Skin discomfort		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Skin disorder	Additional description: Skin disorder		

subjects affected / exposed	2 / 228 (0.88%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences (all)	2	0	0

Skin fissures	Additional description: Skin fissures		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences (all)	1	0	0

Skin hypopigmentation	Additional description: Skin hypopigmentation		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences (all)	0	0	1

Skin irritation	Additional description: Skin irritation		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences (all)	0	1	0

Skin lesion	Additional description: Skin lesion		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences (all)	1	0	1

Skin mass	Additional description: Skin mass		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences (all)	1	0	1

Skin ulcer	Additional description: Skin ulcer		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences (all)	0	1	0

Suggillation	Additional description: Suggillation		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences (all)	0	1	0

Telangiectasia	Additional description: Telangiectasia		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences (all)	1	0	0

Toxic skin eruption	Additional description: Toxic skin eruption		
subjects affected / exposed	1 / 228 (0.44%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences (all)	1	1	0

Urticaria	Additional description: Urticaria		
subjects affected / exposed	1 / 228 (0.44%)	3 / 216 (1.39%)	2 / 237 (0.84%)
occurrences (all)	1	3	3

Renal and urinary disorders	Additional description: Acute kidney injury		
Acute kidney injury	Additional description: Acute kidney injury		
subjects affected / exposed	1 / 228 (0.44%)	1 / 216 (0.46%)	2 / 237 (0.84%)
occurrences (all)	2	1	2

Chromaturia subjects affected / exposed occurrences (all)	Additional description: Chromaturia		
	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Chronic kidney disease subjects affected / exposed occurrences (all)	Additional description: Chronic kidney disease		
	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Cystitis noninfective subjects affected / exposed occurrences (all)	Additional description: Cystitis noninfective		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Dysuria subjects affected / exposed occurrences (all)	Additional description: Dysuria		
	2 / 228 (0.88%) 4	6 / 216 (2.78%) 6	1 / 237 (0.42%) 1
Haematuria subjects affected / exposed occurrences (all)	Additional description: Haematuria		
	1 / 228 (0.44%) 1	2 / 216 (0.93%) 2	2 / 237 (0.84%) 2
Hydronephrosis subjects affected / exposed occurrences (all)	Additional description: Hydronephrosis		
	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Incontinence subjects affected / exposed occurrences (all)	Additional description: Incontinence		
	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Kidney congestion subjects affected / exposed occurrences (all)	Additional description: Kidney congestion		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Leukocyturia subjects affected / exposed occurrences (all)	Additional description: Leukocyturia		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Lower urinary tract symptoms subjects affected / exposed occurrences (all)	Additional description: Lower urinary tract symptoms		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Micturition disorder subjects affected / exposed occurrences (all)	Additional description: Micturition disorder		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Micturition urgency subjects affected / exposed occurrences (all)	Additional description: Micturition urgency		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0

Nocturia subjects affected / exposed occurrences (all)	Additional description: Nocturia		
	1 / 228 (0.44%) 1	1 / 216 (0.46%) 1	4 / 237 (1.69%) 4
Pollakiuria subjects affected / exposed occurrences (all)	Additional description: Pollakiuria		
	3 / 228 (1.32%) 3	2 / 216 (0.93%) 2	2 / 237 (0.84%) 2
Polyuria subjects affected / exposed occurrences (all)	Additional description: Polyuria		
	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Renal colic subjects affected / exposed occurrences (all)	Additional description: Renal colic		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Renal cyst subjects affected / exposed occurrences (all)	Additional description: Renal cyst		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Renal failure subjects affected / exposed occurrences (all)	Additional description: Renal failure		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 2
Renal pain subjects affected / exposed occurrences (all)	Additional description: Renal pain		
	0 / 228 (0.00%) 0	3 / 216 (1.39%) 3	0 / 237 (0.00%) 0
Strangury subjects affected / exposed occurrences (all)	Additional description: Strangury		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Urinary incontinence subjects affected / exposed occurrences (all)	Additional description: Urinary incontinence		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Urinary tract pain subjects affected / exposed occurrences (all)	Additional description: Urinary tract pain		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Urinary tract obstruction subjects affected / exposed occurrences (all)	Additional description: Urinary tract obstruction		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Urinary tract inflammation subjects affected / exposed occurrences (all)	Additional description: Urinary tract inflammation		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0

Urinary retention subjects affected / exposed occurrences (all)	Additional description: Urinary retention		
	2 / 228 (0.88%)	1 / 216 (0.46%)	2 / 237 (0.84%)
	3	1	2
Urge incontinence subjects affected / exposed occurrences (all)	Additional description: Urge incontinence		
	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
	0	0	0
Endocrine disorders	Additional description: Goitre		
	Goitre		
	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
	0	0	0
	Additional description: Hyperthyroidism		
	Hyperthyroidism		
	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
	1	0	0
	Additional description: Hypothyroidism		
	Hypothyroidism		
	3 / 228 (1.32%)	0 / 216 (0.00%)	2 / 237 (0.84%)
	3	0	2
Additional description: Thyroid cyst			
Thyroid cyst			
1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)	
1	0	0	
Musculoskeletal and connective tissue disorders	Additional description: Arthropathy		
	Arthropathy		
	2 / 228 (0.88%)	0 / 216 (0.00%)	1 / 237 (0.42%)
	2	0	1
	Additional description: Arthritis		
	Arthritis		
	3 / 228 (1.32%)	2 / 216 (0.93%)	4 / 237 (1.69%)
	4	3	5
	Additional description: Arthralgia		
	Arthralgia		
	33 / 228 (14.47%)	8 / 216 (3.70%)	25 / 237 (10.55%)
	42	8	26
Additional description: Back pain			
Back pain			
24 / 228 (10.53%)	12 / 216 (5.56%)	26 / 237 (10.97%)	
26	13	27	
Additional description: Bone pain			
Bone pain			
10 / 228 (4.39%)	2 / 216 (0.93%)	6 / 237 (2.53%)	
10	2	6	
Additional description: Bursal haematoma			
Bursal haematoma			

subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Bursitis	Additional description: Bursitis		
subjects affected / exposed occurrences (all)	4 / 228 (1.75%) 4	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Cervical spinal stenosis	Additional description: Cervical spinal stenosis		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Exostosis	Additional description: Exostosis		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Fibromyalgia	Additional description: Fibromyalgia		
subjects affected / exposed occurrences (all)	2 / 228 (0.88%) 2	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Flank pain	Additional description: Flank pain		
subjects affected / exposed occurrences (all)	4 / 228 (1.75%) 4	3 / 216 (1.39%) 3	1 / 237 (0.42%) 1
Groin pain	Additional description: Groin pain		
subjects affected / exposed occurrences (all)	3 / 228 (1.32%) 3	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Hypercreatinaemia	Additional description: Hypercreatinaemia		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Intervertebral disc disorder	Additional description: Intervertebral disc disorder		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Intervertebral disc protrusion	Additional description: Intervertebral disc protrusion		
subjects affected / exposed occurrences (all)	2 / 228 (0.88%) 2	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Joint effusion	Additional description: Joint effusion		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Joint range of motion decreased	Additional description: Joint range of motion decreased		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	1 / 237 (0.42%) 1
Joint swelling	Additional description: Joint swelling		

subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	3 / 237 (1.27%) 4
Limb discomfort	Additional description: Limb discomfort		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Mobility decreased	Additional description: Mobility decreased		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Muscle fatigue	Additional description: Muscle fatigue		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 2
Muscle hypertrophy	Additional description: Muscle hypertrophy		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Muscle spasms	Additional description: Muscle spasms		
subjects affected / exposed occurrences (all)	6 / 228 (2.63%) 7	5 / 216 (2.31%) 5	10 / 237 (4.22%) 11
Muscle tightness	Additional description: Muscle tightness		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Muscle twitching	Additional description: Muscle twitching		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Muscular weakness	Additional description: Muscular weakness		
subjects affected / exposed occurrences (all)	2 / 228 (0.88%) 2	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Musculoskeletal chest pain	Additional description: Musculoskeletal chest pain		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Musculoskeletal discomfort	Additional description: Musculoskeletal discomfort		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Musculoskeletal pain	Additional description: Musculoskeletal pain		
subjects affected / exposed occurrences (all)	8 / 228 (3.51%) 8	3 / 216 (1.39%) 3	12 / 237 (5.06%) 12
Musculoskeletal stiffness	Additional description: Musculoskeletal stiffness		

subjects affected / exposed occurrences (all)	2 / 228 (0.88%) 2	1 / 216 (0.46%) 1	3 / 237 (1.27%) 3
Myalgia	Additional description: Myalgia		
subjects affected / exposed occurrences (all)	16 / 228 (7.02%) 17	9 / 216 (4.17%) 13	18 / 237 (7.59%) 19
Neck pain	Additional description: Neck pain		
subjects affected / exposed occurrences (all)	5 / 228 (2.19%) 5	1 / 216 (0.46%) 1	5 / 237 (2.11%) 5
Myositis	Additional description: Myositis		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Osteoarthritis	Additional description: Osteoarthritis		
subjects affected / exposed occurrences (all)	3 / 228 (1.32%) 3	0 / 216 (0.00%) 0	4 / 237 (1.69%) 4
Osteonecrosis	Additional description: Osteonecrosis		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Osteoporosis	Additional description: Osteoporosis		
subjects affected / exposed occurrences (all)	2 / 228 (0.88%) 2	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Pain in extremity	Additional description: Pain in extremity		
subjects affected / exposed occurrences (all)	9 / 228 (3.95%) 9	4 / 216 (1.85%) 6	12 / 237 (5.06%) 13
Pain in jaw	Additional description: Pain in jaw		
subjects affected / exposed occurrences (all)	2 / 228 (0.88%) 2	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Periarthritis	Additional description: Periarthritis		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Polyarthritis	Additional description: Polyarthritis		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Polymyalgia rheumatica	Additional description: Polymyalgia rheumatica		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Psoriatic arthropathy	Additional description: Psoriatic arthropathy		

subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Rheumatic disorder	Additional description: Rheumatic disorder		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Spinal column stenosis	Additional description: Spinal column stenosis		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Spinal pain	Additional description: Spinal pain		
subjects affected / exposed occurrences (all)	2 / 228 (0.88%) 2	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Tendon disorder	Additional description: Tendon disorder		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Tendonitis	Additional description: Tendonitis		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Vertebral foraminal stenosis	Additional description: Vertebral foraminal stenosis		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Infections and infestations			
Abscess limb	Additional description: Abscess limb		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Abdominal infection	Additional description: Abdominal infection		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Acarodermatitis	Additional description: Acarodermatitis		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Abscess	Additional description: Abscess		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 2	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Acute sinusitis	Additional description: Acute sinusitis		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1

Atypical pneumonia subjects affected / exposed occurrences (all)	Additional description: Atypical pneumonia		
	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Bacterial blepharitis subjects affected / exposed occurrences (all)	Additional description: Bacterial blepharitis		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Bacterial food poisoning subjects affected / exposed occurrences (all)	Additional description: Bacterial food poisoning		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Bacterial infection subjects affected / exposed occurrences (all)	Additional description: Bacterial infection		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Asymptomatic COVID-19 subjects affected / exposed occurrences (all)	Additional description: Asymptomatic COVID-19		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Bacterial prostatitis subjects affected / exposed occurrences (all)	Additional description: Bacterial prostatitis		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Bacteriuria subjects affected / exposed occurrences (all)	Additional description: Bacteriuria		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Body tinea subjects affected / exposed occurrences (all)	Additional description: Body tinea		
	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Borrelia infection subjects affected / exposed occurrences (all)	Additional description: Borrelia infection		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Bronchitis bacterial subjects affected / exposed occurrences (all)	Additional description: Bronchitis bacterial		
	1 / 228 (0.44%) 1	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Bronchopulmonary aspergillosis subjects affected / exposed occurrences (all)	Additional description: Bronchopulmonary aspergillosis		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Bursitis infective subjects affected / exposed occurrences (all)	Additional description: Bursitis infective		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0

Campylobacter gastroenteritis subjects affected / exposed occurrences (all)	Additional description: Campylobacter gastroenteritis		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Candida infection subjects affected / exposed occurrences (all)	Additional description: Candida infection		
	1 / 228 (0.44%) 1	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Bronchitis subjects affected / exposed occurrences (all)	Additional description: Bronchitis		
	17 / 228 (7.46%) 22	19 / 216 (8.80%) 19	23 / 237 (9.70%) 24
Cellulitis subjects affected / exposed occurrences (all)	Additional description: Cellulitis		
	2 / 228 (0.88%) 2	1 / 216 (0.46%) 1	3 / 237 (1.27%) 3
Chronic sinusitis subjects affected / exposed occurrences (all)	Additional description: Chronic sinusitis		
	2 / 228 (0.88%) 2	2 / 216 (0.93%) 2	1 / 237 (0.42%) 1
Clostridium difficile colitis subjects affected / exposed occurrences (all)	Additional description: Clostridium difficile colitis		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Clostridium difficile infection subjects affected / exposed occurrences (all)	Additional description: Clostridium difficile infection		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Conjunctivitis subjects affected / exposed occurrences (all)	Additional description: Conjunctivitis		
	8 / 228 (3.51%) 10	2 / 216 (0.93%) 3	1 / 237 (0.42%) 1
COVID-19 subjects affected / exposed occurrences (all)	Additional description: COVID-19		
	37 / 228 (16.23%) 42	35 / 216 (16.20%) 36	36 / 237 (15.19%) 41
COVID-19 pneumonia subjects affected / exposed occurrences (all)	Additional description: COVID-19 pneumonia		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Cystitis subjects affected / exposed occurrences (all)	Additional description: Cystitis		
	6 / 228 (2.63%) 9	7 / 216 (3.24%) 8	8 / 237 (3.38%) 11
Cytomegalovirus infection subjects affected / exposed occurrences (all)	Additional description: Cytomegalovirus infection		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0

Dacryocanaliculitis subjects affected / exposed occurrences (all)	Additional description: Dacryocanaliculitis		
	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Dacryocystitis subjects affected / exposed occurrences (all)	Additional description: Dacryocystitis		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Device related infection subjects affected / exposed occurrences (all)	Additional description: Device related infection		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Dengue fever subjects affected / exposed occurrences (all)	Additional description: Dengue fever		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Diverticulitis subjects affected / exposed occurrences (all)	Additional description: Diverticulitis		
	2 / 228 (0.88%) 2	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Ear infection subjects affected / exposed occurrences (all)	Additional description: Ear infection		
	2 / 228 (0.88%) 2	2 / 216 (0.93%) 2	1 / 237 (0.42%) 1
Ear infection bacterial subjects affected / exposed occurrences (all)	Additional description: Ear infection bacterial		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Erythema migrans subjects affected / exposed occurrences (all)	Additional description: Erythema migrans		
	0 / 228 (0.00%) 0	2 / 216 (0.93%) 2	0 / 237 (0.00%) 0
Enterococcal infection subjects affected / exposed occurrences (all)	Additional description: Enterococcal infection		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Enterococcal sepsis subjects affected / exposed occurrences (all)	Additional description: Enterococcal sepsis		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Epididymitis subjects affected / exposed occurrences (all)	Additional description: Epididymitis		
	2 / 228 (0.88%) 3	0 / 216 (0.00%) 0	2 / 237 (0.84%) 3
Erysipelas subjects affected / exposed occurrences (all)	Additional description: Erysipelas		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	3 / 237 (1.27%) 3

Eye infection	Additional description: Eye infection		
subjects affected / exposed	7 / 228 (3.07%)	0 / 216 (0.00%)	2 / 237 (0.84%)
occurrences (all)	8	0	2
Eyelid infection	Additional description: Eyelid infection		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences (all)	0	0	1
Febrile infection	Additional description: Febrile infection		
subjects affected / exposed	1 / 228 (0.44%)	3 / 216 (1.39%)	1 / 237 (0.42%)
occurrences (all)	1	3	1
Folliculitis	Additional description: Folliculitis		
subjects affected / exposed	4 / 228 (1.75%)	2 / 216 (0.93%)	2 / 237 (0.84%)
occurrences (all)	4	2	4
Fungal infection	Additional description: Fungal infection		
subjects affected / exposed	1 / 228 (0.44%)	3 / 216 (1.39%)	2 / 237 (0.84%)
occurrences (all)	1	3	2
Fungal skin infection	Additional description: Fungal skin infection		
subjects affected / exposed	2 / 228 (0.88%)	3 / 216 (1.39%)	1 / 237 (0.42%)
occurrences (all)	2	3	1
Furuncle	Additional description: Furuncle		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences (all)	0	0	0
Genital infection fungal	Additional description: Genital infection fungal		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences (all)	0	0	0
Genital herpes	Additional description: Genital herpes		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences (all)	0	1	0
Giardiasis	Additional description: Giardiasis		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences (all)	1	0	0
Gastric infection	Additional description: Gastric infection		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences (all)	0	1	0
Gastroenteritis	Additional description: Gastroenteritis		
subjects affected / exposed	3 / 228 (1.32%)	6 / 216 (2.78%)	5 / 237 (2.11%)
occurrences (all)	3	6	5

Gastroenteritis caliciviral subjects affected / exposed occurrences (all)	Additional description: Gastroenteritis caliciviral		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Gastroenteritis viral subjects affected / exposed occurrences (all)	Additional description: Gastroenteritis viral		
	1 / 228 (0.44%) 1	3 / 216 (1.39%) 3	0 / 237 (0.00%) 0
Gastrointestinal disorders subjects affected / exposed occurrences (all)	Additional description: Gastrointestinal disorders		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Gastrointestinal infection subjects affected / exposed occurrences (all)	Additional description: Gastrointestinal infection		
	4 / 228 (1.75%) 4	2 / 216 (0.93%) 2	3 / 237 (1.27%) 3
Haemophilus infection subjects affected / exposed occurrences (all)	Additional description: Haemophilus infection		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Gingivitis subjects affected / exposed occurrences (all)	Additional description: Gingivitis		
	1 / 228 (0.44%) 1	3 / 216 (1.39%) 3	2 / 237 (0.84%) 2
Herpes infection subjects affected / exposed occurrences (all)	Additional description: Herpes infection		
	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Helicobacter gastritis subjects affected / exposed occurrences (all)	Additional description: Helicobacter gastritis		
	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	3 / 237 (1.27%) 3
Hepatitis B reactivation subjects affected / exposed occurrences (all)	Additional description: Hepatitis B reactivation		
	2 / 228 (0.88%) 2	1 / 216 (0.46%) 1	1 / 237 (0.42%) 1
Hepatitis E subjects affected / exposed occurrences (all)	Additional description: Hepatitis E		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Hepatitis viral subjects affected / exposed occurrences (all)	Additional description: Hepatitis viral		
	1 / 228 (0.44%) 1	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Herpes dermatitis subjects affected / exposed occurrences (all)	Additional description: Herpes dermatitis		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0

Herpes simplex subjects affected / exposed occurrences (all)	Additional description: Herpes simplex		
	6 / 228 (2.63%) 9	0 / 216 (0.00%) 0	4 / 237 (1.69%) 5
Herpes simplex reactivation subjects affected / exposed occurrences (all)	Additional description: Herpes simplex reactivation		
	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Hordeolum subjects affected / exposed occurrences (all)	Additional description: Hordeolum		
	1 / 228 (0.44%) 1	1 / 216 (0.46%) 1	1 / 237 (0.42%) 1
Herpes zoster subjects affected / exposed occurrences (all)	Additional description: Herpes zoster		
	9 / 228 (3.95%) 9	21 / 216 (9.72%) 24	13 / 237 (5.49%) 13
Herpes virus infection subjects affected / exposed occurrences (all)	Additional description: Herpes virus infection		
	3 / 228 (1.32%) 5	2 / 216 (0.93%) 3	3 / 237 (1.27%) 3
Herpes viral infections subjects affected / exposed occurrences (all)	Additional description: Herpes viral infections		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Infection subjects affected / exposed occurrences (all)	Additional description: Infection		
	14 / 228 (6.14%) 17	20 / 216 (9.26%) 26	7 / 237 (2.95%) 11
Infection susceptibility increased subjects affected / exposed occurrences (all)	Additional description: Infection susceptibility increased		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Infectious colitis subjects affected / exposed occurrences (all)	Additional description: Infectious colitis		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Infective iritis subjects affected / exposed occurrences (all)	Additional description: Infective iritis		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Impetigo subjects affected / exposed occurrences (all)	Additional description: Impetigo		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Infected bite subjects affected / exposed occurrences (all)	Additional description: Infected bite		
	2 / 228 (0.88%) 2	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0

Infected dermal cyst subjects affected / exposed occurrences (all)	Additional description: Infected dermal cyst		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Infected skin ulcer subjects affected / exposed occurrences (all)	Additional description: Infected skin ulcer		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Injection site cellulitis subjects affected / exposed occurrences (all)	Additional description: Injection site cellulitis		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Influenza subjects affected / exposed occurrences (all)	Additional description: Influenza		
	9 / 228 (3.95%) 10	9 / 216 (4.17%) 10	7 / 237 (2.95%) 8
Joint abscess subjects affected / exposed occurrences (all)	Additional description: Joint abscess		
	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	1 / 237 (0.42%) 1
Kidney infection subjects affected / exposed occurrences (all)	Additional description: Kidney infection		
	1 / 228 (0.44%) 1	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Labyrinthitis subjects affected / exposed occurrences (all)	Additional description: Labyrinthitis		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Laryngitis subjects affected / exposed occurrences (all)	Additional description: Laryngitis		
	1 / 228 (0.44%) 1	1 / 216 (0.46%) 1	1 / 237 (0.42%) 1
Lip infection subjects affected / exposed occurrences (all)	Additional description: Lip infection		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Localised infection subjects affected / exposed occurrences (all)	Additional description: Localised infection		
	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	1 / 237 (0.42%) 1
Lower respiratory tract infection subjects affected / exposed occurrences (all)	Additional description: Lower respiratory tract infection		
	3 / 228 (1.32%) 4	4 / 216 (1.85%) 5	1 / 237 (0.42%) 1
Lyme disease subjects affected / exposed occurrences (all)	Additional description: Lyme disease		
	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	3 / 237 (1.27%) 3

Lymph gland infection subjects affected / exposed occurrences (all)	Additional description: Lymph gland infection		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Metapneumovirus infection subjects affected / exposed occurrences (all)	Additional description: Metapneumovirus infection		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Mucosal infection subjects affected / exposed occurrences (all)	Additional description: Mucosal infection		
	3 / 228 (1.32%) 3	2 / 216 (0.93%) 2	1 / 237 (0.42%) 1
Nail infection subjects affected / exposed occurrences (all)	Additional description: Nail infection		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Nasal candidiasis subjects affected / exposed occurrences (all)	Additional description: Nasal candidiasis		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Nasopharyngitis subjects affected / exposed occurrences (all)	Additional description: Nasopharyngitis		
	70 / 228 (30.70%) 99	44 / 216 (20.37%) 61	55 / 237 (23.21%) 81
Onychomycosis subjects affected / exposed occurrences (all)	Additional description: Onychomycosis		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	2 / 237 (0.84%) 2
Neutropenic infection subjects affected / exposed occurrences (all)	Additional description: Neutropenic infection		
	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Omphalitis subjects affected / exposed occurrences (all)	Additional description: Omphalitis		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Ophthalmic herpes zoster subjects affected / exposed occurrences (all)	Additional description: Ophthalmic herpes zoster		
	0 / 228 (0.00%) 0	2 / 216 (0.93%) 2	1 / 237 (0.42%) 1
Oral candidiasis subjects affected / exposed occurrences (all)	Additional description: Oral candidiasis		
	1 / 228 (0.44%) 1	6 / 216 (2.78%) 6	7 / 237 (2.95%) 8
Oral fungal infection subjects affected / exposed occurrences (all)	Additional description: Oral fungal infection		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0

Oral herpes	Additional description: Oral herpes		
subjects affected / exposed	12 / 228 (5.26%)	9 / 216 (4.17%)	14 / 237 (5.91%)
occurrences (all)	12	12	16
Oral infection	Additional description: Oral infection		
subjects affected / exposed	1 / 228 (0.44%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences (all)	1	1	0
Oropharyngeal candidiasis	Additional description: Oropharyngeal candidiasis		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences (all)	0	0	0
Osteomyelitis	Additional description: Osteomyelitis		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences (all)	0	0	0
Otitis media	Additional description: Otitis media		
subjects affected / exposed	5 / 228 (2.19%)	3 / 216 (1.39%)	3 / 237 (1.27%)
occurrences (all)	5	3	3
Otitis media acute	Additional description: Otitis media acute		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences (all)	0	0	0
Otitis media chronic	Additional description: Otitis media chronic		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences (all)	1	0	0
Penile infection	Additional description: Penile infection		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences (all)	0	0	1
Papilloma viral infection	Additional description: Papilloma viral infection		
subjects affected / exposed	1 / 228 (0.44%)	1 / 216 (0.46%)	1 / 237 (0.42%)
occurrences (all)	1	1	1
Parainfluenzae virus infection	Additional description: Parainfluenzae virus infection		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences (all)	0	0	0
Paronychia	Additional description: Paronychia		
subjects affected / exposed	1 / 228 (0.44%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences (all)	1	1	0
Parotitis	Additional description: Parotitis		
subjects affected / exposed	0 / 228 (0.00%)	2 / 216 (0.93%)	0 / 237 (0.00%)
occurrences (all)	0	2	0

Peritonsillar abscess subjects affected / exposed occurrences (all)	Additional description: Peritonsillar abscess		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Pharyngitis subjects affected / exposed occurrences (all)	Additional description: Pharyngitis		
	1 / 228 (0.44%) 1	2 / 216 (0.93%) 2	1 / 237 (0.42%) 1
Pharyngitis bacterial subjects affected / exposed occurrences (all)	Additional description: Pharyngitis bacterial		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Pharyngotonsillitis subjects affected / exposed occurrences (all)	Additional description: Pharyngotonsillitis		
	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Pneumonia mycoplasmal subjects affected / exposed occurrences (all)	Additional description: Pneumonia mycoplasmal		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Pneumonia streptococcal subjects affected / exposed occurrences (all)	Additional description: Pneumonia streptococcal		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Post-acute COVID-19 syndrome subjects affected / exposed occurrences (all)	Additional description: Post-acute COVID-19 syndrome		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Postoperative wound infection subjects affected / exposed occurrences (all)	Additional description: Postoperative wound infection		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Pneumonia subjects affected / exposed occurrences (all)	Additional description: Pneumonia		
	17 / 228 (7.46%) 19	17 / 216 (7.87%) 21	10 / 237 (4.22%) 14
Pulpitis dental subjects affected / exposed occurrences (all)	Additional description: Pulpitis dental		
	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Pyelonephritis subjects affected / exposed occurrences (all)	Additional description: Pyelonephritis		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Pyuria subjects affected / exposed occurrences (all)	Additional description: Pyuria		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0

Respiratory syncytial virus infection subjects affected / exposed occurrences (all)	Additional description: Respiratory syncytial virus infection		
	1 / 228 (0.44%) 1	2 / 216 (0.93%) 2	0 / 237 (0.00%) 0
Respiratory tract infection subjects affected / exposed occurrences (all)	Additional description: Respiratory tract infection		
	16 / 228 (7.02%) 16	13 / 216 (6.02%) 15	17 / 237 (7.17%) 21
Respiratory tract infection viral subjects affected / exposed occurrences (all)	Additional description: Respiratory tract infection viral		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Rhinitis subjects affected / exposed occurrences (all)	Additional description: Rhinitis		
	8 / 228 (3.51%) 9	5 / 216 (2.31%) 5	5 / 237 (2.11%) 5
Sialoadenitis subjects affected / exposed occurrences (all)	Additional description: Sialoadenitis		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Root canal infection subjects affected / exposed occurrences (all)	Additional description: Root canal infection		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Scarlet fever subjects affected / exposed occurrences (all)	Additional description: Scarlet fever		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Scrotal infection subjects affected / exposed occurrences (all)	Additional description: Scrotal infection		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Sebaceous gland infection subjects affected / exposed occurrences (all)	Additional description: Sebaceous gland infection		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Sinusitis subjects affected / exposed occurrences (all)	Additional description: Sinusitis		
	25 / 228 (10.96%) 38	8 / 216 (3.70%) 8	12 / 237 (5.06%) 14
Skin infection subjects affected / exposed occurrences (all)	Additional description: Skin infection		
	5 / 228 (2.19%) 5	5 / 216 (2.31%) 5	3 / 237 (1.27%) 3
Soft tissue infection subjects affected / exposed occurrences (all)	Additional description: Soft tissue infection		
	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0

Staphylococcal infection subjects affected / exposed occurrences (all)	Additional description: Staphylococcal infection		
	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	2 / 237 (0.84%) 2
Subcutaneous abscess subjects affected / exposed occurrences (all)	Additional description: Subcutaneous abscess		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Sycosis barbae subjects affected / exposed occurrences (all)	Additional description: Sycosis barbae		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Tinea pedis subjects affected / exposed occurrences (all)	Additional description: Tinea pedis		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Tinea infection subjects affected / exposed occurrences (all)	Additional description: Tinea infection		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Tonsillitis subjects affected / exposed occurrences (all)	Additional description: Tonsillitis		
	1 / 228 (0.44%) 1	2 / 216 (0.93%) 2	1 / 237 (0.42%) 1
Tooth abscess subjects affected / exposed occurrences (all)	Additional description: Tooth abscess		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Tooth infection subjects affected / exposed occurrences (all)	Additional description: Tooth infection		
	4 / 228 (1.75%) 4	1 / 216 (0.46%) 1	9 / 237 (3.80%) 9
Tracheitis subjects affected / exposed occurrences (all)	Additional description: Tracheitis		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Urethritis subjects affected / exposed occurrences (all)	Additional description: Urethritis		
	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Vaginal infection subjects affected / exposed occurrences (all)	Additional description: Vaginal infection		
	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	4 / 237 (1.69%) 5
Urosepsis subjects affected / exposed occurrences (all)	Additional description: Urosepsis		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0

Urinary tract infection viral subjects affected / exposed occurrences (all)	Additional description: Urinary tract infection viral		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Urinary tract infection bacterial subjects affected / exposed occurrences (all)	Additional description: Urinary tract infection bacterial		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Urinary tract infection subjects affected / exposed occurrences (all)	Additional description: Urinary tract infection		
	24 / 228 (10.53%) 27	16 / 216 (7.41%) 20	14 / 237 (5.91%) 22
Upper respiratory tract infection subjects affected / exposed occurrences (all)	Additional description: Upper respiratory tract infection		
	36 / 228 (15.79%) 52	39 / 216 (18.06%) 56	24 / 237 (10.13%) 33
Viral upper respiratory tract infection subjects affected / exposed occurrences (all)	Additional description: Viral upper respiratory tract infection		
	1 / 228 (0.44%) 1	1 / 216 (0.46%) 1	2 / 237 (0.84%) 3
Viral sinusitis subjects affected / exposed occurrences (all)	Additional description: Viral sinusitis		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Viral infection subjects affected / exposed occurrences (all)	Additional description: Viral infection		
	5 / 228 (2.19%) 7	3 / 216 (1.39%) 3	5 / 237 (2.11%) 5
Vestibular neuronitis subjects affected / exposed occurrences (all)	Additional description: Vestibular neuronitis		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Varicella zoster virus infection subjects affected / exposed occurrences (all)	Additional description: Varicella zoster virus infection		
	0 / 228 (0.00%) 0	3 / 216 (1.39%) 3	0 / 237 (0.00%) 0
Vulvovaginal candidiasis subjects affected / exposed occurrences (all)	Additional description: Vulvovaginal candidiasis		
	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Vulvovaginal mycotic infection subjects affected / exposed occurrences (all)	Additional description: Vulvovaginal mycotic infection		
	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Wound infection subjects affected / exposed occurrences (all)	Additional description: Wound infection		
	2 / 228 (0.88%) 2	1 / 216 (0.46%) 1	1 / 237 (0.42%) 1

Metabolism and nutrition disorders			
Abnormal weight gain	Additional description: Abnormal weight gain		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences (all)	0	0	1
Acidosis	Additional description: Acidosis		
subjects affected / exposed	0 / 228 (0.00%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences (all)	0	1	0
Alcohol intolerance	Additional description: Alcohol intolerance		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	1 / 237 (0.42%)
occurrences (all)	0	0	1
Decreased appetite	Additional description: Decreased appetite		
subjects affected / exposed	11 / 228 (4.82%)	14 / 216 (6.48%)	12 / 237 (5.06%)
occurrences (all)	14	18	12
Diabetes mellitus	Additional description: Diabetes mellitus		
subjects affected / exposed	1 / 228 (0.44%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences (all)	1	1	0
Dehydration	Additional description: Dehydration		
subjects affected / exposed	1 / 228 (0.44%)	1 / 216 (0.46%)	0 / 237 (0.00%)
occurrences (all)	1	1	0
Dyslipidaemia	Additional description: Dyslipidaemia		
subjects affected / exposed	0 / 228 (0.00%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences (all)	0	0	0
Fluid overload	Additional description: Fluid overload		
subjects affected / exposed	1 / 228 (0.44%)	0 / 216 (0.00%)	0 / 237 (0.00%)
occurrences (all)	1	0	0
Folate deficiency	Additional description: Folate deficiency		
subjects affected / exposed	3 / 228 (1.32%)	1 / 216 (0.46%)	1 / 237 (0.42%)
occurrences (all)	3	1	1
Gout	Additional description: Gout		
subjects affected / exposed	0 / 228 (0.00%)	2 / 216 (0.93%)	2 / 237 (0.84%)
occurrences (all)	0	2	2
Hyperphosphataemia	Additional description: Hyperphosphataemia		
subjects affected / exposed	4 / 228 (1.75%)	0 / 216 (0.00%)	10 / 237 (4.22%)
occurrences (all)	4	0	14
Hyperkalaemia	Additional description: Hyperkalaemia		

subjects affected / exposed occurrences (all)	8 / 228 (3.51%) 11	6 / 216 (2.78%) 6	18 / 237 (7.59%) 26
Hyperglycaemia	Additional description: Hyperglycaemia		
subjects affected / exposed occurrences (all)	6 / 228 (2.63%) 6	3 / 216 (1.39%) 3	1 / 237 (0.42%) 1
Hypercholesterolaemia	Additional description: Hypercholesterolaemia		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0
Hypercalcaemia	Additional description: Hypercalcaemia		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Hyponatraemia	Additional description: Hyponatraemia		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	2 / 237 (0.84%) 2
Hypomagnesaemia	Additional description: Hypomagnesaemia		
subjects affected / exposed occurrences (all)	1 / 228 (0.44%) 1	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Hypokalaemia	Additional description: Hypokalaemia		
subjects affected / exposed occurrences (all)	5 / 228 (2.19%) 7	4 / 216 (1.85%) 4	4 / 237 (1.69%) 5
Hypoferritinaemia	Additional description: Hypoferritinaemia		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Hypocalcaemia	Additional description: Hypocalcaemia		
subjects affected / exposed occurrences (all)	2 / 228 (0.88%) 2	1 / 216 (0.46%) 1	2 / 237 (0.84%) 3
Hyperuricaemia	Additional description: Hyperuricaemia		
subjects affected / exposed occurrences (all)	7 / 228 (3.07%) 8	2 / 216 (0.93%) 2	9 / 237 (3.80%) 9
Hypophosphataemia	Additional description: Hypophosphataemia		
subjects affected / exposed occurrences (all)	5 / 228 (2.19%) 11	0 / 216 (0.00%) 0	1 / 237 (0.42%) 2
Increased appetite	Additional description: Increased appetite		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Iron deficiency	Additional description: Iron deficiency		

subjects affected / exposed occurrences (all)	4 / 228 (1.75%) 4	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Iron overload	Additional description: Iron overload		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Obesity	Additional description: Obesity		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	0 / 237 (0.00%) 0
Tumour lysis syndrome	Additional description: Tumour lysis syndrome		
subjects affected / exposed occurrences (all)	17 / 228 (7.46%) 20	7 / 216 (3.24%) 7	19 / 237 (8.02%) 22
Type 2 diabetes mellitus	Additional description: Type 2 diabetes mellitus		
subjects affected / exposed occurrences (all)	0 / 228 (0.00%) 0	0 / 216 (0.00%) 0	1 / 237 (0.42%) 1
Vitamin D deficiency	Additional description: Vitamin D deficiency		
subjects affected / exposed occurrences (all)	2 / 228 (0.88%) 2	1 / 216 (0.46%) 1	2 / 237 (0.84%) 2
Vitamin B12 deficiency	Additional description: Vitamin B12 deficiency		
subjects affected / exposed occurrences (all)	3 / 228 (1.32%) 3	1 / 216 (0.46%) 1	0 / 237 (0.00%) 0

Non-serious adverse events	GIVe arm		
Total subjects affected by non-serious adverse events subjects affected / exposed	231 / 231 (100.00%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Additional description: Adenocarcinoma of colon		
Adenocarcinoma of colon subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Anogenital warts	Additional description: Anogenital warts		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Angiomyolipoma	Additional description: Angiomyolipoma		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Basal cell carcinoma	Additional description: Basal cell carcinoma		

subjects affected / exposed occurrences (all)	4 / 231 (1.73%) 4		
Benign soft tissue neoplasm	Additional description: Benign soft tissue neoplasm		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Bowen's disease	Additional description: Bowen's disease		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Choroid melanoma	Additional description: Choroid melanoma		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Colon adenoma	Additional description: Colon adenoma		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Colon cancer	Additional description: Colon cancer		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Cutaneous T-cell lymphoma	Additional description: Cutaneous T-cell lymphoma		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Erythroplasia	Additional description: Erythroplasia		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Fibroma	Additional description: Fibroma		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Haemangioma	Additional description: Haemangioma		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Haemangioma of liver	Additional description: Haemangioma of liver		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Keratoacanthoma	Additional description: Keratoacanthoma		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Lipoma	Additional description: Lipoma		

subjects affected / exposed occurrences (all)	2 / 231 (0.87%) 2		
Malignant melanoma	Additional description: Malignant melanoma		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Melanocytic naevus	Additional description: Melanocytic naevus		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Malignant melanoma in situ	Additional description: Malignant melanoma in situ		
subjects affected / exposed occurrences (all)	2 / 231 (0.87%) 2		
Myelodysplastic syndrome	Additional description: Myelodysplastic syndrome		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Myelofibrosis	Additional description: Myelofibrosis		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Non-small cell lung cancer	Additional description: Non-small cell lung cancer		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Papilloma	Additional description: Papilloma		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Plasmacytoma	Additional description: Plasmacytoma		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Polycythaemia vera	Additional description: Polycythaemia vera		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Prostate cancer	Additional description: Prostate cancer		
subjects affected / exposed occurrences (all)	3 / 231 (1.30%) 3		
Schwannoma	Additional description: Schwannoma		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Seborrhoeic keratosis	Additional description: Seborrhoeic keratosis		

subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Richter's syndrome	Additional description: Richter's syndrome		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Skin papilloma	Additional description: Skin papilloma		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Squamous cell carcinoma	Additional description: Squamous cell carcinoma		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
T-cell lymphoma	Additional description: T-cell lymphoma		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Thyroid neoplasm	Additional description: Thyroid neoplasm		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Transitional cell carcinoma	Additional description: Transitional cell carcinoma		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Vascular disorders			
Aortic aneurysm	Additional description: Aortic aneurysm		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Aortic dilatation	Additional description: Aortic dilatation		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Arteriosclerosis	Additional description: Arteriosclerosis		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Blood pressure fluctuation	Additional description: Blood pressure fluctuation		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Blue toe syndrome	Additional description: Blue toe syndrome		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		

Circulatory collapse subjects affected / exposed occurrences (all)	Additional description: Circulatory collapse	
	0 / 231 (0.00%) 0	
Deep vein thrombosis subjects affected / exposed occurrences (all)	Additional description: Deep vein thrombosis	
	0 / 231 (0.00%) 0	
Embolism subjects affected / exposed occurrences (all)	Additional description: Embolism	
	1 / 231 (0.43%) 1	
Flushing subjects affected / exposed occurrences (all)	Additional description: Flushing	
	2 / 231 (0.87%) 2	
Gestational hypertension subjects affected / exposed occurrences (all)	Additional description: Gestational hypertension	
	1 / 231 (0.43%) 1	
Haematoma subjects affected / exposed occurrences (all)	Additional description: Haematoma	
	29 / 231 (12.55%) 35	
Haemorrhage subjects affected / exposed occurrences (all)	Additional description: Haemorrhage	
	1 / 231 (0.43%) 1	
Hot flush subjects affected / exposed occurrences (all)	Additional description: Hot flush	
	9 / 231 (3.90%) 9	
Hypotension subjects affected / exposed occurrences (all)	Additional description: Hypotension	
	4 / 231 (1.73%) 4	
Hypertensive crisis subjects affected / exposed occurrences (all)	Additional description: Hypertensive crisis	
	0 / 231 (0.00%) 0	
Hypertension subjects affected / exposed occurrences (all)	Additional description: Hypertension	
	29 / 231 (12.55%) 32	
Peripheral arterial occlusive disease subjects affected / exposed occurrences (all)	Additional description: Peripheral arterial occlusive disease	
	0 / 231 (0.00%) 0	

Peripheral coldness subjects affected / exposed occurrences (all)	Additional description: Peripheral coldness 1 / 231 (0.43%) 1		
Phlebitis subjects affected / exposed occurrences (all)	Additional description: Phlebitis 0 / 231 (0.00%) 0		
Poor peripheral circulation subjects affected / exposed occurrences (all)	Additional description: Poor peripheral circulation 1 / 231 (0.43%) 1		
Raynaud's phenomenon subjects affected / exposed occurrences (all)	Additional description: Raynaud's phenomenon 0 / 231 (0.00%) 0		
Thrombophlebitis subjects affected / exposed occurrences (all)	Additional description: Thrombophlebitis 1 / 231 (0.43%) 2		
Thrombophlebitis superficial subjects affected / exposed occurrences (all)	Additional description: Thrombophlebitis superficial 1 / 231 (0.43%) 1		
Thrombosis subjects affected / exposed occurrences (all)	Additional description: Thrombosis 1 / 231 (0.43%) 1		
Varicose vein subjects affected / exposed occurrences (all)	Additional description: Varicose vein 0 / 231 (0.00%) 0		
Vasculitis subjects affected / exposed occurrences (all)	Additional description: Vasculitis 0 / 231 (0.00%) 0		
Venous thrombosis subjects affected / exposed occurrences (all)	Additional description: Venous thrombosis 1 / 231 (0.43%) 1		
Surgical and medical procedures			
Cranial remodelling therapy subjects affected / exposed occurrences (all)	Additional description: Cranial remodelling therapy 0 / 231 (0.00%) 0		
Endodontic procedure	Additional description: Endodontic procedure		

subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Joint irrigation	Additional description: Joint irrigation		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Mastoidectomy	Additional description: Mastoidectomy		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Polypectomy	Additional description: Polypectomy		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Tooth extraction	Additional description: Tooth extraction		
subjects affected / exposed occurrences (all)	2 / 231 (0.87%) 3		
General disorders and administration site conditions			
Axillary pain	Additional description: Axillary pain		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Asthenia	Additional description: Asthenia		
subjects affected / exposed occurrences (all)	2 / 231 (0.87%) 3		
Catheter site extravasation	Additional description: Catheter site extravasation		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Catheter site pain	Additional description: Catheter site pain		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Catheter site swelling	Additional description: Catheter site swelling		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Chest discomfort	Additional description: Chest discomfort		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Chest pain	Additional description: Chest pain		

subjects affected / exposed occurrences (all)	5 / 231 (2.16%) 5		
Chills	Additional description: Chills		
subjects affected / exposed occurrences (all)	14 / 231 (6.06%) 14		
Catheter site bruise	Additional description: Catheter site bruise		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Cyst	Additional description: Cyst		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Drug intolerance	Additional description: Drug intolerance		
subjects affected / exposed occurrences (all)	2 / 231 (0.87%) 2		
Discomfort	Additional description: Discomfort		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Extravasation	Additional description: Extravasation		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Face oedema	Additional description: Face oedema		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Fatigue	Additional description: Fatigue		
subjects affected / exposed occurrences (all)	80 / 231 (34.63%) 87		
Feeling cold	Additional description: Feeling cold		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Gait disturbance	Additional description: Gait disturbance		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Feeling hot	Additional description: Feeling hot		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
General physical health deterioration	Additional description: General physical health deterioration		

subjects affected / exposed occurrences (all)	4 / 231 (1.73%) 4		
Inflammation	Additional description: Inflammation		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Induration	Additional description: Induration		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Influenza like illness	Additional description: Influenza like illness		
subjects affected / exposed occurrences (all)	19 / 231 (8.23%) 21		
Infusion site extravasation	Additional description: Infusion site extravasation		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Injection site pain	Additional description: Injection site pain		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Injection site reaction	Additional description: Injection site reaction		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Injection site swelling	Additional description: Injection site swelling		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Malaise	Additional description: Malaise		
subjects affected / exposed occurrences (all)	9 / 231 (3.90%) 12		
Mass	Additional description: Mass		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Mucosal inflammation	Additional description: Mucosal inflammation		
subjects affected / exposed occurrences (all)	5 / 231 (2.16%) 6		
Non-cardiac chest pain	Additional description: Non-cardiac chest pain		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Oedema	Additional description: Oedema		

subjects affected / exposed occurrences (all)	6 / 231 (2.60%) 6		
Oedema peripheral	Additional description: Oedema peripheral		
subjects affected / exposed occurrences (all)	12 / 231 (5.19%) 12		
Pain	Additional description: Pain		
subjects affected / exposed occurrences (all)	4 / 231 (1.73%) 4		
Papillitis	Additional description: Papillitis		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Peripheral oedema neonatal	Additional description: Peripheral oedema neonatal		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Peripheral swelling	Additional description: Peripheral swelling		
subjects affected / exposed occurrences (all)	6 / 231 (2.60%) 7		
Pyrexia	Additional description: Pyrexia		
subjects affected / exposed occurrences (all)	26 / 231 (11.26%) 30		
Swelling	Additional description: Swelling		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Systemic inflammatory response syndrome	Additional description: Systemic inflammatory response syndrome		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Thirst	Additional description: Thirst		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Tissue infiltration	Additional description: Tissue infiltration		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Immune system disorders			
Anaphylactic reaction	Additional description: Anaphylactic reaction		

subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Autoimmune disorder	Additional description: Autoimmune disorder		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Cytokine release syndrome	Additional description: Cytokine release syndrome		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Drug hypersensitivity	Additional description: Drug hypersensitivity		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Hypersensitivity	Additional description: Hypersensitivity		
subjects affected / exposed occurrences (all)	5 / 231 (2.16%) 5		
Hypogammaglobulinaemia	Additional description: Hypogammaglobulinaemia		
subjects affected / exposed occurrences (all)	2 / 231 (0.87%) 2		
Immune reconstitution inflammatory syndrome	Additional description: Immune reconstitution inflammatory syndrome		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Immunodeficiency	Additional description: Immunodeficiency		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Seasonal allergy	Additional description: Seasonal allergy		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Secondary immunodeficiency	Additional description: Secondary immunodeficiency		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Selective IgG subclass deficiency	Additional description: Selective IgG subclass deficiency		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Reproductive system and breast disorders			

Balanoposthitis	Additional description: Balanoposthitis	
subjects affected / exposed	0 / 231 (0.00%)	
occurrences (all)	0	
Benign prostatic hyperplasia	Additional description: Benign prostatic hyperplasia	
subjects affected / exposed	1 / 231 (0.43%)	
occurrences (all)	1	
Breast induration	Additional description: Breast induration	
subjects affected / exposed	0 / 231 (0.00%)	
occurrences (all)	0	
Breast pain	Additional description: Breast pain	
subjects affected / exposed	3 / 231 (1.30%)	
occurrences (all)	3	
Dyspareunia	Additional description: Dyspareunia	
subjects affected / exposed	1 / 231 (0.43%)	
occurrences (all)	1	
Endometriosis	Additional description: Endometriosis	
subjects affected / exposed	0 / 231 (0.00%)	
occurrences (all)	0	
Erectile dysfunction	Additional description: Erectile dysfunction	
subjects affected / exposed	2 / 231 (0.87%)	
occurrences (all)	2	
Haematospermia	Additional description: Haematospermia	
subjects affected / exposed	2 / 231 (0.87%)	
occurrences (all)	2	
Hypomenorrhoea	Additional description: Hypomenorrhoea	
subjects affected / exposed	0 / 231 (0.00%)	
occurrences (all)	0	
Menopausal symptoms	Additional description: Menopausal symptoms	
subjects affected / exposed	1 / 231 (0.43%)	
occurrences (all)	1	
Menorrhagia	Additional description: Menorrhagia	
subjects affected / exposed	2 / 231 (0.87%)	
occurrences (all)	2	
Menstruation irregular	Additional description: Menstruation irregular	
subjects affected / exposed	0 / 231 (0.00%)	
occurrences (all)	0	

Nipple pain	Additional description: Nipple pain	
subjects affected / exposed	0 / 231 (0.00%)	
occurrences (all)	0	
Ovarian hyperfunction	Additional description: Ovarian hyperfunction	
subjects affected / exposed	0 / 231 (0.00%)	
occurrences (all)	0	
Penis disorder	Additional description: Penis disorder	
subjects affected / exposed	2 / 231 (0.87%)	
occurrences (all)	2	
Pelvic pain	Additional description: Pelvic pain	
subjects affected / exposed	0 / 231 (0.00%)	
occurrences (all)	0	
Prostatic hypoplasia	Additional description: Prostatic hypoplasia	
subjects affected / exposed	0 / 231 (0.00%)	
occurrences (all)	0	
Prostatitis	Additional description: Prostatitis	
subjects affected / exposed	1 / 231 (0.43%)	
occurrences (all)	1	
Scrotal oedema	Additional description: Scrotal oedema	
subjects affected / exposed	1 / 231 (0.43%)	
occurrences (all)	1	
Testicular disorder	Additional description: Testicular disorder	
subjects affected / exposed	0 / 231 (0.00%)	
occurrences (all)	0	
Testicular pain	Additional description: Testicular pain	
subjects affected / exposed	1 / 231 (0.43%)	
occurrences (all)	1	
Vaginal haemorrhage	Additional description: Vaginal haemorrhage	
subjects affected / exposed	3 / 231 (1.30%)	
occurrences (all)	3	
Vaginal discharge	Additional description: Vaginal discharge	
subjects affected / exposed	1 / 231 (0.43%)	
occurrences (all)	1	
Vulvovaginal pruritus	Additional description: Vulvovaginal pruritus	
subjects affected / exposed	0 / 231 (0.00%)	
occurrences (all)	0	

Respiratory, thoracic and mediastinal disorders			
Asthma	Additional description: Asthma		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences (all)	1		
Bronchospasm	Additional description: Bronchospasm		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences (all)	1		
Chronic obstructive pulmonary disease	Additional description: Chronic obstructive pulmonary disease		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences (all)	1		
Cough	Additional description: Cough		
subjects affected / exposed	37 / 231 (16.02%)		
occurrences (all)	43		
Dysaesthesia pharynx	Additional description: Dysaesthesia pharynx		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences (all)	0		
Dysphonia	Additional description: Dysphonia		
subjects affected / exposed	7 / 231 (3.03%)		
occurrences (all)	7		
Dyspnoea	Additional description: Dyspnoea		
subjects affected / exposed	18 / 231 (7.79%)		
occurrences (all)	18		
Dyspnoea exertional	Additional description: Dyspnoea exertional		
subjects affected / exposed	3 / 231 (1.30%)		
occurrences (all)	3		
Epistaxis	Additional description: Epistaxis		
subjects affected / exposed	22 / 231 (9.52%)		
occurrences (all)	27		
Haemoptysis	Additional description: Haemoptysis		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences (all)	0		
Hiccups	Additional description: Hiccups		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences (all)	1		
Hyperventilation	Additional description: Hyperventilation		

subjects affected / exposed occurrences (all)	2 / 231 (0.87%) 2		
Interstitial lung disease	Additional description: Interstitial lung disease		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Laryngeal inflammation	Additional description: Laryngeal inflammation		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Nasal congestion	Additional description: Nasal congestion		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Nasal discomfort	Additional description: Nasal discomfort		
subjects affected / exposed occurrences (all)	2 / 231 (0.87%) 2		
Nasal dryness	Additional description: Nasal dryness		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Nasal inflammation	Additional description: Nasal inflammation		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Nasal obstruction	Additional description: Nasal obstruction		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Nasal ulcer	Additional description: Nasal ulcer		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Oropharyngeal pain	Additional description: Oropharyngeal pain		
subjects affected / exposed occurrences (all)	14 / 231 (6.06%) 15		
Pharyngeal inflammation	Additional description: Pharyngeal inflammation		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Pleural effusion	Additional description: Pleural effusion		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Pneumonitis	Additional description: Pneumonitis		

subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Productive cough	Additional description: Productive cough		
subjects affected / exposed occurrences (all)	5 / 231 (2.16%) 6		
Pulmonary embolism	Additional description: Pulmonary embolism		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Pulmonary hypertension	Additional description: Pulmonary hypertension		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Pulmonary pain	Additional description: Pulmonary pain		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Rhinitis allergic	Additional description: Rhinitis allergic		
subjects affected / exposed occurrences (all)	3 / 231 (1.30%) 3		
Respiratory alkalosis	Additional description: Respiratory alkalosis		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Rhinorrhoea	Additional description: Rhinorrhoea		
subjects affected / exposed occurrences (all)	4 / 231 (1.73%) 4		
Sinus pain	Additional description: Sinus pain		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Sleep apnoea syndrome	Additional description: Sleep apnoea syndrome		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Tachypnoea	Additional description: Tachypnoea		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Throat clearing	Additional description: Throat clearing		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Throat irritation	Additional description: Throat irritation		

subjects affected / exposed occurrences (all)	4 / 231 (1.73%) 5		
Throatache	Additional description: Throatache		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Upper-airway cough syndrome	Additional description: Upper-airway cough syndrome		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Wheezing	Additional description: Wheezing		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Psychiatric disorders	Additional description: Abnormal dreams		
Abnormal dreams subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Agitation	Additional description: Agitation		
subjects affected / exposed occurrences (all)	3 / 231 (1.30%) 3		
Aggression	Additional description: Aggression		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Adjustment disorder	Additional description: Adjustment disorder		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Anxiety	Additional description: Anxiety		
subjects affected / exposed occurrences (all)	2 / 231 (0.87%) 2		
Apathy	Additional description: Apathy		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Bruxism	Additional description: Bruxism		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Confusional state	Additional description: Confusional state		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		

Depression	Additional description: Depression	
subjects affected / exposed	7 / 231 (3.03%)	
occurrences (all)	7	
Delirium	Additional description: Delirium	
subjects affected / exposed	1 / 231 (0.43%)	
occurrences (all)	1	
Depressed mood	Additional description: Depressed mood	
subjects affected / exposed	2 / 231 (0.87%)	
occurrences (all)	2	
Disorientation	Additional description: Disorientation	
subjects affected / exposed	1 / 231 (0.43%)	
occurrences (all)	1	
Hallucination	Additional description: Hallucination	
subjects affected / exposed	0 / 231 (0.00%)	
occurrences (all)	0	
Hyperarousal	Additional description: Hyperarousal	
subjects affected / exposed	0 / 231 (0.00%)	
occurrences (all)	0	
Illusion	Additional description: Illusion	
subjects affected / exposed	1 / 231 (0.43%)	
occurrences (all)	1	
Insomnia	Additional description: Insomnia	
subjects affected / exposed	10 / 231 (4.33%)	
occurrences (all)	11	
Irritability	Additional description: Irritability	
subjects affected / exposed	2 / 231 (0.87%)	
occurrences (all)	2	
Panic attack	Additional description: Panic attack	
subjects affected / exposed	1 / 231 (0.43%)	
occurrences (all)	1	
Restlessness	Additional description: Restlessness	
subjects affected / exposed	1 / 231 (0.43%)	
occurrences (all)	1	
Sleep disorder	Additional description: Sleep disorder	
subjects affected / exposed	4 / 231 (1.73%)	
occurrences (all)	4	

Somnambulism	Additional description: Somnambulism	
subjects affected / exposed	0 / 231 (0.00%)	
occurrences (all)	0	
Stress	Additional description: Stress	
subjects affected / exposed	0 / 231 (0.00%)	
occurrences (all)	0	
Investigations		
Activated partial thromboplastin time prolonged	Additional description: Activated partial thromboplastin time prolonged	
subjects affected / exposed	1 / 231 (0.43%)	
occurrences (all)	1	
Alanine aminotransferase increased	Additional description: Alanine aminotransferase increased	
subjects affected / exposed	9 / 231 (3.90%)	
occurrences (all)	9	
Amylase increased	Additional description: Amylase increased	
subjects affected / exposed	0 / 231 (0.00%)	
occurrences (all)	0	
Aspartate aminotransferase increased	Additional description: Aspartate aminotransferase increased	
subjects affected / exposed	10 / 231 (4.33%)	
occurrences (all)	12	
Blood immunoglobulin G decreased	Additional description: Blood immunoglobulin G decreased	
subjects affected / exposed	2 / 231 (0.87%)	
occurrences (all)	2	
Basophil count decreased	Additional description: Basophil count decreased	
subjects affected / exposed	0 / 231 (0.00%)	
occurrences (all)	0	
Blood alkaline phosphatase increased	Additional description: Blood alkaline phosphatase increased	
subjects affected / exposed	4 / 231 (1.73%)	
occurrences (all)	6	
Blood bilirubin increased	Additional description: Blood bilirubin increased	
subjects affected / exposed	9 / 231 (3.90%)	
occurrences (all)	18	
Blood calcium decreased	Additional description: Blood calcium decreased	
subjects affected / exposed	1 / 231 (0.43%)	
occurrences (all)	1	
Blood chloride increased	Additional description: Blood chloride increased	

subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Blood creatine increased	Additional description: Blood creatine increased		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Blood creatinine increased	Additional description: Blood creatinine increased		
subjects affected / exposed occurrences (all)	7 / 231 (3.03%) 7		
Blood glucose increased	Additional description: Blood glucose increased		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Blood immunoglobulin M decreased	Additional description: Blood immunoglobulin M decreased		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Blood lactate dehydrogenase increased	Additional description: Blood lactate dehydrogenase increased		
subjects affected / exposed occurrences (all)	4 / 231 (1.73%) 4		
Blood phosphorus increased	Additional description: Blood phosphorus increased		
subjects affected / exposed occurrences (all)	9 / 231 (3.90%) 13		
Blood potassium decreased	Additional description: Blood potassium decreased		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Blood potassium increased	Additional description: Blood potassium increased		
subjects affected / exposed occurrences (all)	2 / 231 (0.87%) 2		
Blood pressure increased	Additional description: Blood pressure increased		
subjects affected / exposed occurrences (all)	2 / 231 (0.87%) 2		
Blood thyroid stimulating hormone increased	Additional description: Blood thyroid stimulating hormone increased		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Blood urea increased	Additional description: Blood urea increased		

subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Blood uric acid decreased subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0	Additional description: Blood uric acid decreased	
Blood uric acid increased subjects affected / exposed occurrences (all)	5 / 231 (2.16%) 8	Additional description: Blood uric acid increased	
Body temperature increased subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0	Additional description: Body temperature increased	
Blood iron decreased subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1	Additional description: Blood iron decreased	
Cardiac murmur subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1	Additional description: Cardiac murmur	
Bronchoscopy subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1	Additional description: Bronchoscopy	
C-reactive protein subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1	Additional description: C-reactive protein	
C-reactive protein increased subjects affected / exposed occurrences (all)	5 / 231 (2.16%) 5	Additional description: C-reactive protein increased	
Cortisol decreased subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1	Additional description: Cortisol decreased	
Enterococcus test positive subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1	Additional description: Enterococcus test positive	
Eosinophil count decreased subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0	Additional description: Eosinophil count decreased	
Free haemoglobin present		Additional description: Free haemoglobin present	

subjects affected / exposed	1 / 231 (0.43%)		
occurrences (all)	1		
Gamma-glutamyltransferase increased	Additional description: Gamma-glutamyltransferase increased		
subjects affected / exposed	5 / 231 (2.16%)		
occurrences (all)	12		
Glomerular filtration rate decreased	Additional description: Glomerular filtration rate decreased		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences (all)	1		
Heart rate irregular	Additional description: Heart rate irregular		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences (all)	0		
Hepatic enzyme abnormal	Additional description: Hepatic enzyme abnormal		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences (all)	1		
Hepatic enzyme increased	Additional description: Hepatic enzyme increased		
subjects affected / exposed	2 / 231 (0.87%)		
occurrences (all)	2		
Hepatitis B DNA increased	Additional description: Hepatitis B DNA increased		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences (all)	0		
Immunoglobulins decreased	Additional description: Immunoglobulins decreased		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences (all)	0		
Inflammatory marker increased	Additional description: Inflammatory marker increased		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences (all)	0		
International normalised ratio increased	Additional description: International normalised ratio increased		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences (all)	0		
Intraocular pressure increased	Additional description: Intraocular pressure increased		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences (all)	0		
Left ventricular end-diastolic pressure decreased	Additional description: Left ventricular end-diastolic pressure decreased		

subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Lipase increased	Additional description: Lipase increased		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Liver function test increased	Additional description: Liver function test increased		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Monocyte count decreased	Additional description: Monocyte count decreased		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Myocardial necrosis marker increased	Additional description: Myocardial necrosis marker increased		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
N-terminal prohormone brain natriuretic peptide increased	Additional description: N-terminal prohormone brain natriuretic peptide increased		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Neutrophil count decreased	Additional description: Neutrophil count decreased		
subjects affected / exposed occurrences (all)	33 / 231 (14.29%) 48		
Platelet count decreased	Additional description: Platelet count decreased		
subjects affected / exposed occurrences (all)	22 / 231 (9.52%) 31		
Procalcitonin increased	Additional description: Procalcitonin increased		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Reticulocyte count decreased	Additional description: Reticulocyte count decreased		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
SARS-CoV-2 test positive	Additional description: SARS-CoV-2 test positive		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Serum ferritin decreased	Additional description: Serum ferritin decreased		

subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Transaminases increased	Additional description: Transaminases increased		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Transferrin decreased	Additional description: Transferrin decreased		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Vitamin B12 decreased	Additional description: Vitamin B12 decreased		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Weight decreased	Additional description: Weight decreased		
subjects affected / exposed occurrences (all)	9 / 231 (3.90%) 9		
Weight increased	Additional description: Weight increased		
subjects affected / exposed occurrences (all)	7 / 231 (3.03%) 7		
White blood cell count decreased	Additional description: White blood cell count decreased		
subjects affected / exposed occurrences (all)	9 / 231 (3.90%) 18		
White blood cell count increased	Additional description: White blood cell count increased		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Injury, poisoning and procedural complications			
Arthropod bite	Additional description: Arthropod bite		
subjects affected / exposed occurrences (all)	2 / 231 (0.87%) 2		
Animal bite	Additional description: Animal bite		
subjects affected / exposed occurrences (all)	2 / 231 (0.87%) 2		
Bone contusion	Additional description: Bone contusion		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Chest injury	Additional description: Chest injury		

subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Clavicle fracture	Additional description: Clavicle fracture		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Contusion	Additional description: Contusion		
subjects affected / exposed occurrences (all)	10 / 231 (4.33%) 11		
Ear canal injury	Additional description: Ear canal injury		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Epicondylitis	Additional description: Epicondylitis		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Face injury	Additional description: Face injury		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Fall	Additional description: Fall		
subjects affected / exposed occurrences (all)	2 / 231 (0.87%) 2		
Foreign body in eye	Additional description: Foreign body in eye		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Fracture	Additional description: Fracture		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Hand fracture	Additional description: Hand fracture		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Head injury	Additional description: Head injury		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Infusion related reaction	Additional description: Infusion related reaction		
subjects affected / exposed occurrences (all)	46 / 231 (19.91%) 54		
Injury	Additional description: Injury		

subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Ligament injury	Additional description: Ligament injury		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Joint capsule rupture	Additional description: Joint capsule rupture		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Ligament sprain	Additional description: Ligament sprain		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Limb injury	Additional description: Limb injury		
subjects affected / exposed occurrences (all)	2 / 231 (0.87%) 3		
Mallet finger	Additional description: Mallet finger		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Meniscus injury	Additional description: Meniscus injury		
subjects affected / exposed occurrences (all)	4 / 231 (1.73%) 4		
Mouth injury	Additional description: Mouth injury		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Multiple fractures	Additional description: Multiple fractures		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Muscle strain	Additional description: Muscle strain		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Nasal injury	Additional description: Nasal injury		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Paravenous drug administration	Additional description: Paravenous drug administration		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Procedural pain	Additional description: Procedural pain		

subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Post-traumatic neck syndrome	Additional description: Post-traumatic neck syndrome		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Road traffic accident	Additional description: Road traffic accident		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Scar	Additional description: Scar		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Skin abrasion	Additional description: Skin abrasion		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Skin wound	Additional description: Skin wound		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Spinal compression fracture	Additional description: Spinal compression fracture		
subjects affected / exposed occurrences (all)	2 / 231 (0.87%) 6		
Spinal fracture	Additional description: Spinal fracture		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Tendon rupture	Additional description: Tendon rupture		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Thermal burn	Additional description: Thermal burn		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Thoracic vertebral fracture	Additional description: Thoracic vertebral fracture		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Tooth injury	Additional description: Tooth injury		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Transfusion reaction	Additional description: Transfusion reaction		

subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Traumatic ear amputation	Additional description: Traumatic ear amputation		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Traumatic haematoma	Additional description: Traumatic haematoma		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Vascular access complication	Additional description: Vascular access complication		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Wrist fracture	Additional description: Wrist fracture		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Wound	Additional description: Wound		
subjects affected / exposed occurrences (all)	4 / 231 (1.73%) 5		
Wound complication	Additional description: Wound complication		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Congenital, familial and genetic disorders			
Cryptorchism	Additional description: Cryptorchism		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Glycogen storage disease type I	Additional description: Glycogen storage disease type I		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Hydrocele	Additional description: Hydrocele		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Ichthyosis	Additional description: Ichthyosis		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Phimosis	Additional description: Phimosis		

subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Cardiac disorders			
Additional description: Acute coronary syndrome			
Acute coronary syndrome subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Additional description: Angina pectoris			
Angina pectoris subjects affected / exposed occurrences (all)	2 / 231 (0.87%) 2		
Additional description: Arteriosclerosis coronary artery			
Arteriosclerosis coronary artery subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Additional description: Arrhythmia			
Arrhythmia subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Additional description: Atrial fibrillation			
Atrial fibrillation subjects affected / exposed occurrences (all)	17 / 231 (7.36%) 19		
Additional description: Atrial flutter			
Atrial flutter subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Additional description: Atrial thrombosis			
Atrial thrombosis subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Additional description: Atrioventricular block second degree			
Atrioventricular block second degree subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Additional description: Bradycardia			
Bradycardia subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Additional description: Bundle branch block right			
Bundle branch block right subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Additional description: Cardiac discomfort			
Cardiac discomfort subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		

Cardiac failure subjects affected / exposed occurrences (all)	Additional description: Cardiac failure 0 / 231 (0.00%) 0		
Cardiovascular disorder subjects affected / exposed occurrences (all)	Additional description: Cardiovascular disorder 2 / 231 (0.87%) 2		
Coronary artery disease subjects affected / exposed occurrences (all)	Additional description: Coronary artery disease 1 / 231 (0.43%) 1		
Coronary artery stenosis subjects affected / exposed occurrences (all)	Additional description: Coronary artery stenosis 0 / 231 (0.00%) 0		
Extrasystoles subjects affected / exposed occurrences (all)	Additional description: Extrasystoles 1 / 231 (0.43%) 1		
Hypertensive heart disease subjects affected / exposed occurrences (all)	Additional description: Hypertensive heart disease 0 / 231 (0.00%) 0		
Myocardial ischaemia subjects affected / exposed occurrences (all)	Additional description: Myocardial ischaemia 1 / 231 (0.43%) 1		
Palpitations subjects affected / exposed occurrences (all)	Additional description: Palpitations 10 / 231 (4.33%) 13		
Pericardial effusion subjects affected / exposed occurrences (all)	Additional description: Pericardial effusion 0 / 231 (0.00%) 0		
Right ventricular failure subjects affected / exposed occurrences (all)	Additional description: Right ventricular failure 0 / 231 (0.00%) 0		
Sinus tachycardia subjects affected / exposed occurrences (all)	Additional description: Sinus tachycardia 0 / 231 (0.00%) 0		
Supraventricular tachycardia subjects affected / exposed occurrences (all)	Additional description: Supraventricular tachycardia 2 / 231 (0.87%) 2		

Tachycardia	Additional description: Tachycardia	
subjects affected / exposed	3 / 231 (1.30%)	
occurrences (all)	3	
Tachycardia paroxysmal	Additional description: Tachycardia paroxysmal	
subjects affected / exposed	0 / 231 (0.00%)	
occurrences (all)	0	
Ventricular extrasystoles	Additional description: Ventricular extrasystoles	
subjects affected / exposed	1 / 231 (0.43%)	
occurrences (all)	3	
Nervous system disorders		
Ageusia	Additional description: Ageusia	
subjects affected / exposed	2 / 231 (0.87%)	
occurrences (all)	2	
Amnesia	Additional description: Amnesia	
subjects affected / exposed	2 / 231 (0.87%)	
occurrences (all)	2	
Aphasia	Additional description: Aphasia	
subjects affected / exposed	0 / 231 (0.00%)	
occurrences (all)	0	
Ataxia	Additional description: Ataxia	
subjects affected / exposed	1 / 231 (0.43%)	
occurrences (all)	1	
Balance disorder	Additional description: Balance disorder	
subjects affected / exposed	0 / 231 (0.00%)	
occurrences (all)	0	
Burning sensation	Additional description: Burning sensation	
subjects affected / exposed	1 / 231 (0.43%)	
occurrences (all)	1	
Carpal tunnel syndrome	Additional description: Carpal tunnel syndrome	
subjects affected / exposed	1 / 231 (0.43%)	
occurrences (all)	1	
Cervicobrachial syndrome	Additional description: Cervicobrachial syndrome	
subjects affected / exposed	2 / 231 (0.87%)	
occurrences (all)	2	
Carotid artery stenosis	Additional description: Carotid artery stenosis	

subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Concentration impairment	Additional description: Concentration impairment		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Cognitive disorder	Additional description: Cognitive disorder		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Cubital tunnel syndrome	Additional description: Cubital tunnel syndrome		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Depressed level of consciousness	Additional description: Depressed level of consciousness		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Disturbance in attention	Additional description: Disturbance in attention		
subjects affected / exposed occurrences (all)	6 / 231 (2.60%) 6		
Dizziness	Additional description: Dizziness		
subjects affected / exposed occurrences (all)	23 / 231 (9.96%) 24		
Dizziness postural	Additional description: Dizziness postural		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Dysaesthesia	Additional description: Dysaesthesia		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Dysgeusia	Additional description: Dysgeusia		
subjects affected / exposed occurrences (all)	3 / 231 (1.30%) 4		
Facial paralysis	Additional description: Facial paralysis		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Formication	Additional description: Formication		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Hand-arm vibration syndrome	Additional description: Hand-arm vibration syndrome		

subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Head discomfort	Additional description: Head discomfort		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Headache	Additional description: Headache		
subjects affected / exposed occurrences (all)	39 / 231 (16.88%) 52		
Hypoaesthesia	Additional description: Hypoaesthesia		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Hypertonia	Additional description: Hypertonia		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Hypotonia	Additional description: Hypotonia		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Intention tremor	Additional description: Intention tremor		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Lumbar radiculopathy	Additional description: Lumbar radiculopathy		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Memory impairment	Additional description: Memory impairment		
subjects affected / exposed occurrences (all)	5 / 231 (2.16%) 5		
Mental impairment	Additional description: Mental impairment		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Migraine	Additional description: Migraine		
subjects affected / exposed occurrences (all)	3 / 231 (1.30%) 3		
Muscle spasticity	Additional description: Muscle spasticity		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Neuromuscular blockade	Additional description: Neuromuscular blockade		

subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Olfactory nerve disorder	Additional description: Olfactory nerve disorder		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Neuropathy peripheral	Additional description: Neuropathy peripheral		
subjects affected / exposed occurrences (all)	5 / 231 (2.16%) 6		
Orthostatic intolerance	Additional description: Orthostatic intolerance		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Paraesthesia	Additional description: Paraesthesia		
subjects affected / exposed occurrences (all)	9 / 231 (3.90%) 10		
Parkinson's disease	Additional description: Parkinson's disease		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Parosmia	Additional description: Parosmia		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Peripheral motor neuropathy	Additional description: Peripheral motor neuropathy		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Peripheral sensory neuropathy	Additional description: Peripheral sensory neuropathy		
subjects affected / exposed occurrences (all)	2 / 231 (0.87%) 2		
Polyneuropathy	Additional description: Polyneuropathy		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Post herpetic neuralgia	Additional description: Post herpetic neuralgia		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Presyncope	Additional description: Presyncope		
subjects affected / exposed occurrences (all)	4 / 231 (1.73%) 5		
Restless legs syndrome	Additional description: Restless legs syndrome		

subjects affected / exposed occurrences (all)	2 / 231 (0.87%) 2		
Sciatica	Additional description: Sciatica		
subjects affected / exposed occurrences (all)	2 / 231 (0.87%) 2		
Sensory disturbance	Additional description: Sensory disturbance		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Syncope	Additional description: Syncope		
subjects affected / exposed occurrences (all)	4 / 231 (1.73%) 4		
Somnolence	Additional description: Somnolence		
subjects affected / exposed occurrences (all)	2 / 231 (0.87%) 2		
Taste disorder	Additional description: Taste disorder		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Transient global amnesia	Additional description: Transient global amnesia		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 2		
Tremor	Additional description: Tremor		
subjects affected / exposed occurrences (all)	2 / 231 (0.87%) 2		
Trigeminal neuralgia	Additional description: Trigeminal neuralgia		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Visual field defect	Additional description: Visual field defect		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Blood and lymphatic system disorders			
Agranulocytosis	Additional description: Agranulocytosis		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Anaemia	Additional description: Anaemia		
subjects affected / exposed occurrences (all)	20 / 231 (8.66%) 25		

Autoimmune haemolytic anaemia subjects affected / exposed occurrences (all)	Additional description: Autoimmune haemolytic anaemia	
	1 / 231 (0.43%)	
	2	
Bicytopenia subjects affected / exposed occurrences (all)	Additional description: Bicytopenia	
	0 / 231 (0.00%)	
	0	
Eosinophilia subjects affected / exposed occurrences (all)	Additional description: Eosinophilia	
	0 / 231 (0.00%)	
	0	
Febrile neutropenia subjects affected / exposed occurrences (all)	Additional description: Febrile neutropenia	
	2 / 231 (0.87%)	
	2	
Granulocytopenia subjects affected / exposed occurrences (all)	Additional description: Granulocytopenia	
	1 / 231 (0.43%)	
	1	
Haemolysis subjects affected / exposed occurrences (all)	Additional description: Haemolysis	
	0 / 231 (0.00%)	
	0	
Haemorrhagic diathesis subjects affected / exposed occurrences (all)	Additional description: Haemorrhagic diathesis	
	2 / 231 (0.87%)	
	2	
Hypoglobulinaemia subjects affected / exposed occurrences (all)	Additional description: Hypoglobulinaemia	
	2 / 231 (0.87%)	
	2	
Immune thrombocytopenia subjects affected / exposed occurrences (all)	Additional description: Immune thrombocytopenia	
	0 / 231 (0.00%)	
	0	
Iron deficiency anaemia subjects affected / exposed occurrences (all)	Additional description: Iron deficiency anaemia	
	4 / 231 (1.73%)	
	4	
Leukocytosis subjects affected / exposed occurrences (all)	Additional description: Leukocytosis	
	2 / 231 (0.87%)	
	2	
Leukopenia subjects affected / exposed occurrences (all)	Additional description: Leukopenia	
	17 / 231 (7.36%)	
	27	

Lymph node pain subjects affected / exposed occurrences (all)	Additional description: Lymph node pain 1 / 231 (0.43%) 1		
Lymphadenitis subjects affected / exposed occurrences (all)	Additional description: Lymphadenitis 0 / 231 (0.00%) 0		
Lymphadenopathy subjects affected / exposed occurrences (all)	Additional description: Lymphadenopathy 1 / 231 (0.43%) 1		
Macrocytosis subjects affected / exposed occurrences (all)	Additional description: Macrocytosis 1 / 231 (0.43%) 1		
Microcytic anaemia subjects affected / exposed occurrences (all)	Additional description: Microcytic anaemia 1 / 231 (0.43%) 1		
Neutropenia subjects affected / exposed occurrences (all)	Additional description: Neutropenia 110 / 231 (47.62%) 237		
Pancytopenia subjects affected / exposed occurrences (all)	Additional description: Pancytopenia 2 / 231 (0.87%) 2		
Reticulocytosis subjects affected / exposed occurrences (all)	Additional description: Reticulocytosis 1 / 231 (0.43%) 1		
Thrombocytopenia subjects affected / exposed occurrences (all)	Additional description: Thrombocytopenia 52 / 231 (22.51%) 77		
Ear and labyrinth disorders			
Auditory disorder subjects affected / exposed occurrences (all)	Additional description: Auditory disorder 0 / 231 (0.00%) 0		
Deafness subjects affected / exposed occurrences (all)	Additional description: Deafness 4 / 231 (1.73%) 4		
Deafness unilateral	Additional description: Deafness unilateral		

subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Ear haemorrhage	Additional description: Ear haemorrhage		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Ear pain	Additional description: Ear pain		
subjects affected / exposed occurrences (all)	4 / 231 (1.73%) 4		
Hypoacusis	Additional description: Hypoacusis		
subjects affected / exposed occurrences (all)	2 / 231 (0.87%) 2		
Middle ear effusion	Additional description: Middle ear effusion		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Middle ear inflammation	Additional description: Middle ear inflammation		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Tinnitus	Additional description: Tinnitus		
subjects affected / exposed occurrences (all)	3 / 231 (1.30%) 3		
Vertigo positional	Additional description: Vertigo positional		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Vertigo	Additional description: Vertigo		
subjects affected / exposed occurrences (all)	10 / 231 (4.33%) 12		
Eye disorders	Additional description: Eye disorders		
Blepharitis	Additional description: Blepharitis		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Cataract	Additional description: Cataract		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Conjunctival haemorrhage	Additional description: Conjunctival haemorrhage		
subjects affected / exposed occurrences (all)	2 / 231 (0.87%) 2		

Corneal erosion subjects affected / exposed occurrences (all)	Additional description: Corneal erosion 0 / 231 (0.00%) 0		
Diplopia subjects affected / exposed occurrences (all)	Additional description: Diplopia 1 / 231 (0.43%) 1		
Dry eye subjects affected / exposed occurrences (all)	Additional description: Dry eye 6 / 231 (2.60%) 6		
Erythema of eyelid subjects affected / exposed occurrences (all)	Additional description: Erythema of eyelid 1 / 231 (0.43%) 1		
Exophthalmos subjects affected / exposed occurrences (all)	Additional description: Exophthalmos 0 / 231 (0.00%) 0		
Eye haemorrhage subjects affected / exposed occurrences (all)	Additional description: Eye haemorrhage 1 / 231 (0.43%) 1		
Eye inflammation subjects affected / exposed occurrences (all)	Additional description: Eye inflammation 1 / 231 (0.43%) 1		
Eye irritation subjects affected / exposed occurrences (all)	Additional description: Eye irritation 2 / 231 (0.87%) 2		
Eye oedema subjects affected / exposed occurrences (all)	Additional description: Eye oedema 0 / 231 (0.00%) 0		
Eye pain subjects affected / exposed occurrences (all)	Additional description: Eye pain 0 / 231 (0.00%) 0		
Eyelid haematoma subjects affected / exposed occurrences (all)	Additional description: Eyelid haematoma 1 / 231 (0.43%) 1		
Eyelid oedema subjects affected / exposed occurrences (all)	Additional description: Eyelid oedema 0 / 231 (0.00%) 0		

Eyelid ptosis subjects affected / exposed occurrences (all)	Additional description: Eyelid ptosis	
	1 / 231 (0.43%) 1	
Eye disorder subjects affected / exposed occurrences (all)	Additional description: Eye disorder	
	0 / 231 (0.00%) 0	
Glaucoma subjects affected / exposed occurrences (all)	Additional description: Glaucoma	
	0 / 231 (0.00%) 0	
Hyalosis asteroid subjects affected / exposed occurrences (all)	Additional description: Hyalosis asteroid	
	0 / 231 (0.00%) 0	
Lacrimation increased subjects affected / exposed occurrences (all)	Additional description: Lacrimation increased	
	1 / 231 (0.43%) 1	
Ocular hyperaemia subjects affected / exposed occurrences (all)	Additional description: Ocular hyperaemia	
	2 / 231 (0.87%) 2	
Ocular hypertension subjects affected / exposed occurrences (all)	Additional description: Ocular hypertension	
	0 / 231 (0.00%) 0	
Panophthalmitis subjects affected / exposed occurrences (all)	Additional description: Panophthalmitis	
	0 / 231 (0.00%) 0	
Periorbital oedema subjects affected / exposed occurrences (all)	Additional description: Periorbital oedema	
	0 / 231 (0.00%) 0	
Photophobia subjects affected / exposed occurrences (all)	Additional description: Photophobia	
	1 / 231 (0.43%) 1	
Retinal haemorrhage subjects affected / exposed occurrences (all)	Additional description: Retinal haemorrhage	
	0 / 231 (0.00%) 0	
Uveitis subjects affected / exposed occurrences (all)	Additional description: Uveitis	
	1 / 231 (0.43%) 1	

Vitreous detachment subjects affected / exposed occurrences (all)	Additional description: Vitreous detachment	
	0 / 231 (0.00%) 0	
Vitreous disorder subjects affected / exposed occurrences (all)	Additional description: Vitreous disorder	
	0 / 231 (0.00%) 0	
Vitreous haemorrhage subjects affected / exposed occurrences (all)	Additional description: Vitreous haemorrhage	
	0 / 231 (0.00%) 0	
Visual impairment subjects affected / exposed occurrences (all)	Additional description: Visual impairment	
	0 / 231 (0.00%) 0	
Vision blurred subjects affected / exposed occurrences (all)	Additional description: Vision blurred	
	7 / 231 (3.03%) 7	
Gastrointestinal disorders		
	Additional description: Abdominal pain upper	
Abdominal pain upper subjects affected / exposed occurrences (all)	21 / 231 (9.09%) 23	
	Additional description: Abdominal pain lower	
Abdominal pain lower subjects affected / exposed occurrences (all)	3 / 231 (1.30%) 3	
	Additional description: Abdominal pain	
Abdominal pain subjects affected / exposed occurrences (all)	15 / 231 (6.49%) 15	
	Additional description: Abdominal distension	
Abdominal distension subjects affected / exposed occurrences (all)	3 / 231 (1.30%) 3	
	Additional description: Abdominal discomfort	
Abdominal discomfort subjects affected / exposed occurrences (all)	6 / 231 (2.60%) 7	
	Additional description: Anal ulcer	
Anal ulcer subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1	
	Additional description: Anal pruritus	
Anal pruritus		

subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Anal incontinence	Additional description: Anal incontinence		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Anal haemorrhage	Additional description: Anal haemorrhage		
subjects affected / exposed occurrences (all)	2 / 231 (0.87%) 2		
Anal fissure	Additional description: Anal fissure		
subjects affected / exposed occurrences (all)	2 / 231 (0.87%) 2		
Angular cheilitis	Additional description: Angular cheilitis		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Aphthous ulcer	Additional description: Aphthous ulcer		
subjects affected / exposed occurrences (all)	3 / 231 (1.30%) 3		
Cheilitis	Additional description: Cheilitis		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Coeliac disease	Additional description: Coeliac disease		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Colitis	Additional description: Colitis		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Constipation	Additional description: Constipation		
subjects affected / exposed occurrences (all)	29 / 231 (12.55%) 32		
Crohn's disease	Additional description: Crohn's disease		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Dental caries	Additional description: Dental caries		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Diarrhoea	Additional description: Diarrhoea		

subjects affected / exposed occurrences (all)	118 / 231 (51.08%) 177		
Diarrhoea haemorrhagic	Additional description: Diarrhoea haemorrhagic		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Defaecation disorder	Additional description: Defaecation disorder		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Diverticulum intestinal	Additional description: Diverticulum intestinal		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Dry mouth	Additional description: Dry mouth		
subjects affected / exposed occurrences (all)	10 / 231 (4.33%) 10		
Dyspepsia	Additional description: Dyspepsia		
subjects affected / exposed occurrences (all)	27 / 231 (11.69%) 28		
Dysphagia	Additional description: Dysphagia		
subjects affected / exposed occurrences (all)	2 / 231 (0.87%) 2		
Enterovirus infection	Additional description: Enterovirus infection		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Epigastric discomfort	Additional description: Epigastric discomfort		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Faeces discoloured	Additional description: Faeces discoloured		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Gastric haemorrhage	Additional description: Gastric haemorrhage		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Flatulence	Additional description: Flatulence		
subjects affected / exposed occurrences (all)	8 / 231 (3.46%) 8		
Food poisoning	Additional description: Food poisoning		

subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Frequent bowel movements	Additional description: Frequent bowel movements		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Giant cell epulis	Additional description: Giant cell epulis		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Gingival bleeding	Additional description: Gingival bleeding		
subjects affected / exposed occurrences (all)	2 / 231 (0.87%) 2		
Gastritis	Additional description: Gastritis		
subjects affected / exposed occurrences (all)	3 / 231 (1.30%) 3		
Gastrointestinal haemorrhage	Additional description: Gastrointestinal haemorrhage		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Gastrointestinal motility disorder	Additional description: Gastrointestinal motility disorder		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Gastrointestinal pain	Additional description: Gastrointestinal pain		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Gastrointestinal tract irritation	Additional description: Gastrointestinal tract irritation		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Gastrooesophageal reflux disease	Additional description: Gastrooesophageal reflux disease		
subjects affected / exposed occurrences (all)	8 / 231 (3.46%) 8		
Gingival discolouration	Additional description: Gingival discolouration		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Haemorrhoidal haemorrhage	Additional description: Haemorrhoidal haemorrhage		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Haematochezia	Additional description: Haematochezia		

subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Haemorrhoids	Additional description: Haemorrhoids		
subjects affected / exposed occurrences (all)	3 / 231 (1.30%) 3		
Inguinal hernia	Additional description: Inguinal hernia		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Lip dry	Additional description: Lip dry		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Lip pain	Additional description: Lip pain		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Mouth haemorrhage	Additional description: Mouth haemorrhage		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Mouth ulceration	Additional description: Mouth ulceration		
subjects affected / exposed occurrences (all)	2 / 231 (0.87%) 2		
Nausea	Additional description: Nausea		
subjects affected / exposed occurrences (all)	77 / 231 (33.33%) 100		
Odynophagia	Additional description: Odynophagia		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Oesophagitis	Additional description: Oesophagitis		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Oral dysaesthesia	Additional description: Oral dysaesthesia		
subjects affected / exposed occurrences (all)	2 / 231 (0.87%) 2		
Oral mucosal blistering	Additional description: Oral mucosal blistering		
subjects affected / exposed occurrences (all)	3 / 231 (1.30%) 3		
Oral mucosal erythema	Additional description: Oral mucosal erythema		

subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Oral pain	Additional description: Oral pain		
subjects affected / exposed occurrences (all)	2 / 231 (0.87%) 3		
Paraesthesia oral	Additional description: Paraesthesia oral		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Periodontal disease	Additional description: Periodontal disease		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Proctalgia	Additional description: Proctalgia		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Rectal haemorrhage	Additional description: Rectal haemorrhage		
subjects affected / exposed occurrences (all)	2 / 231 (0.87%) 2		
Rectal polyp	Additional description: Rectal polyp		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Salivary gland calculus	Additional description: Salivary gland calculus		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Stomatitis	Additional description: Stomatitis		
subjects affected / exposed occurrences (all)	12 / 231 (5.19%) 14		
Tongue coated	Additional description: Tongue coated		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Tongue discomfort	Additional description: Tongue discomfort		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Tongue disorder	Additional description: Tongue disorder		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Tongue dry	Additional description: Tongue dry		

subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Tooth loss	Additional description: Tooth loss		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Toothache	Additional description: Toothache		
subjects affected / exposed occurrences (all)	6 / 231 (2.60%) 6		
Vomiting	Additional description: Vomiting		
subjects affected / exposed occurrences (all)	24 / 231 (10.39%) 36		
Hepatobiliary disorders	Additional description: Cholecystitis		
Cholecystitis subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Cholelithiasis	Additional description: Cholelithiasis		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Hepatic pain	Additional description: Hepatic pain		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Hepatic steatosis	Additional description: Hepatic steatosis		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Hepatotoxicity	Additional description: Hepatotoxicity		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Hyperbilirubinaemia	Additional description: Hyperbilirubinaemia		
subjects affected / exposed occurrences (all)	2 / 231 (0.87%) 2		
Liver disorder	Additional description: Liver disorder		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Portal vein dilatation	Additional description: Portal vein dilatation		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		

Portal vein thrombosis subjects affected / exposed occurrences (all)	Additional description: Portal vein thrombosis 0 / 231 (0.00%) 0		
Skin and subcutaneous tissue disorders			
Actinic keratosis subjects affected / exposed occurrences (all)	Additional description: Actinic keratosis 3 / 231 (1.30%) 3		
Alopecia subjects affected / exposed occurrences (all)	Additional description: Alopecia 4 / 231 (1.73%) 4		
Blister subjects affected / exposed occurrences (all)	Additional description: Blister 1 / 231 (0.43%) 1		
Blood blister subjects affected / exposed occurrences (all)	Additional description: Blood blister 1 / 231 (0.43%) 1		
Cafe au lait spots subjects affected / exposed occurrences (all)	Additional description: Cafe au lait spots 0 / 231 (0.00%) 0		
Dermatitis subjects affected / exposed occurrences (all)	Additional description: Dermatitis 1 / 231 (0.43%) 1		
Dermatitis acneiform subjects affected / exposed occurrences (all)	Additional description: Dermatitis acneiform 1 / 231 (0.43%) 1		
Dermatitis allergic subjects affected / exposed occurrences (all)	Additional description: Dermatitis allergic 1 / 231 (0.43%) 1		
Dermatitis atopic subjects affected / exposed occurrences (all)	Additional description: Dermatitis atopic 0 / 231 (0.00%) 0		
Dermatitis contact subjects affected / exposed occurrences (all)	Additional description: Dermatitis contact 0 / 231 (0.00%) 0		
Dermatitis exfoliative	Additional description: Dermatitis exfoliative		

subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Dermatitis exfoliative generalised subjects affected / exposed occurrences (all)	Additional description: Dermatitis exfoliative generalised 0 / 231 (0.00%) 0		
Decubitus ulcer subjects affected / exposed occurrences (all)	Additional description: Decubitus ulcer 1 / 231 (0.43%) 1		
Drug eruption subjects affected / exposed occurrences (all)	Additional description: Drug eruption 1 / 231 (0.43%) 1		
Dry skin subjects affected / exposed occurrences (all)	Additional description: Dry skin 17 / 231 (7.36%) 17		
Ecchymosis subjects affected / exposed occurrences (all)	Additional description: Ecchymosis 5 / 231 (2.16%) 6		
Eczema subjects affected / exposed occurrences (all)	Additional description: Eczema 12 / 231 (5.19%) 12		
Eczema nummular subjects affected / exposed occurrences (all)	Additional description: Eczema nummular 0 / 231 (0.00%) 0		
Erythema subjects affected / exposed occurrences (all)	Additional description: Erythema 4 / 231 (1.73%) 4		
Erythema nodosum subjects affected / exposed occurrences (all)	Additional description: Erythema nodosum 1 / 231 (0.43%) 1		
Eosinophilic cellulitis subjects affected / exposed occurrences (all)	Additional description: Eosinophilic cellulitis 0 / 231 (0.00%) 0		
Erythema multiforme subjects affected / exposed occurrences (all)	Additional description: Erythema multiforme 3 / 231 (1.30%) 3		
Hand dermatitis	Additional description: Hand dermatitis		

subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Hyperkeratosis	Additional description: Hyperkeratosis		
subjects affected / exposed occurrences (all)	2 / 231 (0.87%) 2		
Hyperhidrosis	Additional description: Hyperhidrosis		
subjects affected / exposed occurrences (all)	6 / 231 (2.60%) 6		
Hypertrichosis	Additional description: Hypertrichosis		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Intertrigo	Additional description: Intertrigo		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Lentigo	Additional description: Lentigo		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Lichen planus	Additional description: Lichen planus		
subjects affected / exposed occurrences (all)	2 / 231 (0.87%) 2		
Neurodermatitis	Additional description: Neurodermatitis		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Nail discolouration	Additional description: Nail discolouration		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Nail dystrophy	Additional description: Nail dystrophy		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Nail pitting	Additional description: Nail pitting		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Nail ridging	Additional description: Nail ridging		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Nail toxicity	Additional description: Nail toxicity		

subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Night sweats	Additional description: Night sweats		
subjects affected / exposed occurrences (all)	4 / 231 (1.73%) 4		
Onychoclasia	Additional description: Onychoclasia		
subjects affected / exposed occurrences (all)	6 / 231 (2.60%) 6		
Onycholysis	Additional description: Onycholysis		
subjects affected / exposed occurrences (all)	2 / 231 (0.87%) 2		
Papule	Additional description: Papule		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Pemphigoid	Additional description: Pemphigoid		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Petechiae	Additional description: Petechiae		
subjects affected / exposed occurrences (all)	12 / 231 (5.19%) 17		
Pigmentation disorder	Additional description: Pigmentation disorder		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Rash generalised	Additional description: Rash generalised		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Rash erythematous	Additional description: Rash erythematous		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Pruritus	Additional description: Pruritus		
subjects affected / exposed occurrences (all)	17 / 231 (7.36%) 17		
Pruritus generalised	Additional description: Pruritus generalised		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Psoriasis	Additional description: Psoriasis		

subjects affected / exposed occurrences (all)	2 / 231 (0.87%) 3		
Purpura	Additional description: Purpura		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Rash	Additional description: Rash		
subjects affected / exposed occurrences (all)	37 / 231 (16.02%) 49		
Rash macular	Additional description: Rash macular		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Rash maculo-papular	Additional description: Rash maculo-papular		
subjects affected / exposed occurrences (all)	9 / 231 (3.90%) 12		
Rash pruritic	Additional description: Rash pruritic		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Rash papular	Additional description: Rash papular		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Rosacea	Additional description: Rosacea		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Solar dermatitis	Additional description: Solar dermatitis		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Skin burning sensation	Additional description: Skin burning sensation		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Skin discolouration	Additional description: Skin discolouration		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Skin discomfort	Additional description: Skin discomfort		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Skin disorder	Additional description: Skin disorder		

subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Skin fissures	Additional description: Skin fissures		
subjects affected / exposed occurrences (all)	3 / 231 (1.30%) 3		
Skin hypopigmentation	Additional description: Skin hypopigmentation		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Skin irritation	Additional description: Skin irritation		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Skin lesion	Additional description: Skin lesion		
subjects affected / exposed occurrences (all)	4 / 231 (1.73%) 4		
Skin mass	Additional description: Skin mass		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Skin ulcer	Additional description: Skin ulcer		
subjects affected / exposed occurrences (all)	3 / 231 (1.30%) 3		
Suggillation	Additional description: Suggillation		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Telangiectasia	Additional description: Telangiectasia		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Toxic skin eruption	Additional description: Toxic skin eruption		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Urticaria	Additional description: Urticaria		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 2		
Renal and urinary disorders	Additional description: Acute kidney injury		
Acute kidney injury subjects affected / exposed occurrences (all)	2 / 231 (0.87%) 2		

Chromaturia	Additional description: Chromaturia	
subjects affected / exposed	0 / 231 (0.00%)	
occurrences (all)	0	
Chronic kidney disease	Additional description: Chronic kidney disease	
subjects affected / exposed	0 / 231 (0.00%)	
occurrences (all)	0	
Cystitis noninfective	Additional description: Cystitis noninfective	
subjects affected / exposed	0 / 231 (0.00%)	
occurrences (all)	0	
Dysuria	Additional description: Dysuria	
subjects affected / exposed	3 / 231 (1.30%)	
occurrences (all)	3	
Haematuria	Additional description: Haematuria	
subjects affected / exposed	8 / 231 (3.46%)	
occurrences (all)	8	
Hydronephrosis	Additional description: Hydronephrosis	
subjects affected / exposed	0 / 231 (0.00%)	
occurrences (all)	0	
Incontinence	Additional description: Incontinence	
subjects affected / exposed	0 / 231 (0.00%)	
occurrences (all)	0	
Kidney congestion	Additional description: Kidney congestion	
subjects affected / exposed	0 / 231 (0.00%)	
occurrences (all)	0	
Leukocyturia	Additional description: Leukocyturia	
subjects affected / exposed	0 / 231 (0.00%)	
occurrences (all)	0	
Lower urinary tract symptoms	Additional description: Lower urinary tract symptoms	
subjects affected / exposed	0 / 231 (0.00%)	
occurrences (all)	0	
Micturition disorder	Additional description: Micturition disorder	
subjects affected / exposed	1 / 231 (0.43%)	
occurrences (all)	1	
Micturition urgency	Additional description: Micturition urgency	
subjects affected / exposed	1 / 231 (0.43%)	
occurrences (all)	1	

Nocturia	Additional description: Nocturia	
subjects affected / exposed	1 / 231 (0.43%)	
occurrences (all)	1	
Pollakiuria	Additional description: Pollakiuria	
subjects affected / exposed	2 / 231 (0.87%)	
occurrences (all)	2	
Polyuria	Additional description: Polyuria	
subjects affected / exposed	0 / 231 (0.00%)	
occurrences (all)	0	
Renal colic	Additional description: Renal colic	
subjects affected / exposed	1 / 231 (0.43%)	
occurrences (all)	1	
Renal cyst	Additional description: Renal cyst	
subjects affected / exposed	0 / 231 (0.00%)	
occurrences (all)	0	
Renal failure	Additional description: Renal failure	
subjects affected / exposed	0 / 231 (0.00%)	
occurrences (all)	0	
Renal pain	Additional description: Renal pain	
subjects affected / exposed	0 / 231 (0.00%)	
occurrences (all)	0	
Strangury	Additional description: Strangury	
subjects affected / exposed	1 / 231 (0.43%)	
occurrences (all)	1	
Urinary incontinence	Additional description: Urinary incontinence	
subjects affected / exposed	0 / 231 (0.00%)	
occurrences (all)	0	
Urinary tract pain	Additional description: Urinary tract pain	
subjects affected / exposed	2 / 231 (0.87%)	
occurrences (all)	2	
Urinary tract obstruction	Additional description: Urinary tract obstruction	
subjects affected / exposed	1 / 231 (0.43%)	
occurrences (all)	1	
Urinary tract inflammation	Additional description: Urinary tract inflammation	
subjects affected / exposed	0 / 231 (0.00%)	
occurrences (all)	0	

Urinary retention subjects affected / exposed occurrences (all)	Additional description: Urinary retention	
	2 / 231 (0.87%) 2	
Urge incontinence subjects affected / exposed occurrences (all)	Additional description: Urge incontinence	
	1 / 231 (0.43%) 1	
Endocrine disorders		
Goitre subjects affected / exposed occurrences (all)	Additional description: Goitre	
	1 / 231 (0.43%) 1	
Hyperthyroidism subjects affected / exposed occurrences (all)	Additional description: Hyperthyroidism	
	0 / 231 (0.00%) 0	
Hypothyroidism subjects affected / exposed occurrences (all)	Additional description: Hypothyroidism	
	0 / 231 (0.00%) 0	
Thyroid cyst subjects affected / exposed occurrences (all)	Additional description: Thyroid cyst	
	0 / 231 (0.00%) 0	
Musculoskeletal and connective tissue disorders		
Arthropathy subjects affected / exposed occurrences (all)	Additional description: Arthropathy	
	0 / 231 (0.00%) 0	
Arthritis subjects affected / exposed occurrences (all)	Additional description: Arthritis	
	7 / 231 (3.03%) 9	
Arthralgia subjects affected / exposed occurrences (all)	Additional description: Arthralgia	
	44 / 231 (19.05%) 53	
Back pain subjects affected / exposed occurrences (all)	Additional description: Back pain	
	28 / 231 (12.12%) 31	
Bone pain subjects affected / exposed occurrences (all)	Additional description: Bone pain	
	5 / 231 (2.16%) 5	
Bursal haematoma	Additional description: Bursal haematoma	

subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Bursitis	Additional description: Bursitis		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Cervical spinal stenosis	Additional description: Cervical spinal stenosis		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Exostosis	Additional description: Exostosis		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Fibromyalgia	Additional description: Fibromyalgia		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Flank pain	Additional description: Flank pain		
subjects affected / exposed occurrences (all)	2 / 231 (0.87%) 2		
Groin pain	Additional description: Groin pain		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Hypercreatinaemia	Additional description: Hypercreatinaemia		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Intervertebral disc disorder	Additional description: Intervertebral disc disorder		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Intervertebral disc protrusion	Additional description: Intervertebral disc protrusion		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Joint effusion	Additional description: Joint effusion		
subjects affected / exposed occurrences (all)	2 / 231 (0.87%) 3		
Joint range of motion decreased	Additional description: Joint range of motion decreased		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Joint swelling	Additional description: Joint swelling		

subjects affected / exposed	1 / 231 (0.43%)		
occurrences (all)	2		
Limb discomfort	Additional description: Limb discomfort		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences (all)	1		
Mobility decreased	Additional description: Mobility decreased		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences (all)	1		
Muscle fatigue	Additional description: Muscle fatigue		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences (all)	0		
Muscle hypertrophy	Additional description: Muscle hypertrophy		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences (all)	0		
Muscle spasms	Additional description: Muscle spasms		
subjects affected / exposed	21 / 231 (9.09%)		
occurrences (all)	24		
Muscle tightness	Additional description: Muscle tightness		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences (all)	1		
Muscle twitching	Additional description: Muscle twitching		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences (all)	1		
Muscular weakness	Additional description: Muscular weakness		
subjects affected / exposed	3 / 231 (1.30%)		
occurrences (all)	3		
Musculoskeletal chest pain	Additional description: Musculoskeletal chest pain		
subjects affected / exposed	5 / 231 (2.16%)		
occurrences (all)	5		
Musculoskeletal discomfort	Additional description: Musculoskeletal discomfort		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences (all)	1		
Musculoskeletal pain	Additional description: Musculoskeletal pain		
subjects affected / exposed	8 / 231 (3.46%)		
occurrences (all)	8		
Musculoskeletal stiffness	Additional description: Musculoskeletal stiffness		

subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Myalgia	Additional description: Myalgia		
subjects affected / exposed occurrences (all)	15 / 231 (6.49%) 16		
Neck pain	Additional description: Neck pain		
subjects affected / exposed occurrences (all)	3 / 231 (1.30%) 3		
Myositis	Additional description: Myositis		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Osteoarthritis	Additional description: Osteoarthritis		
subjects affected / exposed occurrences (all)	3 / 231 (1.30%) 3		
Osteonecrosis	Additional description: Osteonecrosis		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Osteoporosis	Additional description: Osteoporosis		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Pain in extremity	Additional description: Pain in extremity		
subjects affected / exposed occurrences (all)	7 / 231 (3.03%) 7		
Pain in jaw	Additional description: Pain in jaw		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Periarthritis	Additional description: Periarthritis		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 2		
Polyarthritis	Additional description: Polyarthritis		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Polymyalgia rheumatica	Additional description: Polymyalgia rheumatica		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Psoriatic arthropathy	Additional description: Psoriatic arthropathy		

subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Rheumatic disorder	Additional description: Rheumatic disorder		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Spinal column stenosis	Additional description: Spinal column stenosis		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Spinal pain	Additional description: Spinal pain		
subjects affected / exposed occurrences (all)	4 / 231 (1.73%) 4		
Tendon disorder	Additional description: Tendon disorder		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Tendonitis	Additional description: Tendonitis		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Vertebral foraminal stenosis	Additional description: Vertebral foraminal stenosis		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Infections and infestations			
Abscess limb	Additional description: Abscess limb		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Abdominal infection	Additional description: Abdominal infection		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Acarodermatitis	Additional description: Acarodermatitis		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Abscess	Additional description: Abscess		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 2		
Acute sinusitis	Additional description: Acute sinusitis		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 2		

Atypical pneumonia subjects affected / exposed occurrences (all)	Additional description: Atypical pneumonia	
	0 / 231 (0.00%) 0	
Bacterial blepharitis subjects affected / exposed occurrences (all)	Additional description: Bacterial blepharitis	
	0 / 231 (0.00%) 0	
Bacterial food poisoning subjects affected / exposed occurrences (all)	Additional description: Bacterial food poisoning	
	0 / 231 (0.00%) 0	
Bacterial infection subjects affected / exposed occurrences (all)	Additional description: Bacterial infection	
	1 / 231 (0.43%) 1	
Asymptomatic COVID-19 subjects affected / exposed occurrences (all)	Additional description: Asymptomatic COVID-19	
	0 / 231 (0.00%) 0	
Bacterial prostatitis subjects affected / exposed occurrences (all)	Additional description: Bacterial prostatitis	
	0 / 231 (0.00%) 0	
Bacteriuria subjects affected / exposed occurrences (all)	Additional description: Bacteriuria	
	0 / 231 (0.00%) 0	
Body tinea subjects affected / exposed occurrences (all)	Additional description: Body tinea	
	0 / 231 (0.00%) 0	
Borrelia infection subjects affected / exposed occurrences (all)	Additional description: Borrelia infection	
	0 / 231 (0.00%) 0	
Bronchitis bacterial subjects affected / exposed occurrences (all)	Additional description: Bronchitis bacterial	
	0 / 231 (0.00%) 0	
Bronchopulmonary aspergillosis subjects affected / exposed occurrences (all)	Additional description: Bronchopulmonary aspergillosis	
	0 / 231 (0.00%) 0	
Bursitis infective subjects affected / exposed occurrences (all)	Additional description: Bursitis infective	
	0 / 231 (0.00%) 0	

Campylobacter gastroenteritis subjects affected / exposed occurrences (all)	Additional description: Campylobacter gastroenteritis	
	0 / 231 (0.00%) 0	
Candida infection subjects affected / exposed occurrences (all)	Additional description: Candida infection	
	3 / 231 (1.30%) 3	
Bronchitis subjects affected / exposed occurrences (all)	Additional description: Bronchitis	
	27 / 231 (11.69%) 29	
Cellulitis subjects affected / exposed occurrences (all)	Additional description: Cellulitis	
	3 / 231 (1.30%) 4	
Chronic sinusitis subjects affected / exposed occurrences (all)	Additional description: Chronic sinusitis	
	2 / 231 (0.87%) 3	
Clostridium difficile colitis subjects affected / exposed occurrences (all)	Additional description: Clostridium difficile colitis	
	1 / 231 (0.43%) 1	
Clostridium difficile infection subjects affected / exposed occurrences (all)	Additional description: Clostridium difficile infection	
	0 / 231 (0.00%) 0	
Conjunctivitis subjects affected / exposed occurrences (all)	Additional description: Conjunctivitis	
	17 / 231 (7.36%) 22	
COVID-19 subjects affected / exposed occurrences (all)	Additional description: COVID-19	
	42 / 231 (18.18%) 48	
COVID-19 pneumonia subjects affected / exposed occurrences (all)	Additional description: COVID-19 pneumonia	
	0 / 231 (0.00%) 0	
Cystitis subjects affected / exposed occurrences (all)	Additional description: Cystitis	
	11 / 231 (4.76%) 22	
Cytomegalovirus infection subjects affected / exposed occurrences (all)	Additional description: Cytomegalovirus infection	
	0 / 231 (0.00%) 0	

Dacryocanaliculitis subjects affected / exposed occurrences (all)	Additional description: Dacryocanaliculitis 0 / 231 (0.00%) 0		
Dacryocystitis subjects affected / exposed occurrences (all)	Additional description: Dacryocystitis 1 / 231 (0.43%) 1		
Device related infection subjects affected / exposed occurrences (all)	Additional description: Device related infection 1 / 231 (0.43%) 1		
Dengue fever subjects affected / exposed occurrences (all)	Additional description: Dengue fever 0 / 231 (0.00%) 0		
Diverticulitis subjects affected / exposed occurrences (all)	Additional description: Diverticulitis 3 / 231 (1.30%) 3		
Ear infection subjects affected / exposed occurrences (all)	Additional description: Ear infection 6 / 231 (2.60%) 8		
Ear infection bacterial subjects affected / exposed occurrences (all)	Additional description: Ear infection bacterial 0 / 231 (0.00%) 0		
Erythema migrans subjects affected / exposed occurrences (all)	Additional description: Erythema migrans 1 / 231 (0.43%) 1		
Enterococcal infection subjects affected / exposed occurrences (all)	Additional description: Enterococcal infection 0 / 231 (0.00%) 0		
Enterococcal sepsis subjects affected / exposed occurrences (all)	Additional description: Enterococcal sepsis 0 / 231 (0.00%) 0		
Epididymitis subjects affected / exposed occurrences (all)	Additional description: Epididymitis 2 / 231 (0.87%) 2		
Erysipelas subjects affected / exposed occurrences (all)	Additional description: Erysipelas 5 / 231 (2.16%) 6		

Eye infection subjects affected / exposed occurrences (all)	Additional description: Eye infection 3 / 231 (1.30%) 3		
Eyelid infection subjects affected / exposed occurrences (all)	Additional description: Eyelid infection 1 / 231 (0.43%) 1		
Febrile infection subjects affected / exposed occurrences (all)	Additional description: Febrile infection 5 / 231 (2.16%) 5		
Folliculitis subjects affected / exposed occurrences (all)	Additional description: Folliculitis 3 / 231 (1.30%) 3		
Fungal infection subjects affected / exposed occurrences (all)	Additional description: Fungal infection 1 / 231 (0.43%) 1		
Fungal skin infection subjects affected / exposed occurrences (all)	Additional description: Fungal skin infection 3 / 231 (1.30%) 3		
Furuncle subjects affected / exposed occurrences (all)	Additional description: Furuncle 3 / 231 (1.30%) 4		
Genital infection fungal subjects affected / exposed occurrences (all)	Additional description: Genital infection fungal 1 / 231 (0.43%) 1		
Genital herpes subjects affected / exposed occurrences (all)	Additional description: Genital herpes 0 / 231 (0.00%) 0		
Giardiasis subjects affected / exposed occurrences (all)	Additional description: Giardiasis 0 / 231 (0.00%) 0		
Gastric infection subjects affected / exposed occurrences (all)	Additional description: Gastric infection 0 / 231 (0.00%) 0		
Gastroenteritis subjects affected / exposed occurrences (all)	Additional description: Gastroenteritis 8 / 231 (3.46%) 8		

Gastroenteritis caliciviral subjects affected / exposed occurrences (all)	Additional description: Gastroenteritis caliciviral 0 / 231 (0.00%) 0		
Gastroenteritis viral subjects affected / exposed occurrences (all)	Additional description: Gastroenteritis viral 0 / 231 (0.00%) 0		
Gastrointestinal disorders subjects affected / exposed occurrences (all)	Additional description: Gastrointestinal disorders 0 / 231 (0.00%) 0		
Gastrointestinal infection subjects affected / exposed occurrences (all)	Additional description: Gastrointestinal infection 2 / 231 (0.87%) 2		
Haemophilus infection subjects affected / exposed occurrences (all)	Additional description: Haemophilus infection 1 / 231 (0.43%) 1		
Gingivitis subjects affected / exposed occurrences (all)	Additional description: Gingivitis 2 / 231 (0.87%) 3		
Herpes infection subjects affected / exposed occurrences (all)	Additional description: Herpes infection 0 / 231 (0.00%) 0		
Helicobacter gastritis subjects affected / exposed occurrences (all)	Additional description: Helicobacter gastritis 0 / 231 (0.00%) 0		
Hepatitis B reactivation subjects affected / exposed occurrences (all)	Additional description: Hepatitis B reactivation 1 / 231 (0.43%) 1		
Hepatitis E subjects affected / exposed occurrences (all)	Additional description: Hepatitis E 0 / 231 (0.00%) 0		
Hepatitis viral subjects affected / exposed occurrences (all)	Additional description: Hepatitis viral 0 / 231 (0.00%) 0		
Herpes dermatitis subjects affected / exposed occurrences (all)	Additional description: Herpes dermatitis 0 / 231 (0.00%) 0		

Herpes simplex subjects affected / exposed occurrences (all)	Additional description: Herpes simplex	
	5 / 231 (2.16%) 5	
Herpes simplex reactivation subjects affected / exposed occurrences (all)	Additional description: Herpes simplex reactivation	
	0 / 231 (0.00%) 0	
Hordeolum subjects affected / exposed occurrences (all)	Additional description: Hordeolum	
	2 / 231 (0.87%) 2	
Herpes zoster subjects affected / exposed occurrences (all)	Additional description: Herpes zoster	
	8 / 231 (3.46%) 8	
Herpes virus infection subjects affected / exposed occurrences (all)	Additional description: Herpes virus infection	
	2 / 231 (0.87%) 2	
Herpes viral infections subjects affected / exposed occurrences (all)	Additional description: Herpes viral infections	
	0 / 231 (0.00%) 0	
Infection subjects affected / exposed occurrences (all)	Additional description: Infection	
	9 / 231 (3.90%) 10	
Infection susceptibility increased subjects affected / exposed occurrences (all)	Additional description: Infection susceptibility increased	
	0 / 231 (0.00%) 0	
Infectious colitis subjects affected / exposed occurrences (all)	Additional description: Infectious colitis	
	1 / 231 (0.43%) 1	
Infective iritis subjects affected / exposed occurrences (all)	Additional description: Infective iritis	
	1 / 231 (0.43%) 1	
Impetigo subjects affected / exposed occurrences (all)	Additional description: Impetigo	
	3 / 231 (1.30%) 3	
Infected bite subjects affected / exposed occurrences (all)	Additional description: Infected bite	
	0 / 231 (0.00%) 0	

Infected dermal cyst subjects affected / exposed occurrences (all)	Additional description: Infected dermal cyst 0 / 231 (0.00%) 0		
Infected skin ulcer subjects affected / exposed occurrences (all)	Additional description: Infected skin ulcer 1 / 231 (0.43%) 1		
Injection site cellulitis subjects affected / exposed occurrences (all)	Additional description: Injection site cellulitis 0 / 231 (0.00%) 0		
Influenza subjects affected / exposed occurrences (all)	Additional description: Influenza 7 / 231 (3.03%) 8		
Joint abscess subjects affected / exposed occurrences (all)	Additional description: Joint abscess 0 / 231 (0.00%) 0		
Kidney infection subjects affected / exposed occurrences (all)	Additional description: Kidney infection 0 / 231 (0.00%) 0		
Labyrinthitis subjects affected / exposed occurrences (all)	Additional description: Labyrinthitis 1 / 231 (0.43%) 1		
Laryngitis subjects affected / exposed occurrences (all)	Additional description: Laryngitis 3 / 231 (1.30%) 3		
Lip infection subjects affected / exposed occurrences (all)	Additional description: Lip infection 1 / 231 (0.43%) 1		
Localised infection subjects affected / exposed occurrences (all)	Additional description: Localised infection 1 / 231 (0.43%) 2		
Lower respiratory tract infection subjects affected / exposed occurrences (all)	Additional description: Lower respiratory tract infection 2 / 231 (0.87%) 5		
Lyme disease subjects affected / exposed occurrences (all)	Additional description: Lyme disease 0 / 231 (0.00%) 0		

Lymph gland infection subjects affected / exposed occurrences (all)	Additional description: Lymph gland infection 0 / 231 (0.00%) 0		
Metapneumovirus infection subjects affected / exposed occurrences (all)	Additional description: Metapneumovirus infection 1 / 231 (0.43%) 1		
Mucosal infection subjects affected / exposed occurrences (all)	Additional description: Mucosal infection 2 / 231 (0.87%) 2		
Nail infection subjects affected / exposed occurrences (all)	Additional description: Nail infection 3 / 231 (1.30%) 3		
Nasal candidiasis subjects affected / exposed occurrences (all)	Additional description: Nasal candidiasis 1 / 231 (0.43%) 1		
Nasopharyngitis subjects affected / exposed occurrences (all)	Additional description: Nasopharyngitis 46 / 231 (19.91%) 68		
Onychomycosis subjects affected / exposed occurrences (all)	Additional description: Onychomycosis 2 / 231 (0.87%) 2		
Neutropenic infection subjects affected / exposed occurrences (all)	Additional description: Neutropenic infection 0 / 231 (0.00%) 0		
Omphalitis subjects affected / exposed occurrences (all)	Additional description: Omphalitis 1 / 231 (0.43%) 1		
Ophthalmic herpes zoster subjects affected / exposed occurrences (all)	Additional description: Ophthalmic herpes zoster 0 / 231 (0.00%) 0		
Oral candidiasis subjects affected / exposed occurrences (all)	Additional description: Oral candidiasis 1 / 231 (0.43%) 1		
Oral fungal infection subjects affected / exposed occurrences (all)	Additional description: Oral fungal infection 1 / 231 (0.43%) 1		

Oral herpes subjects affected / exposed occurrences (all)	Additional description: Oral herpes 8 / 231 (3.46%) 8		
Oral infection subjects affected / exposed occurrences (all)	Additional description: Oral infection 1 / 231 (0.43%) 1		
Oropharyngeal candidiasis subjects affected / exposed occurrences (all)	Additional description: Oropharyngeal candidiasis 1 / 231 (0.43%) 1		
Osteomyelitis subjects affected / exposed occurrences (all)	Additional description: Osteomyelitis 1 / 231 (0.43%) 1		
Otitis media subjects affected / exposed occurrences (all)	Additional description: Otitis media 2 / 231 (0.87%) 2		
Otitis media acute subjects affected / exposed occurrences (all)	Additional description: Otitis media acute 1 / 231 (0.43%) 1		
Otitis media chronic subjects affected / exposed occurrences (all)	Additional description: Otitis media chronic 0 / 231 (0.00%) 0		
Penile infection subjects affected / exposed occurrences (all)	Additional description: Penile infection 0 / 231 (0.00%) 0		
Papilloma viral infection subjects affected / exposed occurrences (all)	Additional description: Papilloma viral infection 0 / 231 (0.00%) 0		
Parainfluenzae virus infection subjects affected / exposed occurrences (all)	Additional description: Parainfluenzae virus infection 1 / 231 (0.43%) 1		
Paronychia subjects affected / exposed occurrences (all)	Additional description: Paronychia 3 / 231 (1.30%) 3		
Parotitis subjects affected / exposed occurrences (all)	Additional description: Parotitis 0 / 231 (0.00%) 0		

Peritonsillar abscess subjects affected / exposed occurrences (all)	Additional description: Peritonsillar abscess	
	1 / 231 (0.43%) 1	
Pharyngitis subjects affected / exposed occurrences (all)	Additional description: Pharyngitis	
	4 / 231 (1.73%) 4	
Pharyngitis bacterial subjects affected / exposed occurrences (all)	Additional description: Pharyngitis bacterial	
	0 / 231 (0.00%) 0	
Pharyngotonsillitis subjects affected / exposed occurrences (all)	Additional description: Pharyngotonsillitis	
	0 / 231 (0.00%) 0	
Pneumonia mycoplasmal subjects affected / exposed occurrences (all)	Additional description: Pneumonia mycoplasmal	
	0 / 231 (0.00%) 0	
Pneumonia streptococcal subjects affected / exposed occurrences (all)	Additional description: Pneumonia streptococcal	
	0 / 231 (0.00%) 0	
Post-acute COVID-19 syndrome subjects affected / exposed occurrences (all)	Additional description: Post-acute COVID-19 syndrome	
	0 / 231 (0.00%) 0	
Postoperative wound infection subjects affected / exposed occurrences (all)	Additional description: Postoperative wound infection	
	1 / 231 (0.43%) 1	
Pneumonia subjects affected / exposed occurrences (all)	Additional description: Pneumonia	
	23 / 231 (9.96%) 30	
Pulpitis dental subjects affected / exposed occurrences (all)	Additional description: Pulpitis dental	
	1 / 231 (0.43%) 1	
Pyelonephritis subjects affected / exposed occurrences (all)	Additional description: Pyelonephritis	
	0 / 231 (0.00%) 0	
Pyuria subjects affected / exposed occurrences (all)	Additional description: Pyuria	
	1 / 231 (0.43%) 1	

Respiratory syncytial virus infection subjects affected / exposed occurrences (all)	Additional description: Respiratory syncytial virus infection 0 / 231 (0.00%) 0		
Respiratory tract infection subjects affected / exposed occurrences (all)	Additional description: Respiratory tract infection 12 / 231 (5.19%) 14		
Respiratory tract infection viral subjects affected / exposed occurrences (all)	Additional description: Respiratory tract infection viral 0 / 231 (0.00%) 0		
Rhinitis subjects affected / exposed occurrences (all)	Additional description: Rhinitis 8 / 231 (3.46%) 9		
Sialoadenitis subjects affected / exposed occurrences (all)	Additional description: Sialoadenitis 2 / 231 (0.87%) 2		
Root canal infection subjects affected / exposed occurrences (all)	Additional description: Root canal infection 0 / 231 (0.00%) 0		
Scarlet fever subjects affected / exposed occurrences (all)	Additional description: Scarlet fever 1 / 231 (0.43%) 1		
Scrotal infection subjects affected / exposed occurrences (all)	Additional description: Scrotal infection 1 / 231 (0.43%) 1		
Sebaceous gland infection subjects affected / exposed occurrences (all)	Additional description: Sebaceous gland infection 1 / 231 (0.43%) 1		
Sinusitis subjects affected / exposed occurrences (all)	Additional description: Sinusitis 18 / 231 (7.79%) 21		
Skin infection subjects affected / exposed occurrences (all)	Additional description: Skin infection 5 / 231 (2.16%) 7		
Soft tissue infection subjects affected / exposed occurrences (all)	Additional description: Soft tissue infection 1 / 231 (0.43%) 1		

Staphylococcal infection subjects affected / exposed occurrences (all)	Additional description: Staphylococcal infection 0 / 231 (0.00%) 0		
Subcutaneous abscess subjects affected / exposed occurrences (all)	Additional description: Subcutaneous abscess 1 / 231 (0.43%) 1		
Sycosis barbae subjects affected / exposed occurrences (all)	Additional description: Sycosis barbae 0 / 231 (0.00%) 0		
Tinea pedis subjects affected / exposed occurrences (all)	Additional description: Tinea pedis 2 / 231 (0.87%) 3		
Tinea infection subjects affected / exposed occurrences (all)	Additional description: Tinea infection 2 / 231 (0.87%) 2		
Tonsillitis subjects affected / exposed occurrences (all)	Additional description: Tonsillitis 6 / 231 (2.60%) 6		
Tooth abscess subjects affected / exposed occurrences (all)	Additional description: Tooth abscess 1 / 231 (0.43%) 1		
Tooth infection subjects affected / exposed occurrences (all)	Additional description: Tooth infection 4 / 231 (1.73%) 4		
Tracheitis subjects affected / exposed occurrences (all)	Additional description: Tracheitis 0 / 231 (0.00%) 0		
Urethritis subjects affected / exposed occurrences (all)	Additional description: Urethritis 1 / 231 (0.43%) 1		
Vaginal infection subjects affected / exposed occurrences (all)	Additional description: Vaginal infection 6 / 231 (2.60%) 6		
Urosepsis subjects affected / exposed occurrences (all)	Additional description: Urosepsis 0 / 231 (0.00%) 0		

Urinary tract infection viral subjects affected / exposed occurrences (all)	Additional description: Urinary tract infection viral	
	0 / 231 (0.00%) 0	
Urinary tract infection bacterial subjects affected / exposed occurrences (all)	Additional description: Urinary tract infection bacterial	
	1 / 231 (0.43%) 2	
Urinary tract infection subjects affected / exposed occurrences (all)	Additional description: Urinary tract infection	
	29 / 231 (12.55%) 47	
Upper respiratory tract infection subjects affected / exposed occurrences (all)	Additional description: Upper respiratory tract infection	
	37 / 231 (16.02%) 55	
Viral upper respiratory tract infection subjects affected / exposed occurrences (all)	Additional description: Viral upper respiratory tract infection	
	0 / 231 (0.00%) 0	
Viral sinusitis subjects affected / exposed occurrences (all)	Additional description: Viral sinusitis	
	0 / 231 (0.00%) 0	
Viral infection subjects affected / exposed occurrences (all)	Additional description: Viral infection	
	4 / 231 (1.73%) 5	
Vestibular neuronitis subjects affected / exposed occurrences (all)	Additional description: Vestibular neuronitis	
	0 / 231 (0.00%) 0	
Varicella zoster virus infection subjects affected / exposed occurrences (all)	Additional description: Varicella zoster virus infection	
	0 / 231 (0.00%) 0	
Vulvovaginal candidiasis subjects affected / exposed occurrences (all)	Additional description: Vulvovaginal candidiasis	
	0 / 231 (0.00%) 0	
Vulvovaginal mycotic infection subjects affected / exposed occurrences (all)	Additional description: Vulvovaginal mycotic infection	
	1 / 231 (0.43%) 1	
Wound infection subjects affected / exposed occurrences (all)	Additional description: Wound infection	
	0 / 231 (0.00%) 0	

Metabolism and nutrition disorders			
Abnormal weight gain	Additional description: Abnormal weight gain		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences (all)	0		
Acidosis	Additional description: Acidosis		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences (all)	0		
Alcohol intolerance	Additional description: Alcohol intolerance		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences (all)	0		
Decreased appetite	Additional description: Decreased appetite		
subjects affected / exposed	16 / 231 (6.93%)		
occurrences (all)	19		
Diabetes mellitus	Additional description: Diabetes mellitus		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences (all)	1		
Dehydration	Additional description: Dehydration		
subjects affected / exposed	2 / 231 (0.87%)		
occurrences (all)	2		
Dyslipidaemia	Additional description: Dyslipidaemia		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences (all)	1		
Fluid overload	Additional description: Fluid overload		
subjects affected / exposed	0 / 231 (0.00%)		
occurrences (all)	0		
Folate deficiency	Additional description: Folate deficiency		
subjects affected / exposed	1 / 231 (0.43%)		
occurrences (all)	1		
Gout	Additional description: Gout		
subjects affected / exposed	3 / 231 (1.30%)		
occurrences (all)	4		
Hyperphosphataemia	Additional description: Hyperphosphataemia		
subjects affected / exposed	6 / 231 (2.60%)		
occurrences (all)	6		
Hyperkalaemia	Additional description: Hyperkalaemia		

subjects affected / exposed occurrences (all)	10 / 231 (4.33%) 11		
Hyperglycaemia	Additional description: Hyperglycaemia		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Hypercholesterolaemia	Additional description: Hypercholesterolaemia		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Hypercalcaemia	Additional description: Hypercalcaemia		
subjects affected / exposed occurrences (all)	4 / 231 (1.73%) 5		
Hyponatraemia	Additional description: Hyponatraemia		
subjects affected / exposed occurrences (all)	5 / 231 (2.16%) 6		
Hypomagnesaemia	Additional description: Hypomagnesaemia		
subjects affected / exposed occurrences (all)	5 / 231 (2.16%) 6		
Hypokalaemia	Additional description: Hypokalaemia		
subjects affected / exposed occurrences (all)	14 / 231 (6.06%) 20		
Hypoferritinaemia	Additional description: Hypoferritinaemia		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Hypocalcaemia	Additional description: Hypocalcaemia		
subjects affected / exposed occurrences (all)	6 / 231 (2.60%) 8		
Hyperuricaemia	Additional description: Hyperuricaemia		
subjects affected / exposed occurrences (all)	9 / 231 (3.90%) 10		
Hypophosphataemia	Additional description: Hypophosphataemia		
subjects affected / exposed occurrences (all)	9 / 231 (3.90%) 15		
Increased appetite	Additional description: Increased appetite		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Iron deficiency	Additional description: Iron deficiency		

subjects affected / exposed occurrences (all)	9 / 231 (3.90%) 9		
Iron overload	Additional description: Iron overload		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Obesity	Additional description: Obesity		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		
Tumour lysis syndrome	Additional description: Tumour lysis syndrome		
subjects affected / exposed occurrences (all)	13 / 231 (5.63%) 13		
Type 2 diabetes mellitus	Additional description: Type 2 diabetes mellitus		
subjects affected / exposed occurrences (all)	0 / 231 (0.00%) 0		
Vitamin D deficiency	Additional description: Vitamin D deficiency		
subjects affected / exposed occurrences (all)	5 / 231 (2.16%) 5		
Vitamin B12 deficiency	Additional description: Vitamin B12 deficiency		
subjects affected / exposed occurrences (all)	1 / 231 (0.43%) 1		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
20 February 2017	<p>Israel and Ireland were included as participating countries.</p> <p>Availability of SmPC as reference document for Venetoclax due to approval by EMA in December 2016, additionally, new data for administration of venetoclax became available.</p> <p>The study duration was adapted after start of recruitment.</p> <p>The recommended prophylaxis in case of HBV DNA detection was adapted following the newest guidelines.</p> <p>Due to new safety information for obinutuzumab regarding infections, dose and schedule modifications in the RVe/GVe or GIVe arm were adapted.</p> <p>New safety information for ibrutinib regarding interstitial lung disease became available and was included in the protocol.</p> <p>Ultrasound testing at baseline was deleted from the protocol, as CT/MRI is mandatory at baseline.</p>
13 July 2017	<p>The non-use of Rituximab bio-similars was specified in the protocol.</p> <p>MRD measurements are no longer performed by four-color, but by multi-colour-flow-cytometry.</p> <p>Dose and schedule modifications for venetoclax in case of febrile neutropenia and thrombocytopenia during ramp up were clarified.</p> <p>An additional appendix for TLS-risk-management was added.</p>
05 September 2017	<p>Amendment following updated Venetoclax IMPD.</p> <p>Changes in PIC due to EU general data protection regulation were made, not all countries were affected.</p>
12 December 2018	<p>Cancer Trials Ireland and the Israeli CLL Study Group were added as participating study group in the title.</p> <p>Additional participating protocol committee members were added as well as the coordinating physician.</p> <p>Accepted delay of study visits was extended to +/- 14 days.</p> <p>Prior treatment with rituximab was added as an exclusion criterion.</p> <p>Hospitalization as prophylaxis of TLS in venetoclax as well as the 2h-post-venetoclax laboratory assessment were not necessarily recommended anymore.</p> <p>Non TLS-related hyperphosphatemia is not a reason for interruption of venetoclax treatment anymore.</p> <p>Due to possibly increased rate of aspergilloses in ibrutinib-containing treatment, recommendations concerning infection prophylaxis were added to the protocol.</p> <p>Adjustments according to SmPC of venetoclax were made.</p>
19 February 2020	<p>Changes on frequency of HBV PCR testing were made, pelvis and was included in radiological assessment at baseline, additional sampling (ctDNA) from pB was added in the protocol.</p> <p>Adjustments in safety reporting were made.</p>
26 April 2021	<p>Adjustments and specifications of the statistical chapter were made, MRD analysis by MGS was added as an exploratory endpoint.</p> <p>A chapter regarding Benefit-Risk-Assessment during the Covid-19 pandemic was added to the protocol.</p>
26 April 2021	<p>non-substantial amendment.</p> <p>New SmPCs available</p>
12 December 2022	<p>FU intervals were updated and extended to 13 months.</p>

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported

Online references

<http://www.ncbi.nlm.nih.gov/pubmed/37172204>

<http://www.ncbi.nlm.nih.gov/pubmed/32601378>

<http://www.ncbi.nlm.nih.gov/pubmed/37163621>

<http://www.ncbi.nlm.nih.gov/pubmed/38821083>